Clinical trial NCT03478956
Conditions: Ulcerative Colitis Crohn's Disease
Sponsor: Hoffmann-La Roche
Start date: 2018-03-27; Completion date: 2023-09-27
Enrollment: 24 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to \<18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).

Detailed description:

Arms: arm 1: Etrolizumab 1.5 milligrams per kilogram of body weight (mg/kg) was administered by subcutaneous (SC) injection once every 4 weeks (Q4W) for a total of 4 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase. arm 2: Etrolizumab 3.0 mg/kg was administered by subcutaneous (SC) injection once every 8 weeks (Q8W) for a total of 2 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
Interventions: intervention 1: Etrolizumab
Intervention descriptions: intervention 1: Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.

Protocol documents:
Prot_SAP_001.pdf: 
Official Title: A Phase I, Open-Label, Randomized, Pharmacokinetic, 
Pharmacodynamic, and Safety Study of Etrolizumab Followed by 
Open-Label Extension and Safety Monitoring in Pediatric Patients 
From 4 Years to Less Than 18 Years of age With Moderate to Severe 
Ulcerative Colitis or Moderate to Severe Crohn’s Disease 
NCT Number: NCT03478956 
Document Dates: Protocol Version 4: 28-May-2021 


PROTOCOL AMENDMENT APPROVAL
CONFIDENTIAL
This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, 
Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, 
including Genentech, Inc. in the United States.  The information contained in this document, especially 
any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
you, your staff, and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information will not be disclosed to others without written authorization from Roche except to the 
extent necessary to obtain informed consent from persons to whom the drug may be administered.
Etrolizumab—F. Hoffmann-La Roche Ltd
Protocol CA40192, Version 4
PROTOCOL
TITLE:
A PHASE I, OPEN-LABEL, RANDOMIZED,
PHARMACOKINETIC, PHARMACODYNAMIC, AND 
SAFETY STUDY OF ETROLIZUMAB FOLLOWED 
BY OPEN-LABEL EXTENSION AND SAFETY 
MONITORING IN PEDIATRIC PATIENTS FROM 
4 YEARS TO LESS THAN 18 YEARS OF AGE WITH 
MODERATE TO SEVERE ULCERATIVE COLITIS 
OR MODERATE TO SEVERE CROHN’S DISEASE
PROTOCOL NUMBER:
CA40192
VERSION NUMBER:
4
EUDRACT NUMBER:
2017-003649-10
IND NUMBER:
100366, 119725
TEST PRODUCT:
Etrolizumab (PRO145223, RO5490261)
MEDICAL MONITOR:
, M.D.
SPONSOR:
F. Hoffmann-La Roche Ltd
APPROVAL DATE:
See electronic date stamp below.
 
28-May-2021 16:41:31
Title
Approver's Name
Date and Time (UTC)


Etrolizumab—F. Hoffmann-La Roche Ltd
2/Protocol CA40192, Version 4
PROTOCOL HISTORY
Protocol
Associated Country-Specific Protocol
Version
Date Final
Country
Version
Date Final
4
See electronic date 
stamp on title page



3
22 November 2019



2
9 August 2018



1
15 October 2017
Germany
2
27 March 2018


Etrolizumab—F. Hoffmann-La Roche Ltd
3/Protocol CA40192, Version 4
PROTOCOL AMENDMENT, VERSION 4:
RATIONALE
Protocol CA40192 has been amended to clarify the 12-week safety follow up period after 
completion or early termination of the open-label extension phase, to add results from 
completed Phase III ulcerative colitis studies, and to add coronavirus disease 2019 
(COVID-19) vaccine-related language.  Changes to the protocol, along with a rationale 
for each change, are summarized below:

Sections 1.3, 1.4, 1.5, 5.1.1, and Table 4 have been updated to include safety and 
efficacy results from completed Phase III studies in ulcerative colitis.

Section 3.1, Appendix 1e, Figure 2, and Figure 3 have been updated and 
Appendix 1d has been added to clarify the 12-week long safety follow-up period 
after completion or early termination of the open-label extension phase.

Guselkumab has been removed from the list of prohibited therapy (Section 4.4.3).

The Medical Monitor has been updated in Section 5.4.1.

COVID-19 vaccine-related language has been added to Section 4.4.1.1.

Language has been added to indicate that the Informed Consent Form will instruct 
female patients to inform the investigator if they become pregnant (Section 5.4.3.1).

Language regarding investigator reporting of pregnancies has been clarified
(Section 5.4.3.2).

The name of a Roche policy on data sharing has been corrected (Section 9.5).

Appendix 1c has been updated to include visits during the open-label extension 
phase for conducting pregnancy tests.
Additional minor changes have been made to improve clarity and consistency.  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.


Etrolizumab—F. Hoffmann-La Roche Ltd
4/Protocol CA40192, Version 4
TABLE OF CONTENTS
PROTOCOL AMENDMENT ACCEPTANCE FORM .......................................... 11
PROTOCOL SYNOPSIS .................................................................................... 12
1.
BACKGROUND .......................................................................................... 24
1.1
Background on pediatric Ulcerative Colitis ............................ 24
1.2
Background on Pediatric Crohn’s Disease ............................ 26
1.3
Background on Etrolizumab................................................... 28
1.4
Study Rationale and Benefit-Risk Assessment...................... 30
2.
OBJECTIVES AND ENDPOINTS ............................................................... 32
3.
STUDY DESIGN......................................................................................... 34
3.1
Description of the Study......................................................... 34
3.1.1
Safety Monitoring Committee ................................................ 38
3.2
End of Study and Length of Study......................................... 38
3.3
Rationale for Study Design.................................................... 38
3.3.1
Rationale for Patient Population ............................................ 38
3.3.2
Rationale for Etrolizumab Dose and Schedule ...................... 40
3.3.3
Rationale for PK Sampling Schedule..................................... 40
3.3.4
Rationale for Biomarker Assessments................................... 41
4.
MATERIALS AND METHODS .................................................................... 41
4.1
Patients.................................................................................. 41
4.1.1
Inclusion Criteria.................................................................... 41
4.1.2
Exclusion Criteria................................................................... 43
4.1.2.1
Exclusion Criteria Related to Inflammatory Bowel 
Disease.................................................................................. 43
4.1.2.2
Exclusion Criteria Related to Ulcerative Colitis...................... 43
4.1.2.3
Exclusion Criteria Related to Crohn’s Disease ...................... 43
4.1.2.4
Exclusion Criteria Related to Prior or 
Concomitant Therapy ............................................................ 43
4.1.2.5
Exclusion Criteria Related to General Safety......................... 44
4.1.2.6
Exclusion Criteria Related to Infection Risk........................... 45
4.1.2.7
Exclusion Criteria Related to Laboratory Values 
(at Screening)........................................................................ 46


Etrolizumab—F. Hoffmann-La Roche Ltd
5/Protocol CA40192, Version 4
4.2
Method of Treatment Assignment and Blinding..................... 47
4.3
Study Treatment and Other Treatments Relevant 
to the Study Design ............................................................... 47
4.3.1
Study Treatment Formulation, Packaging, and 
Handling ................................................................................ 47
4.3.1.1
Etrolizumab............................................................................ 47
4.3.2
Study Treatment Dosage, Administration, and 
Compliance............................................................................ 48
4.3.2.1
Etrolizumab............................................................................ 48
4.3.3
Investigational Medicinal Product Accountability ................... 49
4.3.4
Continued Access to Etrolizumab.......................................... 49
4.4
Concomitant Therapy ............................................................ 50
4.4.1
Permitted Therapy................................................................. 50
4.4.1.1
Coronavirus Disease 2019 Vaccines ..................................... 50
4.4.2
Cautionary Therapy ............................................................... 51
4.4.2.1
Herbal Therapies................................................................... 51
4.4.2.2
Rescue Therapies ................................................................. 51
4.4.3
Prohibited Therapy ................................................................ 51
4.5
Study Assessments ............................................................... 52
4.5.1
Informed Consent Forms and Screening Log........................ 53
4.5.2
Rescreening .......................................................................... 53
4.5.3
Medical History, Concomitant Medication, and 
Demographic Data................................................................. 54
4.5.4
Physical Examinations........................................................... 54
4.5.5
Vital Signs.............................................................................. 54
4.5.6
Laboratory, Biomarker, and Other Biological 
Samples................................................................................. 54
4.5.7
Chest X-Ray .......................................................................... 57
4.5.8
Electrocardiograms................................................................ 57
4.5.9
Clinical Outcome Assessments ............................................. 57
4.5.10
Optional Samples for Research Biosample 
Repository ............................................................................. 58
4.5.10.1
Overview of the Research Biosample Repository.................. 58
4.5.10.2
Approval by the Institutional Review Board or 
Ethics Committee .................................................................. 59


Etrolizumab—F. Hoffmann-La Roche Ltd
6/Protocol CA40192, Version 4
4.5.10.3
Sample Collection.................................................................. 59
4.5.10.4
Confidentiality........................................................................ 60
4.5.10.5
Consent to Participate in the Research 
Biosample Repository............................................................ 60
4.5.10.6
Withdrawal from the Research Biosample 
Repository ............................................................................. 61
4.5.10.7
Monitoring and Oversight....................................................... 61
4.6
Treatment, Patient, Study, and Site 
Discontinuation...................................................................... 61
4.6.1
Study Treatment Discontinuation........................................... 61
4.6.2
Patient Discontinuation from Study........................................ 62
4.6.3
Study Discontinuation............................................................ 62
4.6.4
Site Discontinuation............................................................... 63
5.
ASSESSMENT OF SAFETY....................................................................... 63
5.1
Safety Plan ............................................................................ 63
5.1.1
Potential Risks Associated with Etrolizumab ......................... 63
5.1.1.1
Serious Infections.................................................................. 64
5.1.1.2
Hypersensitivity Reactions..................................................... 67
5.1.1.3
Hepatic Effects ...................................................................... 67
5.1.1.4
Local Injection-Site Reactions ............................................... 68
5.1.1.5
Malignancies.......................................................................... 68
5.1.1.6
Immunogenicity ..................................................................... 69
5.1.1.7
Decreased Effectiveness of Immunizations........................... 69
5.1.1.8
Risks Associated with Worsening of Ulcerative 
Colitis and Crohn’s Disease................................................... 70
5.1.2
Management of Patients Who Experience 
Specific Adverse Events........................................................ 70
5.1.2.1
Management Guidelines........................................................ 70
5.2
Safety Parameters and Definitions ........................................ 74
5.2.1
Adverse Events ..................................................................... 74
5.2.2
Serious Adverse Events (Immediately Reportable 
to the Sponsor)...................................................................... 74
5.2.3
Adverse Events of Special Interest (Immediately 
Reportable to the Sponsor).................................................... 75


Etrolizumab—F. Hoffmann-La Roche Ltd
7/Protocol CA40192, Version 4
5.3
Methods and Timing for Capturing and 
Assessing Safety Parameters................................................ 76
5.3.1
Adverse Event Reporting Period ........................................... 76
5.3.2
Eliciting Adverse Event Information....................................... 77
5.3.3
Assessment of Severity of Adverse Events ........................... 77
5.3.4
Assessment of Causality of Adverse Events ......................... 78
5.3.5
Procedures for Recording Adverse Events............................ 78
5.3.5.1
Injection-Site Reactions......................................................... 79
5.3.5.2
Worsening Ulcerative Colitis and Crohn’s 
Disease.................................................................................. 79
5.3.5.3
Diagnosis versus Signs and Symptoms................................. 79
5.3.5.4
Adverse Events That Are Secondary to Other 
Events.................................................................................... 79
5.3.5.5
Persistent or Recurrent Adverse Events................................ 80
5.3.5.6
Abnormal Laboratory Values ................................................. 80
5.3.5.7
Abnormal Vital Sign Values ................................................... 81
5.3.5.8
Abnormal Liver Function Tests.............................................. 81
5.3.5.9
Deaths ................................................................................... 82
5.3.5.10
Preexisting Medical Conditions.............................................. 82
5.3.5.11
Lack of Efficacy or Worsening of Ulcerative 
Colitis or Crohn’s Disease ..................................................... 82
5.3.5.12
Hospitalization or Prolonged Hospitalization.......................... 83
5.3.5.13
Adverse Events Associated with an Overdose or 
Error in Drug Administration .................................................. 83
5.3.5.14
Clinical Outcomes Assessment Data..................................... 83
5.4
Immediate Reporting Requirements from 
Investigator to Sponsor.......................................................... 84
5.4.1
Emergency Medical Contacts................................................ 84
5.4.2
Reporting Requirements for Serious Adverse 
Events, Adverse Events of Special Interest........................... 85
5.4.2.1
Events That Occur prior to Study Drug Initiation.................... 85
5.4.2.2
Events That Occur after Study Drug Initiation........................ 85
5.4.3
Reporting Requirements for Pregnancies.............................. 85
5.4.3.1
Pregnancies in Female Patients............................................ 85
5.4.3.2
Pregnancies in Female Partners of Male Patients................. 86


Etrolizumab—F. Hoffmann-La Roche Ltd
8/Protocol CA40192, Version 4
5.4.3.3
Congenital Anomalies/Birth Defects and 
Abortions ............................................................................... 86
5.4.4
Reporting Requirements for Vial and Syringe 
Complaints/Events................................................................. 86
5.5
Follow-Up of Patients after Adverse Events .......................... 87
5.5.1
Investigator Follow-Up........................................................... 87
5.5.2
Sponsor Follow-Up ................................................................ 87
5.6
Adverse Events That Occur after the Adverse 
Event Reporting Period.......................................................... 87
5.7
Expedited Reporting to Health Authorities, 
Investigators, Institutional Review Boards, 
and Ethics Committees.......................................................... 88
6.
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN....................... 88
6.1
Determination of Sample Size ............................................... 88
6.2
Summaries of Conduct of Study............................................ 88
6.3
Summaries of Treatment Group Comparability ..................... 89
6.4
Pharmacokinetic Analyses..................................................... 89
6.5
Pharmacodynamic Analyses ................................................. 89
6.6
Safety Analyses..................................................................... 89
6.7
Immunogenicity Analyses...................................................... 90
6.8
Biomarker Analyses............................................................... 90
6.9
Exploratory Analyses............................................................. 90
7.
DATA COLLECTION AND MANAGEMENT ............................................... 91
7.1
Data Quality Assurance......................................................... 91
7.2
Electronic Case Report Forms............................................... 91
7.3
Source Data Documentation.................................................. 91
7.4
Use of Computerized Systems .............................................. 92
7.5
Retention of Records............................................................. 92
8.
ETHICAL CONSIDERATIONS.................................................................... 93
8.1
Compliance with Laws and Regulations ................................ 93
8.2
Informed Consent.................................................................. 93
8.3
Institutional Review Board or Ethics Committee.................... 94
8.4
Confidentiality........................................................................ 94
8.5
Financial Disclosure .............................................................. 95


Etrolizumab—F. Hoffmann-La Roche Ltd
9/Protocol CA40192, Version 4
9.
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION ..................................................................................... 95
9.1
Study Documentation ............................................................ 95
9.2
Protocol Deviations................................................................ 95
9.3
Site Inspections ..................................................................... 96
9.4
Administrative Structure......................................................... 96
9.5
Publication of Data and Protection of Trade 
Secrets .................................................................................. 96
9.6
Protocol Amendments ........................................................... 97
10. REFERENCES ........................................................................................... 98
LIST OF TABLES
Table 1
Objectives and Corresponding Endpoints for the 
Randomized Treatment Phase ................................................... 33
Table 2
Objectives and Corresponding Endpoints for the Open-label 
Extension Phase......................................................................... 33
Table 3
Objectives and Corresponding Endpoints for the Progressive 
Multifocal Leukoencephalopathy Monitoring Phase.................... 34
Table 4
Guidelines for Management of Patients Who Experience 
Specific Adverse Events ............................................................. 70
Table 5
Adverse Event Severity Grading Scale for Events Not 
Specifically Listed in NCI CTCAE ............................................... 77
Table 6
Causal Attribution Guidance ....................................................... 78
LIST OF FIGURES
Figure 1
Study Schema:  Randomized Treatment Phase (Treatment 
Period and Safety Followup Period).......................................... 36
Figure 2
Study Schema:  Open-label Extension Phase ............................ 37
Figure 3
Study Schema:  Progressive Multifocal 
Leukoencephalopathy Monitoring Phase .................................... 37


Etrolizumab—F. Hoffmann-La Roche Ltd
10/Protocol CA40192, Version 4
LIST OF APPENDICES
Appendix 1a
Schedule of Assessments:  Randomized Treatment Phase 
(Treatment Period).................................................................... 103
Appendix 1b
Schedule of Assessments: Randomized Treatment Phase 
(Safety Follow-up Period) ......................................................... 108
Appendix 1c
Schedule of Assessments:  Open-Label Extension Phase ....... 110
Appendix 1d
Schedule of Assessments:  12-week Safety Follow-Up After 
Completion or Early Termination of Open-Label Extension 
Phase ...................................................................................... 117
Appendix 1e
Schedule of Assessments:  Progressive Multifocal 
Leukoencephalopathy Monitoring Phase .................................. 118
Appendix 2
Pediatric Ulcerative Colitis Activity Index (PUCAI).................... 119
Appendix 3
Pediatrics Crohn’s Disease Activity Index (PCDAI)................... 121
Appendix 4
Anaphylaxis Precautions........................................................... 122
Appendix 5
Tanner Stages .......................................................................... 123
Appendix 6
Childbearing Potential, Pregnancy Testing, and 
Contraception............................................................................ 124
Appendix 7
Worksheet for the PML Neurologic Examination....................... 126
Appendix 8
Algorithm for Evaluation of  Progressive Multifocal 
Leukoencephalopathy............................................................... 129
Appendix 9
Clinical Criteria for Diagnosing Anaphylaxis.............................. 130


Etrolizumab—F. Hoffmann-La Roche Ltd
11/Protocol CA40192, Version 4
PROTOCOL AMENDMENT ACCEPTANCE FORM
TITLE:
A PHASE I, OPEN-LABEL, RANDOMIZED, 
PHARMACOKINETIC, PHARMACODYNAMIC, AND 
SAFETY STUDY OF ETROLIZUMAB FOLLOWED 
BY OPEN-LABEL EXTENSION AND SAFETY 
MONITORING IN PEDIATRIC PATIENTS FROM 
4 YEARS TO LESS THAN 18 YEARS OF AGE WITH 
MODERATE TO SEVERE ULCERATIVE COLITIS 
OR MODERATE TO SEVERE CROHN’S DISEASE
PROTOCOL NUMBER:
CA40192
VERSION NUMBER:
4
EUDRACT NUMBER:
2017-003649-10
IND NUMBER:
100366, 119725
TEST PRODUCT:
Etrolizumab (PRO145223, RO5490261)
MEDICAL MONITOR:
, M.D.
SPONSOR:
F. Hoffmann-La Roche Ltd
I agree to conduct the study in accordance with the current protocol.
Principal Investigator’s Name  (print)
Principal Investigator’s Signature
Date
Please retain the signed original of this form for your study files.  Please return a copy of 
the signed form to Sponsor representative.


Etrolizumab—F. Hoffmann-La Roche Ltd
12/Protocol CA40192, Version 4
PROTOCOL SYNOPSIS
TITLE:
A PHASE I, OPEN-LABEL, RANDOMIZED, PHARMACOKINETIC,
PHARMACODYNAMIC, AND SAFETY STUDY OF ETROLIZUMAB 
FOLLOWED BY OPEN-LABEL EXTENSION AND SAFETY 
MONITORING IN PEDIATRIC PATIENTS FROM 4 YEARS TO 
LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE 
ULCERATIVE COLITIS OR MODERATE TO SEVERE CROHN’S 
DISEASE
PROTOCOL NUMBER:
CA40192
VERSION NUMBER:
4
EUDRACT NUMBER:
2017-003649-10
IND NUMBER:
100366, 119725
TEST PRODUCT:
Etrolizumab (PRO145223, RO5490261)
PHASE:
I
INDICATIONS:
Moderate to severe ulcerative colitis; moderate to severe 
Crohn’s disease
SPONSOR:
F. Hoffmann-La Roche Ltd
Objectives and Endpoints
This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in 
pediatric patients of 4 to 18 years of age with moderate to severe ulcerative colitis (UC) or with 
moderate to severe Crohn’s disease (CD).  
This study will consist of multiple phases; a randomized treatment phase that will evaluate 
pharmacokinetics, pharmacodynamics, and safety, followed by an open-label extension (OLE)
phase, and then a progressive multifocal leukoencephalopathy (PML) monitoring phase.  The 
objective of the 24-week randomized treatment phase is to evaluate the pharmacokinetics, 
pharmacodynamics, safety, and tolerability of etrolizumab in pediatric patients from 4 to 
18 years of age with moderate to severe UC or moderate to severe CD.  The objective of the 
312-week (6-year) OLE phase is to assess the long-term safety and efficacy of etrolizumab in 
pediatric patients from the randomized treatment phase.  The objective of the 104week PML 
safety-monitoring phase (that includes the 12-week safety follow-up period after completion or 
early discontinuation from the OLE) is to assess safety with focus on the occurrence of PML in 
patients who are no longer on etrolizumab.


Etrolizumab—F. Hoffmann-La Roche Ltd
13/Protocol CA40192, Version 4
Objectives and Corresponding Endpoints for the Randomized Treatment Phase
Primary Objective
Corresponding Endpoints

To evaluate the pharmacokinetics and 
pharmacodynamics of etrolizumab in a 
pediatric IBD patient population

PK parameters: Cmax, AUCtau, t1/2, Ctrough

PD parameters:  7 receptor occupancy by flow 
cytometry on peripheral blood lymphocytes
Safety Objective
Corresponding Endpoints

To evaluate the overall safety and 
tolerability of etrolizumab in pediatric 
population

Incidence and severity of infection-related 
adverse events

Incidence of immunogenic responses (ADAs)

Incidence and severity of hypersensitivity 
reaction events
Exploratory Objectives
Corresponding Endpoints

To evaluate additional 
pharmacodynamic biomarkers of 
etrolizumab

To evaluate clinical disease biomarkers 
with etrolizumab treatment

To evaluate the clinical efficacy of 
etrolizumab

Changes in serum MAdCAM-1

Changes in serum CRP and fecal calprotectin

Clinical response at Week 16, as assessed by 
the PUCAI (UC) and PCDAI (CD)
ADAanti-drug antibody; AUCtauarea under the concentrationtime curve within a dosing 
interval; CDCrohn's disease; Cmaxmaximum concentration observed; CRPC-reactive protein; 
Ctroughsteady-state concentration at the end of a dosing interval; IBDinflammatory bowel 
disease; MAdCAM-1mucosal vascular addressin cell adhesion molecule-1; 
PDpharmacodynamic; PK pharmacokinetic; PCDAIPediatric Crohn's Disease Activity Index; 
PUCAIPediatric Ulcerative Colitis Activity Index; t1/2elimination half-life; UCulcerative colitis. 
Objectives and Corresponding Endpoints for the Open-label Extension Phase
Safety Objective
Corresponding Endpoints

To evaluate long-term safety of 
etrolizumab in pediatric population

Incidence and severity of infection-related adverse 
events

Incidence and severity of malignancies 

Incidence of ADAs to etrolizumab

Incidence and severity of hypersensitivity reactions
Efficacy Objective
Corresponding Endpoint

To evaluate long term efficacy of 
etrolizumab in pediatric population

Clinical response at Week 132, as assessed by the 
PUCAI (UC) and PCDAI (CD)
ADAanti-drug antibody; CDCrohn's disease; PCDAIPediatric Crohn's Disease Activity Index; 
PUCAIPediatric Ulcerative Colitis Activity Index; UCulcerative colitis.
Objectives and Corresponding Endpoints for the Progressive Multifocal 
Leukoencephalopathy Monitoring Phase
Safety Objective
Corresponding Endpoint

Post-trial safety surveillance with 
focus on PML monitoring in patients 
who have stopped treatment  

Occurrence of confirmed PML events
PMLprogressive multifocal leukoencephalopathy.


Etrolizumab—F. Hoffmann-La Roche Ltd
14/Protocol CA40192, Version 4
Study Design
Description of Study
This pediatric pharmacokinetic (PK)/pharmacodynamic (PD) study consists of multiple phases.  
The randomized treatment phase is an open-label, randomized phase in which etrolizumab is 
administered to patients on the basis of body weight (mg/kg); randomization will be stratified by 
weight (40 kg, 40 kg).  Patients will be randomized in a 1:1 ratio to receive either 
high-frequency etrolizumab once every 4 weeks (Q4W) or low-frequency etrolizumab once 
every 8 weeks (Q8W).  The high-frequency dose of 1.5 mg/kg etrolizumab will be administered 
Q4W (Weeks 0, 4, 8, and 12).  The low-frequency dose of 3.0 mg/kg etrolizumab will be 
administered Q8W (Weeks 0 and 8).  
After the 24week randomized treatment phase (which includes a 16week treatment period
and an 8week safety follow-up period), patients will then have the option to participate in the 
312week OLE phase (treatment with etrolizumab 1.5 mg/kg will be administered Q4W).  
All patients who participate in the 24week randomized treatment phase and the 312week 
OLE phase will enter the 12week safety follow up period (no etrolizumab treatment) and
will complete the safety surveillance PML monitoring phase (no etrolizumab treatment for a
total of 104 weeks).  All patients who choose not to enter the OLE after the 24week 
randomized treatment phase will be offered participation in the 104-week PML monitoring 
phase.  
Patients can enter the OLE phase after completion of the 24week randomized treatment 
phase.  If the last visit of the randomized treatment phase and Day 1 of the OLE occur on the 
same day, the assessments from the randomized treatment phase should be completed.  
The assessments from the randomized treatment phase can apply to the OLE assessments 
(i.e., the same assessments should not be repeated for the OLE).  
The 104week PML monitoring phase will consist of telephone calls approximately every 
6 months with administration of the PML Subjective Checklist.  If there are any signs or 
symptoms suggestive of PML identified on this subjective checklist during the telephone call, 
the patient will be asked to come into the clinic for a neurologic examination.  The PML 
Algorithm will be followed for any suspected case of PML, and any confirmed case of PML will 
be reported as a serious adverse event.
Patients who experience clinically significant worsening in their UC or CD status during the 
study can receive rescue therapy based on current standard of care.  Patients can receive 
rescue therapy at any time during the study, including the treatment phase, safety followup 
phase, OLE phase and PML monitoring phase. 
Approximately 24 pediatric patients from 4 to 18 years of age with moderate to severe UC or 
with moderate to severe CD will be enrolled to target at least 12 patients with evaluable PK 
profiles.  At least 4 patients from 4 years to 12 years of age should be enrolled.  This study 
requirement is according to the health authority requirement.  If PK and PD samples are 
missing, patients will be replaced at the discretion of the sponsor.  Every effort should be made 
to collect all PK and PD samples.  
Patients who initially failed screening may be rescreened twice at the discretion of the 
investigator.
If a patient fails any laboratory inclusion/exclusion criteria at screening the investigator may 
repeat the test twice within the screening period. If the patient fails the laboratory criteria for a 
third time they will be considered a screen failure. It will not be considered a re-screening if 
blood samples have to be redrawn due to sample handling problems, breakage, or sample 
integrity.  This multi-center study will be conducted at global sites.
Rescue therapy can be prescribed based on the discretion of the investigator and disease flare, 
and can include methotrexate, corticosteroids, immunomodulators, and excludes anti-TNFs, 
vedolizumab and other biologic agents.  Based on the patient’s disease status and physicians 
care practices, the patient can be withdrawn from the study at any time to receive excluded 
therapy.
Number of Patients
A minimum of 12 patients with UC and CD from 4 years to 18 years of age will be enrolled in 
the study.  There will be at least 4 children from 4 years to 12 years of age with evaluable PK 
profiles, which is a study obligation according to the health authority requirement.


Etrolizumab—F. Hoffmann-La Roche Ltd
15/Protocol CA40192, Version 4
Target Population
Inclusion Criteria
Patients must meet the following criteria for study entry:

Signed Informed Consent Form by parent or legal guardian

Age of 4 years to 18 years at the time of signing the Informed Consent Form

Ability to comply with the study protocol, in the investigator’s judgment

Weight of 13 kg or more

Diagnosis of UC or CD confirmed by biopsy and established for 3 months (i.e., after first 
diagnosis by a physician according to American College of Gastroenterology [ACG] 
guidelines) prior to screening  

Inadequate response, loss of response or intolerance to prior immunosuppressants and/or 
corticosteroid treatment and/or anti-TNF therapy

For patients with UC: moderately to severely active UC as determined by an MCS of 612 
with an endoscopic subscore 2 (within the last 12 months prior to screening) and a rectal 
bleeding subscore 1

For patients with CD: moderately to severely active CD as determined by a Pediatric 
Crohn’s Disease Activity Index (PCDAI) score of 30 at baseline 

Patients must meet the following surveillance colonoscopy requirements: 
–
Document evidence of surveillance for dysplasia every 1 to 2 years, beginning 
approximately 7 to 10 years after their initial diagnosis

For postpubertal females of childbearing potential:  agreement to remain abstinent (refrain 
from heterosexual intercourse) or use acceptable contraceptive methods during the 
treatment period and for at least 24 weeks after the last dose of etrolizumab.
A female is considered to be of childbearing potential if she is postmenarcheal, has not 
reached a postmenopausal state (12 continuous months of amenorrhea with no 
identified cause other than menopause), and has not undergone surgical sterilization 
(removal of ovaries and/or uterus).
Examples of acceptable contraceptive methods include bilateral tubal ligation, male 
sterilization, combined oral contraceptive pill or transdermal patch, spermicide and 
barrier [condoms], intrauterine device, implants for contraception, injections for 
contraception [with prolonged release], hormonal vaginal device. 
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of contraception.

For male patients:  agreement to remain abstinent (refrain from heterosexual intercourse) or 
use contraceptive measures, and agreement to refrain from donating sperm, as defined 
below:
With female partners of childbearing potential or pregnant female partners, men must 
remain abstinent or use a condom during the treatment period and for at least 
24 weeks after the last dose of study drug to avoid exposing the embryo to study drug.  
Men must refrain from donating sperm during this same period. 
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of contraception.
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
Exclusion Criteria Related to Inflammatory Bowel Disease

Prior extensive colonic resection, subtotal or total colectomy, or planned surgery 

Past or present ileostomy or colostomy


Etrolizumab—F. Hoffmann-La Roche Ltd
16/Protocol CA40192, Version 4

Diagnosis of indeterminate colitis

Suspicion of ischemic colitis, radiation colitis, or microscopic colitis

Diagnosis of toxic megacolon within 12 months of initial screening visit

Abdominal abscess

A history or current evidence of colonic mucosal dysplasia

Patients with fixed symptomatic stenosis of the intestine

Patients with history or evidence of adenomatous colonic polyps that have not been 
removed

Patients who are not up to date on vaccinations per the local vaccine schedule will be 
excluded.
Exclusion Criteria Related to Ulcerative Colitis

Severe extensive colitis per investigator judgment that colectomy is imminent OR the 
patient has two of the following five symptoms at screening or baseline visit:
–
6 bowel movements daily with obvious blood
–
Abdominal examination worrisome for imminent surgery
–
Persistent fever
–
Tachycardia
–
Anemia (hemoglobin 8 g/dL)
Exclusion Criteria Related to Crohn’s Disease

Sinus tract with evidence for infection (e.g., purulent discharge) in the clinical judgment of 
the investigator

Short-bowel syndrome 

Evidence of abdominal or perianal abscess

Expected to require surgery to manage CD-related complications during the study
Exclusion Criteria Related to Prior or Concomitant Therapy

Any prior treatment with anti-integrin agents (including natalizumab, vedolizumab, and 
efalizumab)

Any prior treatment with ustekinumab

Any prior treatment with anti-adhesion molecules (e.g., anti-MAdCAM-1)

Any prior treatment with rituximab

Use of IV steroids within 30 days prior to screening with the exception of a single 
administration of IV steroid

Use of agents that deplete B or T cells (e.g., alemtuzumab or visilizumab) within 12 months 
prior to Day 1, with the exception of AZA and 6-MP

Use of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 4 weeks 
prior to Day 1

Use of other biologics (e.g., anti-TNF) within 8 weeks before dosing, unless drug level is 
below detectability before completion of the 8-week interval

Chronic nonsteroidal anti-inflammatory drug (NSAID) use (Note: occasional use of NSAIDs 
and acetaminophen [e.g., headache, arthritis, myalgias, or menstrual cramps] and aspirin 
up to 325 mg daily is permitted.)

Patients who are currently using anticoagulants, including but not limited to warfarin, 
heparin, enoxaparin, dabigatran, apixaban, rivaroxaban.  (Note that antiplatelet agents, 
such as aspirin up to 325 mg daily or clopidogrel, are permitted.)

Apheresis (i.e., Adacolumnapheresis) within 2 weeks prior to Day 1


Etrolizumab—F. Hoffmann-La Roche Ltd
17/Protocol CA40192, Version 4

Received any investigational treatment including investigational vaccines within 12 weeks 
prior to Day 1 of the study or 5 half-lives of the investigational product, whichever is greater

History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, 
human, or humanized antibodies, fusion proteins, or murine proteins or hypersensitivity to 
etrolizumab (active drug substance) or any of the excipients (L-histidine, L-arginine, 
succinic acid, polysorbate 20)
Exclusion Criteria Related to General Safety

Pregnant or lactating

Lack of peripheral venous access

Congenital or acquired immune deficiency

Hospitalized (other than for elective reasons) during the screening period

Inability to comply with study protocol, in the opinion of the investigator

Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart failure 
New York Heart Association [NYHA] Class III/IV), pulmonary, renal, hepatic, endocrine, or 
GI disorders (excluding UC and CD)

Neurological conditions or diseases that may interfere with monitoring for PML

History of demyelinating disease

Clinically significant abnormalities on the screening PML Subjective Checklist

History of major neurological disorders, including stroke, multiple sclerosis, brain tumor,
neurodegenerative disease, or poorly controlled epilepsy

History of alcohol, drug, or chemical abuse 6 months prior to screening

Conditions other than UC or CD that could require treatment with 10 mg/day of prednisone 
(or equivalent) during the course of the study

Presence of metal in the body that could pose a hazard during any potential scanning in 
patients for whom a magnetic resonance imaging (MRI) scan is considered unsafe

History of cancer, including hematologic malignancy, solid tumors, and carcinoma in situ, 
within 5 years before screening with the following caveats:
–
Local basal or squamous cell carcinoma of the skin that has been excised and is 
considered cured is not exclusionary.
–
A history of chronic myelogenous leukemia, hairy cell leukemia, melanoma, renal cell 
carcinoma, or Kaposi sarcoma is exclusionary, irrespective of the duration of time 
before screening.
–
History of a cervical smear indicating the presence of adenocarcinoma in situ (AIS), 
high-grade squamous intraepithelial lesions (HSIL), or cervical intraepithelial neoplasia 
(CIN) of Grade 1 is exclusionary, irrespective of the duration of time before 
screening.
Exclusion Criteria Related to Infection Risk

Congenital or acquired immune deficiency

Patients must undergo screening for HIV and test positive for preliminary and confirmatory 
tests

Positive hepatitis C virus (HCV) antibody test result, unless the patient (1) has undetectable 
HCV RNA levels for 6 months after completing a successful course of HCV anti-viral 
treatment and an undetectable HCV RNA at screening or (2) has a known history of HCV 
antibody positivity with a history of undetectable HCV RNA and undetectable HCV RNA at 
screening in the absence of history of HCV anti-viral treatment.


Etrolizumab—F. Hoffmann-La Roche Ltd
18/Protocol CA40192, Version 4

Patients must undergo screening for hepatitis B virus (HBV).  This includes testing for 
HBsAg (HBV surface antigen), anti-HBc total (HBV core antibody total), and HBV DNA 
(patients who test negative for these tests are eligible for this study):
–
Patients who test positive for surface antigen (HBsAg +) are not eligible for this study, 
regardless of the results of other hepatitis B tests.
–
Patients who test positive only for core antibody (anti-HBc +) must undergo further 
testing for hepatitis B DNA (HBV DNA test).
–
If the HBV DNA test is positive, the patient is not eligible for this study.
–
In the event the HBV DNA test cannot be performed, the patient is not eligible for this 
study.
–
If the HBV DNA test is negative, the patient is eligible for this study.  These patients 
will undergo periodic monitoring for HBV DNA during the study.

Positive stool test result for ova or parasites or positive stool culture for pathogens at time of 
screening

Evidence of or treatment for Clostridium difficile (as assessed by C. difficile toxin testing) 
within 60 days prior to Day 1or other intestinal pathogens (as assessed by stool culture and 
ova and parasite evaluation) within 30 days prior to Day 1

Evidence of or treatment for clinically significant cytomegalovirus (CMV) colitis (based on 
the investigator’s judgment) within 60 days prior to Day 1.  Laboratory confirmation of CMV 
from colon biopsy sample is required during screening evaluation only if clinical suspicion is 
high and to determine the need for CMV treatment

History of active or latent treated TB, regardless of treatment history)
–
Patients with a history of active or latent TB (based on a positive screening assay, 
either purified protein derivative [PPD] skin test or QuantiFERON-TB Gold test, see 
below) are not eligible for this study.
–
Patients with a chest X-ray (posteroanterior and lateral) within 3 months of Day 1 
suspicious for pulmonary TB are not eligible for this study.

Suspicion of active TB on chest radiograph (X-ray, posteroanterior and lateral) taken within 
3 months of randomization

History of recurrent opportunistic infections and/or history of severe disseminated viral 
infections (e.g., herpes)

Opportunistic infection within 3 months before screening

Any current or recent signs or symptoms (within 4 weeks before screening and during 
screening) of infection, except for the following:
–
Minor infections (e.g., common cold) that have, in the investigator’s judgment, 
completely resolved prior to Day 1
–
Fungal infections of the nail beds
–
Oral or vaginal candidiasis that has resolved with or without treatment prior to Day 1

Any major episode of infection requiring treatment with IV antibiotics within 8 weeks prior to 
screening or oral antibiotics within 4 weeks prior to screening
–
Treatment with antibiotics as adjunctive therapy for UC/CD in the absence of 
documented infection is not exclusionary.

Received a live attenuated vaccine within 4 weeks prior to Day 1

History of organ transplant
Exclusion Criteria Related to Laboratory Values (at Screening)

Serum creatinine 1.5 times upper limit of normal (ULN)

ALT or AST 3 ULN, or alkaline phosphatase 3 ULN, or total bilirubin 2.5 ULN 
(unconjugated hyperbilirubinemia that is associated with known Gilbert's syndrome is not an 
exclusion criterion)


Etrolizumab—F. Hoffmann-La Roche Ltd
19/Protocol CA40192, Version 4

In patients with diabetes: glycosylated hemoglobin (HbA1c) 8.0%

Platelet count 100,000/mL

Hemoglobin 8 g/dL

Absolute neutrophil count 1500/mL

Absolute lymphocyte count 500/mL
End of Study
The end of this study is defined as the date when the last patient, last visit (LPLV) occurs or the 
date at which the last data point required for PK/PD or statistical analysis or safety follow-up is 
received from the last patient, whichever occurs later. The end of the study is expected to occur 
108 months after the last patient is enrolled. 
Length of Study
The total length of the study, from screening of the first patient to the end of the study, is 
expected to be approximately 9 years.
The randomized treatment phase will continue for 24 weeks (includes a 16week treatment 
period and an 8week safety follow-up period) after the last patient is enrolled into the study or 
until the sponsor decides to terminate the study, whichever is earlier.  Patients who withdraw 
from the treatment period should complete the 8week safety follow-up period.  All patients will 
be offered participation in the 104week extended PML monitoring phase.
The OLE phase will continue for approximately 6 years after the last patient is enrolled into the 
study or until the Sponsor decides to terminate the study, whichever is earlier.
The PML monitoring phase will last 104 weeks for patients who enter, either from the 
randomized treatment phase or the OLE phase (includes 12-week safety follow-up period after 
completion or early discontinuation from OLE).
Investigational Medicinal Products
Test Product (Investigational Drug)
The investigational medicinal product (IMP) for this study is etrolizumab.  All patients will receive 
etrolizumab one subcutaneous injection of 0.01 mL per kg of patient weight (1.5 mg/kg) Q4W or 
injection of 0.02 mL per kg of patient weight (3 mg/kg) Q8W.
Statistical Methods
Primary Analysis
The primary analysis of the study will be performed when all the data from the randomized 
controlled part of the study are in the database and has been cleaned and verified.
Determination of Sample Size
A sample size of 1216 patients has been considered sufficient in order to evaluate the PK and 
PD endpoints.  No formal sample size and power calculations were performed.
Pharmacokinetic Analyses
The PK analysis population will consist of patients with sufficient data to enable estimation of 
key parameters such as AUC (area under the curve), Cmax (maximum concentration), Ctrough 
(trough concentration) and t1/2 (elimination half-life). 
Non-compartmental analysis will be used to derive PK parameters including Cmax and Tmax after 
the first and final dose, t1/2, AUC within dosing interval (AUC84-112) and (AUC56-112) for 1.5 mg/kg 
Q4W and 3 mg/kg Q8W, respectively.   
All PK parameters will be listed and summarized by descriptive summary statistics including 
means, geometric means, ranges, standard deviations, and coefficients of variation.
Individual and mean concentration versus time data will be tabulated and plotted by dose level. 
PK data from this study may be combined with data from the adult study to perform a population 
PK analysis.  Population typical value of PK parameters will be estimated for the entire study 
population, along with estimates of intra- and inter-patient variance and an estimate of random 
error.  Individual patient parameter estimates will be computed using the post hoc analysis 


Etrolizumab—F. Hoffmann-La Roche Ltd
20/Protocol CA40192, Version 4
procedure.  A prospective analysis plan will be prepared, and the population PK analysis will be 
presented in a report separate from the Clinical Study Report of this study.
Additional exploratory PK/PD analyses or modeling may be conducted as appropriate.
Pharmacodynamic Analyses
All PD parameters will be listed and summarized by descriptive summary statistics including 
means, standard deviations, medians, ranges, and coefficients of variation.
Safety Analyses
The safety analysis population will consist of all patients who received at least one dose of 
study drug, with patients grouped according to dose regimen received. 
Safety will be assessed through descriptive summaries of adverse events (including serious 
adverse events, malignancies, infections – in particular gastrointestinal infections, systemic 
hypersensitivity events, and injection site reactions), laboratory test results, and vital signs.
Immunogenicity Analyses
The immunogenicity analysis population will consist of all patients with at least one anti-drug 
antibody (ADA) assessment.  Patients will be grouped according to treatment received or, if no 
treatment is received prior to study discontinuation, according to treatment assigned.
The numbers and proportions of ADA-positive patients and ADA-negative patients at baseline 
(baseline prevalence) and after etrolizumab treatment (post-treatment incidence) will be 
summarized by treatment group.  When determining post treatment incidence, patients are 
considered to be ADA positive if they are ADA negative or have missing data at baseline but 
developed an ADA response following study drug exposure (treatment-induced ADA response), 
or if they are ADA positive at baseline and the titer of one or more postbaseline samples is at 
least 0.60 titer unit greater than the titer of the baseline sample (treatment-enhanced ADA 
response).  Patients are considered to be ADA negative if they are ADA negative or have 
missing data at baseline and all postbaseline samples are negative, or if they are ADA positive 
at baseline but do not have any postbaseline samples with a titer that is at least 0.60 titer unit 
greater than the titer of the baseline sample (treatment unaffected).
The relationship between ADA status and safety, efficacy, PK, and PD endpoints will be 
assessed and reported via descriptive statistics.
Biomarker Analyses
Βeta 7 receptor occupancy and serum MAdCAM-1 results will be summarized by dosing group 
and timepoints as absolute values and/or change from baseline.  Summary statistics may be 
provided.
A PK/PD model may be developed to evaluate the PK/PD relationship after combining data 
from adult’s study.  This modeling work will be reported separately outside the Clinical Study 
Report of this study.
Exploratory Analyses
PUCAI/PCDAI response or remission rates will be summarized descriptively over time within 
each treatment group.  Disease activity scores and subscores, fecal calprotectin levels and 
serum C-reactive protein (CRP) levels and their change from baseline will also be summarized 
descriptively over time to assess the efficacy of etrolizumab in reducing signs and symptoms of 
disease and levels of inflammatory biomarkers.


Etrolizumab—F. Hoffmann-La Roche Ltd
21/Protocol CA40192, Version 4
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation
Definition
5-ASA
5-aminosalicylate
6-MP
6-mercaptopurine
ACG
American College of Gastroenterology
ADA
anti-drug antibody
AIS
adenocarcinoma in situ
AUC
area under the concentration-time curve
AUC
area under the concentration-time curve within the last 
dose interval
AUCinf
area under the concentration-time curve from time zero 
to infinity
AZA
azathioprine
BCG
Bacille Calmette-Guerin
CD
Crohn’s disease
CIN
cervical intraepithelial neoplasia
CMV
cytomegalovirus
CNS
central nervous system
COVID-19
coronavirus disease 2019
COA
clinical outcome assessment
CRP
C-reactive protein
Cmax
maximum serum concentration observed
Ctrough
steady-state concentration at the end of a dosing 
interval (i.e., just prior to next drug administration)
CSF
cerebrospinal fluid
CTCAE
Common Terminology Criteria for Adverse Events
EC
Ethics Committee
eCRF
electronic Case Report Form
EDC
electronic data capture
EMA
European Medicines Agency
EU
European Union
FDA
(U.S.) Food and Drug Administration
HBV
hepatitis B virus
anti-HBc total
HBV core antibody total
HBcAb
HBv core anti-body
HBsAg
HBV surface antigen
HCP
health care provider
HCV
hepatitis C virus


Etrolizumab—F. Hoffmann-La Roche Ltd
22/Protocol CA40192, Version 4
Abbreviation
Definition
HIPAA
Health Insurance Portability and Accountability Act
HSIL
High-grade squamous intraepithelial lesion
ICH
International Council for Harmonisation
IBD
inflammatory bowel disease
IMP
investigational medicinal product
IND
Investigational New Drug (application)
IRB
Institutional Review Board
JCV
John Cunningham virus
LD
loading dose
LPLV
last patient, last visit
MAbs
monoclonal antibodies
MAdCAM
mucosal vascular addressin cell adhesion molecule
MCS
Mayo Clinic Score
MMF
mycophenolate mofetil
MRI
magnetic resonance imaging
MTX
methotrexate
NCI
National Cancer Institute
NGS
next-generation sequencing
NOAEL
no-observed-adverse-effect-level
NSAID
nonsteroidal anti-inflammatory drug
NYHA
New York Heart Association
OLE
open-label extension
PCDAI
Pediatric Crohn’s Disease Activity Index
PCR
polymerase chain reaction
PD
pharmacodynamics
PK
pharmacokinetic
PML
progressive multifocal leukoencephalopathy
PopPK
population PK
PPD
purified protein derivative
PUCAI
Pediatric Ulcerative Colitis Activity Index
Q4W
every 4 weeks
Q8W
every 8 weeks
QOL
quality of life
RBR
Research Biosample Repository
RO
receptor occupancy
SC
subcutaneous
SPC
Summary of Product Characteristics


Etrolizumab—F. Hoffmann-La Roche Ltd
23/Protocol CA40192, Version 4
Abbreviation
Definition
t1/2
elimination half-life
TB
tuberculosis
tmax
time to maximum observed concentration
TNF-
tumor necrosis factoralpha
UC
ulcerative colitis
U.S.
United States
WES
whole exome sequencing
WGS
whole genome sequencing


Etrolizumab—F. Hoffmann-La Roche Ltd
24/Protocol CA40192, Version 4
1.
BACKGROUND
1.1
BACKGROUND ON PEDIATRIC ULCERATIVE COLITIS
Ulcerative colitis (UC) is an idiopathic inflammatory bowel disease (IBD) that affects the 
colon in a diffuse, continuous, and superficial pattern.  Approximately 40%50% of 
patients have disease limited to the rectum and rectosigmoid colon, 30%40% have 
disease extending beyond the sigmoid but not involving the whole colon, and 20% have 
a total colitis.  Proximal spread occurs in continuity without areas of uninvolved mucosa.  
When the whole colon is involved, the inflammation extends 23 cm into the terminal 
ileum in 10%20% of patients.
UC is characterized by mucosal ulceration, rectal bleeding, diarrhea, and abdominal pain 
and may be complicated by severe bloody diarrhea and toxic megacolon, requiring 
major and sometimes urgent surgery.  UC represents dysregulation of the mucosal 
immune system in genetically susceptible individuals in response to commensal 
microbiota and other environmental triggers.  The disease can affect any age group, but 
occurrence peaks between the ages of 15 and 35 years.
Pediatric-onset UC affects both sexes equally, with the mean age of diagnosis of
approximately 12 years of age (Kugathasan et al. 2003). The annual incidence of UC 
reported among United States (U.S.) pediatric populations 18 years of age is 0.454.9 
per 100,000 (Abramson et al. 2010; Benchimol et al. 2011). Benchimol et al. 
summarized all pediatric IBD studies published to date, globally, and found incidence 
ranged generally 06 per 100,000, with a few exceptions (Benchimol et al. 2011).
More recent nationwide European studies conducted among pediatric populations 
18 years of age indicate that incidence differs by country; higher rates were reported in 
Finland and Denmark (49 and 6.27.2 per 100,000, respectively) while comparatively 
lower rates were reported in Slovenia, Iceland, Scotland, and Spain (2.9, 2.4, 2.06, and 
0.88 per 100,000, respectively; Lehtinen et al. 2011; Henderson et al. 2012; Agnarsson 
et al. 2013; Martín-de-Carpi et al. 2013; Urlep et al. 2015; Larsen et al. 2016). It is rarely 
seen in patients 4 years of age; the annual incidence in this age group is 0.20.7 per
100,000 and the prevalence is 1.12.3 per 100,000 (Herrinton et al. 2008; Abramson et 
al. 2010; Malaty et al. 2010). Combining the range of age-specific UC prevalence
estimates reported in the literature with the age-specific 2013 U.S. population estimates, 
the number of children 18 years of age diagnosed with UC is estimated to be between 
10,400 and 14,600 in the U.S.
The goals of treatment, both in adult and pediatric patients, are to induce and maintain 
remission, decrease corticosteroid use (as measured by steroid-free remission), induce 
mucosal healing, reduce hospitalization and surgery, improve health-related quality of 
life (QOL), and avoid disability.  For mildly to moderately active UC, oral and rectal 
preparations of 5-aminosalicylate (5-ASA) medications are used either alone or together 
and result in remission in approximately 50% of patients.  Patients whose UC fails to 


Etrolizumab—F. Hoffmann-La Roche Ltd
25/Protocol CA40192, Version 4
respond to 5-ASA drugs or who have moderately to severely active UC often receive 
conventional therapy, including corticosteroids and immunomodulator therapy 
(e.g., azathioprine [AZA], 6-mercaptopurine [6-MP], and methotrexate [MTX]).  
Corticosteroids achieve remission in about 70% of patients, but approximately 20% 
become steroid dependent and only half maintain steroid-free remission (Faubion et al. 
2001).  
The systemic toxicities of chronic corticosteroid use include adrenal suppression,
infection, growth failure, insulin resistance, cataracts, osteoporosis, and glaucoma.  
Mood disturbances and sleep disorders are also common with steroid treatment
(Turner et al. 2012). These side effects, in particular growth failure, bone loss, and
glucose intolerance with corticosteroids, are particularly detrimental to pediatric patients 
with UC because they occur at a critical growth and development period.  
Immunomodulators, such as 6-MP, AZA, and MTX, have also been used to achieve 
steroid-free remission, but efficacy in maintaining steroid-free remission is modest 
(Lobel et al. 2004; Chebli et al. 2010; Mañosa et al. 2011; Khan et al. 2013).  In addition, 
these medications are associated with significant side effects, including hepatotoxicity, 
pancreatitis, and bone marrow suppression.
More recently, monoclonal antibodies (MAbs) targeting tumor necrosis factoralpha 
(TNF-), such as infliximab (Remicade) and adalimumab (Humira), have been used to 
induce and maintain remission in patients whose immunomodulatory therapy fails, are 
steroid dependent or refractory, and have moderately to severely active UC.  These 
biologic agents induce remission in up to 40% of patients, but sustained remission is 
seen in only 10%20% of patients over 1 year (Rutgeerts et al. 2005; Sandborn et 
al. 2013).  Importantly, anti-TNF therapies are associated with serious adverse events, 
such as bacterial infection, including tuberculosis (TB), disseminated fungal infections, 
lymphoma, and demyelination (Chang and Lichtenstein 2006).  Infliximab was approved 
for use in pediatric patients aged 617 years in Europe and in the United States (U.S.) in
2011 following a Phase III safety and efficacy trial, which demonstrated approximately 
30% 1-year remission rates (Hyams et al. 2012). Adalimumab has also been approved 
for use in pediatric patients age 6 years of age and older with UC and Crohn’s disease
(CD) in the U.S. (Humira, U.S Package Insert).
Additionally, in the pivotal studies for vedolizumab, an anti-integrin approved for the 
treatment of UC in adults, 47% of patients with UC had a clinical response with 6 weeks 
of induction treatment.  Up to 45% of patients with UC who were vedolizumab 
responders at the end of induction achieved remission with 46 weeks of maintenance 
treatment, compared with 16% of UC patients, given placebo (Sandborn et al. 2013; 
Feagan et al. 2013). Though vedolizumab is not approved for pediatric use, it has been 
used off label in both CD and UC.  A retrospective review of pediatric patients with CD 
and UC 18 years of age shows that patients receiving vedolizumab appear to respond 
to treatment (Singh et al. 2016).


Etrolizumab—F. Hoffmann-La Roche Ltd
26/Protocol CA40192, Version 4
However, in short, a large proportion of patients with moderately to severely active UC 
do not maintain a durable response to therapy.  Available therapies are associated with 
significant adverse events and at best achieve sustained remission in only 10%30% of 
patients with IBD who have chronic disease (Hanauer et al. 2002; Sandborn et al. 2005).  
Patients whose disease fails to respond to medical therapy may be treated with total 
proctocolectomy with an ileal pouch-anal anastomosis.  Although surgical intervention 
may be curative, complications such as chronic pouchitis, fecal incontinence, or 
decreased female fertility can occur (Bradley and Oliva-Hemker 2012).  The current
treatments are associated with significant adverse events, resulting in low rates of 
sustained remission, or are highly invasive.
Consequently, there continues to be a high unmet medical need in moderately to 
severely active UC.  Targeted therapy with an improved safety profile and ability to 
sustain remission and prevent long-term complications would provide a valuable 
therapeutic option for these patients.
1.2
BACKGROUND ON PEDIATRIC CROHN’S DISEASE
CD is a chronic, relapsing form of IBD that can affect any portion of the gastrointestinal
(GI) tract, with 40%−50% of cases affecting the small bowel. CD is characterized by 
patchy, transmural inflammation, ulcers, and granulomatous lesions that are 
interspersed with healthy sections of bowel (skip lesions). The disease is progressive; 
uncontrolled inflammation develops into stricturing or penetrating complications such as 
prestenotic dilatation, obstruction (stricturing), and intra-abdominal or perianal fistulas 
and abscesses (penetrating). Clinical signs and symptoms include chronic diarrhea, 
abdominal pain, cachexia, abdominal mass, or tenderness as well as the overt signs of 
fistulas. 
Pediatric-onset CD affects both sexes with an increased prevalence in males 
(Abramson et al. 2010). Approximately 20% of affected adults develop CD before 
20 years of age (Kappelman et al. 2013). In a Belgium cohort, the median age at 
presentation of pediatric CD is approximately 12.5 years and presentation rarely 
occurred before 4 years of age (de Greef et al. 2013).
An overall trend of increasing rates of pediatric IBD, primarily due to the rising incidence 
of CD, has been reported throughout the world (Benchimol et al. 2011). The incidence 
of CD in pediatric patients from Wisconsin was estimated to be approximately 
4.6/100,000 persons per year in one study (Kugathasan et al. 2003), and in a separate 
study, the prevalence of CD in patients 20 years of age was 43 per 100,000 using 
U.S. health insurance claims data (Kappelman et al. 2007).
So far, there is no cure for CD. The selection of appropriate medical therapy depends
upon an understanding of the location of the disease, its severity, and the complications 
the patient experiences. The treatment goals for CD are to induce and maintain 


Etrolizumab—F. Hoffmann-La Roche Ltd
27/Protocol CA40192, Version 4
remission, induce mucosal healing, avoid surgery, and improve quality of life 
(Lichtenstein et al. 2009; Van Assche et al. 2010). 
Systemic corticosteroids have been the mainstay treatment for inducing remission and 
are effective in approximately 80% of patients (Summers et al. 1979; Malchow et al. 
1984). However, they are less effective as a maintenance therapy, with only 28% of 
patients achieving a prolonged response after 1 year of treatment and 32% of patients 
becoming steroid dependent (Faubion et al. 2001; Peyrin-Biroulet et al. 2010). 
Corticosteroid-induced toxicities and side effects as described previously are detrimental 
in the pediatric population because of their critical period of growth and development; 
50% of patients will stop their treatment because of these side effects.
Immunosuppressants (e.g., AZA, 6-MP, or MTX) are typically administered to induce 
remission in patients who are intolerant of or refractory to steroids and to maintain 
remission in patients who achieve quiescent CD. Immunosuppressants are given with or 
without a steroid bridge, depending on a patient’s symptoms during the 2- to 4-month 
onset of immunosuppressant efficacy.
The development of MAbs against TNF-has provided an additional treatment option.  
Although anti-TNFs are effective in a significant proportion of patients, efficacy is 
suboptimal; remission rates after 4 weeks of induction therapy are lower than 35% and, 
among patients who respond to induction therapy, fewer than 50% have achieved 
remission when assessed in maintenance at 20−30 weeks (Peyrin-Biroulet et al. 2011). 
Furthermore, 30% of patients are reported to be primary non-responders to anti-TNF 
therapy when assessed after 4 weeks of induction therapy (Targan et al. 1997; 
Sandborn et al. 2007). Anti-TNFs are also associated with significant side effects, 
including serious infection, opportunistic infection, lupus-like reactions, and an increased 
risk of lymphoma (Siegal and Melmed 2009). Tolerability concerns include injection site 
reactions, occurring in 10% of patients receiving adalimumab (van der Heijde et al. 
2006), and infusion reactions, occurring in 9%−17% of patients treated with infliximab 
(de Vries et al. 2011). 
The anti-integrins are another class of biologics approved for the treatment of CD.  
Natalizumab (Tysabri) is an anti-integrin approved in the United States for the treatment 
of moderate to severely active CD.  The use of natalizumab, which blocks both 41 and 
47 integrins, has been limited because of concerns that inhibition of 41/vascular 
cell adhesion molecule 1 (VCAM-1) binding increases the risk of progressive multifocal 
leukoencephalopathy (PML), a rare but serious infection of the central nervous system 
(CNS).  
Vedolizumab is the most recently approved gut-selective anti-integrin for CD; it targets 
only the 47 integrin receptor, inhibiting T-lymphocyte binding to the adhesion 
molecule, mucosal vascular addressin cell adhesion molecule (MAdCAM-1), and is 
administered as an IV infusion.  In the pivotal trials for vedolizumab, 31% of patients had 


Etrolizumab—F. Hoffmann-La Roche Ltd
28/Protocol CA40192, Version 4
a clinical response with 6 weeks of induction treatment; up to 39% of the vedolizumab 
responders achieved remission with 46 weeks of maintenance treatment, compared with 
22% of patients given placebo (Sandborn et al. 2013).  Though vedolizumab is not 
approved for pediatric use, it has been used off label in both CD and UC. 
A retrospective review of pediatric patients with CD and UC 18 years of age shows that 
patients receiving vedolizumab appear to respond to treatment (Singh et al. 2016).  
Altogether, biologic use is more common in pediatric CD than in pediatric UC, with
respective estimates of 24% and 15% (ages 6-12 years) and 33% and 17% (age 
≥1317 years) of the treated population (Yang et al. 2012). Although anti-TNF-agents 
appear to be more effective than immunosupressants in the treatment of moderate to 
severe CD, the benefits of early anti-TNF use must be compared against the potential 
risks.  Indeed, anti-TNF agents expose patients to the risks of systemic
immunosuppression with the potential for serious complications such as opportunistic 
infections (RemicadeSummary of Product Characteristics [SPC]; HumiraSPC).
Despite a number of therapeutic options, there remains a need in pediatric patients with 
moderate to severe CD for agents with a strong and positive benefit-risk profile.  Agents 
targeted at the level of the specific organ that avoid systemic immunosuppression may 
contribute to fulfill that need.
1.3
BACKGROUND ON ETROLIZUMAB
Etrolizumab is a humanized MAb based on the human IgG1 subgroup-III VH, 
subgroup-1 VL consensus sequences and was constructed using standard 
recombinant DNA techniques.  This recombinant antibody consists of two heavy chains 
(446 residues) and two light chains (214 residues) and is produced in Chinese hamster 
ovary cells that have been genetically engineered to synthesize the antibody.  The 
protein is manufactured in bioreactors and purified using a series of harvest, purification, 
and formulation steps.  The potency of etrolizumab is determined by an in vitro assay 
that measures the inhibition of adhesion of 47-expressing cells to MAdCAMfragment 
crystallizable region.
Etrolizumab distinguishes itself from natalizumab and vedolizumab because it 
specifically binds the integrin 7 subunit, found in both 47 (Holzmann et al. 1989; 
Hu et al. 1992) and E7 integrins (Cepek et al. 1993), which regulate trafficking and 
retention of leukocyte/lymphocyte subsets, respectively, in the intestinal mucosa.
It is important to note that etrolizumab does not bind to 41 (target for natalizumab), 
which regulates trafficking to both mucosal and non-mucosal tissues, including the CNS.  
Etrolizumab, therefore, represents a novel gut mucosalselective anti-trafficking agent 
whose selectivity may enhance efficacy in UC and CD and eliminate generalized 
immunosuppression by preferentially targeting trafficking to the gut rather than to other 
organs and tissues.  Data from multiple nonclinical toxicology studies of up to 6 months 
duration in adult animals demonstrated no adverse effects in any organ system 


Etrolizumab—F. Hoffmann-La Roche Ltd
29/Protocol CA40192, Version 4
(including the CNS, hematologic, and cardiovascular systems).  No adverse events were 
observed in the embryo-fetal developmental toxicity studies and there was no evidence of 
increased rates of infection.
The pharmacokinetics and pharmacodynamics of etrolizumab were characterized in 
Phase I (ABS4262g) and Phase II (ABS4986g) studies in adult patients with moderately 
to severely active UC. Study ABS4262g tested both single dose and multiple doses of 
etrolizumab either IV or subcutaneous (SC) at dose levels of 0.310 mg/kg (single dose 
IV), 3 mg/kg (single dose SC), 0.53 mg/kg SC or 4 mg/kg IV (multiple doses given once 
every 4 weeks [Q4W]3).  Study (ABS4986g) tested two dose regimens: 100 mg 
(nominal dose) SC Q4W and 420 mg SC at Week 1 followed by 300 mg SC at Weeks 2, 
4, and 8. The pharmacokinetic (PK) profile of etrolizumab is generally dose proportional 
with regard to maximum serum concentration observed (Cmax) and area under the serum 
concentration-time curve from time zero to infinity (AUCinf) (or AUC within the last dose 
interval [AUC]) for the dose ranges tested.  The mean elimination half-life in UC 
patients was approximately 1315 days following multiple doses of 100 mg and 300 mg 
SC administration.
In study ABS4262g, a dose-dependent increase in the duration of 7 receptor 
occupancy was observed following a single IV dose of 0.3, 1 and 10 mg/kg of 
etrolizumab. The group mean occupancy was maintained for approximately 2 weeks, 
6 weeks, and 10 weeks, respectively. In study ABS4986g, maximal/near maximal 7 
receptor occupancy was observed up to 71 days following multiple doses of 100 mg and 
300 mg SC administration.
Exploratory PK/pharmacodynamics (PD) analysis showed a relationship between PK 
(serum drug levels) and PD (7 receptor occupancy) in which approximately 13 g/mL 
of serum etrolizumab maintained maximal/near maximal occupancy of 7 integrin on 
peripheral blood mucosal-homing T cell subsets.
The safety of etrolizumab has been assessed in Phase I, Phase II, and five Phase III
studies in adult patients with moderate to severe UC.
The following is a summary of the etrolizumab safety experience to date:

No significant adverse safety signal, including any evidence of increased rates of 
serious or opportunistic infections, was associated with etrolizumab treatment in the 
Phase I or Phase II trials in adult patients with moderately to severely active UC who 
received either single or multiple doses of IV or SC etrolizumab.

The safety profile of etrolizumab in completed Phase III studies in UC was 
consistent with that observed in previous Phase II studies. No new or clinically 
significant safety signal was identified from an overall review of these studies.
To date, there have been six adverse drug reactions (ADRs) identified, based on a 
review of pooled all exposure Phase II and III UC studies. These ADRs are 
Appendicitis, Arthralgia, Eczema, Fatigue, Rash, and Rash Macular.


Etrolizumab—F. Hoffmann-La Roche Ltd
30/Protocol CA40192, Version 4

To date, no events of PML have been reported in etrolizumab-treated patients.
See the most recent Etrolizumab Investigator's Brochure for details on nonclinical and 
clinical studies.
1.4
STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, and
safety of etrolizumab in pediatric patients (ages 4 years to 18 years) with moderately to
severely active UC or moderately to severely active CD. The PK and PD information 
obtained from this Phase I study will be used to identify an appropriate dosing regimen 
for a separate Phase III safety and efficacy study in a pediatric IBD population.
A significant proportion of patients with UC will not experience a durable clinical benefit 
with anti-TNF agent treatment options.  Furthermore, adverse events associated with 
anti-TNFs include elevated rates of serious bacterial infection, including TB, and (more 
rarely) lymphoma and demyelination (Chang and Lichtenstein 2006).  No currently 
available therapy achieves sustained remission in more than 10%30% of patients with 
IBD (Hanauer et al. 2002; Sandborn et al. 2005). 
No clinically significant safety signals have been detected on administration of 
etrolizumab to patients with moderate to severe UC across a dose range of 0.310.0 mg 
IV/SC in the single-ascending dose stage and 0.53.0 mg/kg SC and 4 mg/kg IV 
monthly for three doses in the multidose stage of the Phase I study.
A global, Phase II, multicenter study (Study ABS4986g; EUCALYPTUS) designed to 
determine the exposure-response relationship and to further characterize the safety and 
tolerability of etrolizumab in treatment of adult patients with moderately to severely active 
UC has been completed.  In this study, 120 patients were randomized in a 1:1:1 ratio to 
receive 100 mg etrolizumab SC (0.7 mL of 150 mg/mL solution via vial and syringe, with 
an intended nominal dose of 100 mg) at Weeks 0, 4, and 8 or 420 mg SC at 
Week 1(loading dose [LD]) followed by 300 mg SC (three injections of 0.7 mL of 
150 mg/mL solution via vial and syringe, with an intended nominal dose of 300 mg) at 
Weeks 2, 4, and 8 (40 patients per dose arm) versus matching placebo SC (40 patients 
per arm).  The primary objective of the study was to obtain evidence of clinical efficacy of 
etrolizumab as measured by induction of clinical remission (Mayo Clinic Score [MCS] 2 
and no individual subscore 1) at Week 10 (2 weeks after the final dose). In 
EUCALYPTUS, etrolizumab showed clinically meaningful efficacy for both doses relative 
to placebo for the primary endpoint:  the proportion of patients in clinical remission at 
Week 10 was 20.5% in the 100-mg dose group and 10.3% in the 300-mgLD group 
versus 0% in the placebo group (p0.004 and p0.048, respectively).  In the TNF-naïve
subgroup, clinical remission at Week 10 was observed in 43.8% of patients in the 
100-mg etrolizumab group versus 0% of patients in the placebo group; clinical remission 
was observed 25% of patients in the 300-mgLD group.


Etrolizumab—F. Hoffmann-La Roche Ltd
31/Protocol CA40192, Version 4
Favorable safety and efficacy data were observed in the Phase II EUCALYPTUS study 
and in the OLE study (SPRUCE).  Overall, etrolizumab showed compelling efficacy 
compared with placebo and there were no clinically significant safety signals.  
Etrolizumab is currently being studied in a global Phase III program in patients with 
moderate to severely active CD and UC.
An analysis of the data from completed adult Phase III studies in moderately to severely 
active UC (GA28948, GA28949, GA28950, GA29102, and GA29103) demonstrated
that etrolizumab did not appear to consistently provide benefit over placebo and also did 
not provide benefit over adalimumab or infliximab. This new safety information does 
not change the overall benefit-risk ratio for etrolizumab.  
Etrolizumab is a gut-selective anti-trafficking agent and does not bind to 41 (target for 
natalizumab), which regulates trafficking to both mucosal and non-mucosal tissues, 
including the CNS.  Although natalizumab has been associated with an increased risk of 
PML, no events of PML have been reported with etrolizumab use in clinical studies to 
date.
Preliminary expression studies of the pharmacological target for etrolizumab, the integrin 
7 receptor, on gut CD4and CD8T cells isolated from resections of patients with UC 
and patients with CD suggests that expression levels are similar between both diseases. 
The reported efficacy of vedolizumab, an anti-47 MAb, in CD demonstrates a role for 
47 in the pathobiology of this disease (Sandborn et al. 2013) and suggests that 
etrolizumab may be efficacious. In addition, because E7expression is reportedly 
elevated in patients with CD (Elewaut et al. 1998; Oshitani et al. 2003) with an observed 
increase in expression from distal to proximal bowel, the dual mechanism of action of
etrolizumab may bring enhanced efficacy in CD without generalized immunosuppression 
compared with available anti-integrin and anti-TNF therapies. 
Considering the significant clinical and non-clinical data generated to date for 
etrolizumab, there is a strong rationale and a positive benefit-risk assessment for 
studying etrolizumab, supported by: 

Studies of an anti-47 MAb, vedolizumab, approved for the treatment of patients 
with moderate to severe CD or moderate to severe UC

Completed Phase II studies with etrolizumab in UC demonstrating clinically 
meaningful benefit, as well as a full characterization of the PK/PD profile in UC and, 
importantly, an acceptable safety profile in previous etrolizumab studies 

Data that implicate 47 receptors in the pathobiology of CD with the possibility that 
inhibition of the E7/E-cadherin interaction by etrolizumab could bring enhanced 
efficacy 

An acceptable safety profile in the ongoing clinical development program, and a 
carefully designed Phase III UC and CD program with robust safety monitoring


Etrolizumab—F. Hoffmann-La Roche Ltd
32/Protocol CA40192, Version 4
Refer to the most recent Etrolizumab Investigator’s Brochure for additional details on 
clinical and nonclinical studies.
Patient safety will be monitored throughout the study via an internal safety monitoring 
board and periodic assessments of vital signs, safety laboratory assessments, 
neurological exams, and continuous review of adverse events.
Despite the lack of theoretical or experimental evidence for the specific role of 7 
integrins in contributing to a risk for PML, since there is a risk of PML associated with 
non-selective anti-integrins, extensive risk monitoring procedures will be still in place in 
this study as the safety database continues to grow (see Section 5.1.1.1.1).
Patients who experience a clinical relapse in their UC or CD status will have the option 
to receive rescue therapy during the study (see Section 4.4.2.2).
To minimize risk pertaining to injection reactions, all SC injections of etrolizumab in this 
study will be administered to patients in the clinic or at home or another suitable location
by a trained nursing professional, with at least a 1-hour observation period after dosing.
Patients will be regularly assessed by the treating physician to ensure ongoing safety. 
Since this is the first study of etrolizumab in a pediatric population, the risk and benefit in
the pediatric population is unknown.
2.
OBJECTIVES AND ENDPOINTS
This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab 
in pediatric patients of 4 to 18 years of age with moderate to severe UC or with 
moderate to severe CD.  
This study will consist of multiple phases; a randomized treatment phase, followed by an 
OLE phase, and then a PML-monitoring phase. The objective of the 24week 
randomized treatment phase is to evaluate the pharmacokinetics, pharmacodynamics, 
safety, and tolerability of etrolizumab in pediatric patients from 4 to 18 years of age with 
moderately to severe UC or moderate to severe CD. The objective of the 312week
(6-year) OLE phase is to assess the long-term safety and efficacy of etrolizumab in 
pediatric patients from the randomized treatment phase.  The objective of the 104week 
PML safety-monitoring phase (that includes the 12-week safety follow-up period after 
completion or early discontinuation from the OLE) is to assess safety with focus on the 
occurrence of PML in patients who are no longer on etrolizumab.  
Specific objectives and corresponding endpoints for the study are outlined below.


Etrolizumab—F. Hoffmann-La Roche Ltd
33/Protocol CA40192, Version 4
Table 1
Objectives and Corresponding Endpoints for the Randomized 
Treatment Phase
Primary Objective
Corresponding Endpoints

To evaluate the pharmacokinetics and 
pharmacodynamics of etrolizumab in a 
pediatric IBD patient population

PK parameters: Cmax, AUCtau, t1/2, Ctrough

PD parameters:  7 receptor occupancy by flow 
cytometry on peripheral blood lymphocytes
Safety Objective
Corresponding Endpoints

To evaluate the overall safety and 
tolerability of etrolizumab in pediatric 
population

Incidence and severity of infection-related 
adverse events

Incidence of immunogenic responses (ADAs)

Incidence and severity of hypersensitivity 
reaction events
Exploratory Objectives
Corresponding Endpoints

To evaluate additional 
pharmacodynamic biomarkers of 
etrolizumab

To evaluate clinical disease biomarkers 
with etrolizumab treatment

To evaluate the clinical efficacy of 
etrolizumab

Changes in serum MAdCAM-1

Changes in serum CRP and fecal calprotectin

Clinical response at Week 16, as assessed by 
the PUCAI (UC) and PCDAI (CD)
ADAanti-drug antibody; AUCtauarea under the concentrationtime curve within a dosing 
interval; CDCrohn's disease; Cmaxmaximum concentration observed; CRPC-reactive 
protein; Ctroughsteady-state concentration at the end of a dosing interval; MAdCAM-1mucosal 
vascular addressin cell adhesion molecule-1; PDpharmacodynamic; PKpharmacokinetic; 
PCDAIPediatric Crohn's Disease Activity Index; PUCAIPediatric Ulcerative Colitis Activity 
Index; t1/2elimination half-life. 
Table 2
Objectives and Corresponding Endpoints for the Open-label
Extension Phase
Safety Objective
Corresponding Endpoints

To evaluate long-term safety of 
etrolizumab in pediatric population

Incidence and severity of infection-related adverse 
events

Incidence and severity of malignancies 

Incidence of ADAs to etrolizumab

Incidence and severity of hypersensitivity reactions
Efficacy Objective
Corresponding Endpoint

To evaluate long term efficacy of 
etrolizumab in pediatric population

Clinical response at Week 132, as assessed by the 
PUCAI (UC) and PCDAI (CD)
ADAanti-drug antibody; CDCrohn's disease; OLEopen-label extension; PCDAIPediatric 
Crohn's Disease Activity Index; PUCAIPediatric Ulcerative Colitis Activity Index; 
UCulcerative colitis.


Etrolizumab—F. Hoffmann-La Roche Ltd
34/Protocol CA40192, Version 4
Table 3
Objectives and Corresponding Endpoints for the Progressive 
Multifocal Leukoencephalopathy Monitoring Phase
Safety Objective
Corresponding Endpoint

Post-trial safety surveillance with 
focus on PML monitoring in patients 
who have stopped treatment  

Occurrence of confirmed PML events
PMLprogressive multifocal leukoencephalopathy.
3.
STUDY DESIGN
3.1
DESCRIPTION OF THE STUDY
This pediatric PK/PD study consists of multiple phases.  The randomized treatment 
phase is an open-label, randomized phase in which etrolizumab is administered to 
patients on the basis of body weight (mg/kg); randomization will be stratified by weight 
(40 kg, 40 kg).  Patients will be randomized in a 1:1 ratio to receive either 
high-frequency etrolizumab once every 4 weeks (Q4W) or low-frequency etrolizumab 
once every 8 weeks (Q8W).  The high-frequency dose of 1.5 mg/kg etrolizumab will be 
administered Q4W (Weeks 0, 4, 8, and 12).  The low-frequency dose of 3.0 mg/kg 
etrolizumab will be administered Q8W (Weeks 0 and 8).  
After the 24week randomized treatment phase (which includes a 16week treatment 
period and an 8week safety follow-up period), patients will then have the option to 
participate in the 312week OLE phase (treatment with etrolizumab 1.5 mg/kg will be 
administered Q4W).  All patients who participate in the 24week randomized treatment 
phase and the 312week OLE phase will enter the 12week safety follow-up period
(see Appendix 1d; no etrolizumab treatment) and will complete the safety surveillance 
PML-monitoring phase (see Appendix 1e; no etrolizumab treatment for a total of 
104 weeks).  All patients who choose not to enter the OLE phase after the 24week 
randomized treatment phase will enter the 104-week PML monitoring phase. 
Patients can enter the OLE phase after completion of the 24week randomized 
treatment phase. If the last visit of the randomized treatment phase and Day 1 of the 
OLE phase occur on the same day, the assessments from the randomized treatment 
phase should be completed.  The assessments from the randomized treatment phase 
can apply to the OLE assessments (i.e., the same assessments should not be repeated 
for the OLE). 
The 104week PML monitoring phase will consist of telephone calls approximately every
6 months (see Appendix 7) with administration of the PML Subjective Checklist.  If there 
are any signs or symptoms suggestive of PML identified on this subjective checklist 
during the telephone call, the patient will be asked to come into the clinic for a neurologic 
examination.  The PML Algorithm (see Appendix 8) will be followed for any suspected 


Etrolizumab—F. Hoffmann-La Roche Ltd
35/Protocol CA40192, Version 4
case of PML, and any confirmed case of PML will be reported as a serious adverse 
event (see Section 5.4.2).
Patients who experience clinically significant worsening in their UC or CD status during 
the study can receive rescue therapy based on current standard of care.  Patients can 
receive rescue therapy at any time during the study, including the treatment phase, 
safety follow-up phase, OLE phase and PML monitoring phase. 
Approximately 24 pediatric patients from 4 to 18 years of age with moderate to severe 
UC or with moderate to severe CD will be enrolled to target at least 12 patients with 
evaluable PK profiles.  At least 4 patients from 4 years to 12 years of age should be 
enrolled, which is a study obligation according to the health authority requirement.  If PK 
and PD samples are missing, patients will be replaced at the discretion of the sponsor.
Every effort should be made to collect all PK and PD samples.  
Patients who initially failed screening may be rescreened twice at the discretion of the 
investigator.
If a patient fails any laboratory inclusion/exclusion criteria at screening, the investigator 
may repeat the test twice within the screening period. If the patient fails the laboratory 
criteria for a third time they will be considered a screen failure. It will not be considered 
a re-screening if blood samples have to be redrawn due to sample handling problems, 
breakage, or sample integrity. This multi-center study will be conducted at global sites.
The study design schemas are presented in Figure 1, Figure 2, and Figure 3.  
A schedule of activities is provided in Appendix 1.


Etrolizumab—F. Hoffmann-La Roche Ltd
36/Protocol CA40192, Version 4
Figure 1
Study Schema:  Randomized Treatment Phase (Treatment Period 
and Safety Followup Period)
CDCrohn’s disease; OLE open-label extension; Q4W every 4 weeks; Q8W every 8 weeks; 
UCulcerative colitis.
Notes:  Etrolizumab dose: 1.5 mg/kg Q4W or 3 mg/kg Q8W SC injection of 0.01 mL per kg of 
patient weight.
Rescue therapy prescribed based on the discretion of the investigator and disease flare, 
can include methotrexate, corticosteroids, immunomodulators, and excludes anti-TNFs, 
vedolizumab, and other biologic agents (see Section 4.4.2.2). Based on the patients 
disease status and physicians care practices the patient can be withdrawn from the 
study at any time to receive excluded therapy.  


Etrolizumab—F. Hoffmann-La Roche Ltd
37/Protocol CA40192, Version 4
Figure 2
Study Schema:  Open-label Extension Phase
Q4W every 4 weeks; SCsubcutaneous.
Figure 3
Study Schema:  Progressive Multifocal Leukoencephalopathy
Monitoring Phase
OLE open-label extension; PMLprogressive multifocal leukoencephalopathy.


Etrolizumab—F. Hoffmann-La Roche Ltd
38/Protocol CA40192, Version 4
3.1.1
Safety Monitoring Committee
The Sponsor’s Safety Monitoring Committee will assess safety on an ongoing basis.  
The Committee’s evaluations will include, but are not limited to, adverse events, serious 
adverse events, and laboratory abnormalities.  This committee will include a medical 
monitor, drug safety scientist, and biostatistician from the Sponsor.  The Safety 
Monitoring Committee may request that additional Sponsor scientists (e.g., PK or clinical 
scientists) participate in data analysis. 
3.2
END OF STUDY AND LENGTH OF STUDY
The end of this study is defined as the date when the last patient, last visit (LPLV) occurs 
or the date at which the last data point required for PK/PD or statistical analysis or safety 
follow-up is received from the last patient, whichever occurs later.  The end of the study 
is expected to occur 108 months after the last patient is enrolled. The total length of the 
study, from screening of the first patient to the end of the study, is expected to be 
approximately 9 years.
The randomized treatment phase will continue for 24 weeks (includes a 16week 
treatment period and an 8week safety follow-up period) after the last patient is enrolled 
into the study or until the Sponsor decides to terminate the study, whichever is earlier.  
Patients who withdraw from the treatment period should complete the 8-week safety 
follow-up period.  All patients will enter the 104week extended PML monitoring phase.
The OLE phase will continue for approximately 6 years after the last patient is enrolled 
into the study or until the Sponsor decides to terminate the study, whichever is earlier.
The PML monitoring phase will last 104 weeks for patients who enter, either from the 
randomized treatment phase or the OLE phase (includes 12week safety follow up 
period after completion or early discontinuation from OLE). 
The total length of the study, from screening of the first patient to the end of the study, is 
expected to be approximately 5 years.
The total length of the study, from screening of the first patient to the end of the study, is 
expected to be approximately 9 years.
3.3
RATIONALE FOR STUDY DESIGN
3.3.1
Rationale for Patient Population
Etrolizumab will be studied in children between 4 and 11 years of age and adolescents 
from 12 to 18 years of age. Children younger than 4 years of age will not be studied on 
the grounds that studies would be impossible or highly impractical due to the small 
number of patients in this age group and because the specific medicinal product has the 
potential to be unsafe in this age range of the pediatric population. 


Etrolizumab—F. Hoffmann-La Roche Ltd
39/Protocol CA40192, Version 4
In the United States, the incidence of UC in children younger than 4 years of age is very 
low, with the annual incidence in this age group ranging between 0.20.7 per 100,000 
and prevalence ranging between 1.12.3 per 100,000 (Herrinton et al. 2008; Abramson 
et al. 2010; Malaty et al. 2010). Similarly, the incidence of CD in the United States in 
children younger than 4 years of age is very low and presentation rarely occurs before 
4 years of age (de Greef et al. 2013). Because of the small number of patients with UC 
and CD in children 04 years of age, it is impossible or highly impracticable to conduct a
study in this age population. In children approximately >6 years of age, the functional 
development of the immune system and the GI tract is similar to that of adults (Holladay 
and Smialowicz 2000). 
The nonclinical safety strategy supporting etrolizumab clinical development in children
417 years of age takes into consideration the age of animals in the repeat-dose toxicity
studies, as well as the planned assessment of the F1 generation in the proposed
prenatal/postnatal developmental study. The male animals included in the 12and 
26-week repeat-dose toxicity studies in cynomolgus monkeys were 24.2 years of age at 
study initiation (comparable to approximately 817 years of age in humans, with a 
conversion factor of 4) and were sexually immature or peripubertal as assessed by 
microscopic evaluation of relevant reproductive tract tissues at the end of dosing in both 
studies. 
The female animals in the 12-week study were 2.33.3 years of age at study initiation 
(comparable to approximately 913 years of age in humans).  Although the definitive 
maturity for females was not specifically captured in the microscopic evaluation of 
reproductive tissues in this study, the animals were likely peripubertal based on their age 
range. The female animals in the 26-week study were of 3.24.2 years of age at study 
initiation (comparable to approximately 1317 years of age in humans) and did 
demonstrate sexual maturity at the end of the 6-month dosing phase as assessed by 
microscopic evaluation of relevant reproductive tract tissues. 
No findings attributed to etrolizumab were identified in male and female reproductive 
tissues in these studies, as assessed by organ weights and macroscopic and 
microscopic evaluation. In the 26week toxicity study in mice, animals were 67 weeks 
of age at study initiation and should have reached puberty before the end of study 
(Beckman and Feuston 2003; Marty et al. 2003). No drug-related effects were found in 
male or female reproductive tissues following etrolizumab administration, as assessed 
by organ weights and macroscopic and microscopic evaluation.
The pharmacokinetics of monoclonal antibodies in pediatric patients could be different 
from adults due to the difference in catabolic enzymes, changes in body composition, 
elimination in organs, receptor-mediated endocytosis and target receptor expression. 
Etrolizumab was cleared partially through the target-mediated drug disposition.
The target receptor expression in pediatrics may be different from 
adults. The differences lead to changes in the volume of distribution, clearance, and 


Etrolizumab—F. Hoffmann-La Roche Ltd
40/Protocol CA40192, Version 4
absorption of monoclonal antibody. Due to the complexity of the contributors involved, 
the direction and extent of the differences in pediatric population are not always readily 
predictable. The results obtained from this Phase I PK/PD study in pediatrics will 
provide a solid rationale for a proper dosing adjustment for pediatric population.
3.3.2
Rationale for Etrolizumab Dose and Schedule
Two dosing regimens are selected in this pediatric PK/PD study. One is 1.5 mg/kg every 
4 weeks, dosed on Week 0, 4, 8, and 12, the other is 3 mg/kg every 8 weeks, dosed on 
Weeks 0 and 8. The rationale of the dose selection for this pediatric study is to allow 
evaluation of full PK and PD profiles in a pediatric population and to understand the 
kinetics at both linear and nonlinear concentration ranges. Two doses will allow the 
dose proportionality to be evaluated in a pediatric population and longer dosing interval 
helps to evaluate PK and PD profiles within the nonlinear concentration range. 
The PK and PD (β7 receptor occupancy [RO]) profiles following SC administration of 
1.5 mg/kg Q4W and 3 mg/kg Q8W were simulated by extrapolating from an adult 
population PK (PopPK)/PD model. The simulated median RO profile suggested that RO 
was fully saturated within the dosing interval across all age groups following 1.5 mg/kg 
Q4W.  The median RO following 3 mg/kg Q8W was fully saturated most of time within 
the dosing interval for patients with body weight higher than 70 kg. For patients with a
body weight 30 kg, the duration of maximum RO was about half of the dosing interval.
The simulated median Cmax and AUCfrom patients with a body weight of 100 kg were 
21.4 µg /mL and 534 µg day/mL following 3 mg/kg Q8W. The safety of these proposed 
dosing regimens in pediatric population is well supported by nonclinical safety data. 
At the no-observed-adverse-effect-level (NOAEL) dose of 50 mg/kg SC 27 doses in 
cynomolgus monkey given every week for 26 weeks (the highest dose tested), the 
steady-state Cmax and AUC183-190 were 1250 µg/mL and 9310 µg day/mL, respectively. 
On the basis of the steady state Cmax or systemic exposure (AUC), the NOAEL dose in 
cynomolgus monkeys provides safety factors of 58- or 17-fold, respectively, for the 
highest proposed dose of 3 mg/kg Q8W.  Compared to the highest dose tested in 
humans (an LD of 420 mg SC at Week 1, and 300 mg SC at Weeks 2, 4, and 8), the 
safety margins for the dose of 3 mg/kg Q8W are approximately 2fold for both Cmax
and AUC.
3.3.3
Rationale for PK Sampling Schedule
The sampling schedule that follows the first and last dose of etrolizumab is designed to 
provide sufficient data to define the critical PK and PD parameters and to understand the 
absorption, distribution, and elimination of this drug in a pediatric IBD population, 
including time to maximum observed concentration (tmax), clearance, and elimination
half-life (t1/2).


Etrolizumab—F. Hoffmann-La Roche Ltd
41/Protocol CA40192, Version 4
Considering blood draw restrictions in the pediatric population, optimized blood sampling
was planned to allow determination of etrolizumab PK parameters such as 
AUC(following the last dose), Cmax (following the first and last doses), steady-state 
concentration at the end of a dosing interval (i.e., just prior to next drug administration) 
(Ctrough) and half-life (t1/2) with minimal number of samples necessary.  Cmax estimates will 
be based on a single time point after the first and last dose where the maximum 
concentrations are expected based on the adult PK data. PK time points have been
aligned with the proposal for the European Medicines Agency (EMA) health authority.
3.3.4
Rationale for Biomarker Assessments
Pharmacodynamic biomarkers
Pharmacodynamic biomarkers, including β7 receptors on peripheral gut homing 
leucocytes serum and soluble MAdCAM-1, will be measured to assess the target 
engagement and pharmacological effect of etrolizumab and to understand if the PK/PD 
relationship between etrolizumab exposure and receptor occupancy of the β7 expressing 
cells in the blood (and potential variability) observed in the adult UC patients are 
consistent with the pediatric patients with UC or CD. This will help to identify the serum 
concentration required for maintaining receptor occupancy in the pediatric population
and to support the dose selection for Phase III pediatric clinical trial. PD sample time 
points have been aligned with the proposal for the EMA health authority.
Inflammatory biomarkers
All patients enrolled in the study will have fecal calprotectin and serum C-reactive protein
(CRP) samples collected at the baseline (predose) and over the study period to assess 
the effect of etrolizumab treatment in reducing levels of inflammatory biomarkers.
Associations between exposure and these inflammatory biomarkers may also be 
explored. 
4.
MATERIALS AND METHODS
4.1
PATIENTS
A minimum of 12 patients with UC and CD from 4 years to 18 years of age will be 
enrolled in the study. There will be at least 4 children from 4 years to 12 years of age
with evaluable PK profiles, which is a study obligation according to the health authority 
requirement.
4.1.1
Inclusion Criteria
Patients must meet the following criteria for study entry:

Signed Informed Consent Form by parent or legal guardian

Age of 4 years to 18 years at the time of signing the Informed Consent Form

Ability to comply with the study protocol, in the investigator’s judgment

Weight of 13 kg or more


Etrolizumab—F. Hoffmann-La Roche Ltd
42/Protocol CA40192, Version 4

Diagnosis of UC or CD confirmed by biopsy and established for 3 months 
(i.e., after first diagnosis by a physician according to American College of 
Gastroenterology [ACG] guidelines) prior to screening

Inadequate response, loss of response or intolerance to prior immunosuppressants 
and/or corticosteroid treatment and/or anti-TNF therapy

For patients with UC: moderately to severely active UC as determined by an MCS of 
612 with an endoscopic subscore 2 (within the last 12 months prior to screening)
and a rectal bleeding subscore 1

For patients with CD: moderately to severely active CD as determined by a Pediatric 
Crohn’s Disease Activity Index (PCDAI) score of 30 at baseline 

Must meet the following surveillance colonoscopy requirements:
–
Document evidence of surveillance for dysplasia every 1 to 2 years, beginning 
approximately 7 to 10 years after their initial diagnosis

For postpubertal females of childbearing potential:  agreement to remain abstinent 
(refrain from heterosexual intercourse) or use acceptable contraceptive methods 
during the treatment period and for at least 24 weeks after the last dose of 
etrolizumab.
A female is considered to be of childbearing potential if she is postmenarcheal, 
has not reached a postmenopausal state (12 continuous months of 
amenorrhea with no identified cause other than menopause), and has not 
undergone surgical sterilization (removal of ovaries and/or uterus).
Examples of acceptable contraceptive methods include bilateral tubal ligation, 
male sterilization, combined oral contraceptive pill or transdermal patch, 
spermicide and barrier [condoms], intrauterine device, implants for 
contraception, injections for contraception [with prolonged release], hormonal 
vaginal device (see Appendix 6).
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.

For male patients:  agreement to remain abstinent (refrain from heterosexual 
intercourse) or use contraceptive measures, and agreement to refrain from donating 
sperm, as defined below:
With female partners of childbearing potential or pregnant female partners, men 
must remain abstinent or use a condom during the treatment period and for at 
least 24 weeks after the last dose of study drug to avoid exposing the embryo 
to study drug.  Men must refrain from donating sperm during this same period. 
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.


Etrolizumab—F. Hoffmann-La Roche Ltd
43/Protocol CA40192, Version 4
4.1.2
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
4.1.2.1
Exclusion Criteria Related to Inflammatory Bowel Disease

Prior extensive colonic resection, subtotal or total colectomy, or planned surgery 

Past or present ileostomy or colostomy

Diagnosis of indeterminate colitis

Suspicion of ischemic colitis, radiation colitis, or microscopic colitis

Diagnosis of toxic megacolon within 12 months of initial screening visit

Abdominal abscess

A history or current evidence of colonic mucosal dysplasia

Patients with fixed symptomatic stenosis of the intestine

Patients with history or evidence of adenomatous colonic polyps that have not been 
removed.

Patients who are not up to date on vaccinations per the local vaccine schedule will 
be excluded.
4.1.2.2
Exclusion Criteria Related to Ulcerative Colitis

Severe extensive colitis per investigator judgment that colectomy is imminent OR 
the patient has two of the following five symptoms at screening or baseline visit:
–
6 bowel movements daily with obvious blood
–
Abdominal examination worrisome for imminent surgery
–
Persistent fever
–
Tachycardia
–
Anemia (hemoglobin 8 g/dL)
4.1.2.3
Exclusion Criteria Related to Crohn’s Disease

Sinus tract with evidence for infection (e.g., purulent discharge) in the clinical 
judgment of the investigator

Short-bowel syndrome

Evidence of abdominal or perianal abscess

Expected to require surgery to manage CD-related complications during the study
4.1.2.4
Exclusion Criteria Related to Prior or Concomitant Therapy

Any prior treatment with anti-integrin agents (including natalizumab, vedolizumab, 
and efalizumab)

Any prior treatment with ustekinumab

Any prior treatment with anti-adhesion molecules (e.g., anti-MAdCAM-1)

Any prior treatment with rituximab


Etrolizumab—F. Hoffmann-La Roche Ltd
44/Protocol CA40192, Version 4

Use of IV steroids within 30 days prior to screening with the exception of a single 
administration of IV steroid

Use of agents that deplete B or T cells (e.g., alemtuzumab or visilizumab) within 
12 months prior to Day 1, with the exception of AZA and 6-MP

Use of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 
4 weeks prior to Day 1

Use of other biologics (e.g., anti-TNF) within 8 weeks before dosing, unless drug 
level is below detectability before completion of the 8-week interval

Chronic nonsteroidal anti-inflammatory drug (NSAID) use (Note: occasional use of 
NSAIDs and acetaminophen [e.g., headache, arthritis, myalgias, or menstrual 
cramps] and aspirin up to 325 mg daily is permitted.)

Patients who are currently using anticoagulants, including but not limited to warfarin, 
heparin, enoxaparin, dabigatran, apixaban, rivaroxaban.  (Note that antiplatelet 
agents, such as aspirin up to 325 mg daily or clopidogrel, are permitted.)

Apheresis (i.e., Adacolumnapheresis) within 2 weeks prior to Day 1

Received any investigational treatment including investigational vaccines within 
12 weeks prior to Day 1 of the study or 5 half-lives of the investigational product, 
whichever is greater

History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to 
chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or 
hypersensitivity to etrolizumab (active drug substance) or any of the excipients 
(Lhistidine, L-arginine, succinic acid, polysorbate 20)
4.1.2.5
Exclusion Criteria Related to General Safety

Pregnant or lactating

Lack of peripheral venous access

Congenital or acquired immune deficiency 

Hospitalized (other than for elective reasons) during the screening period

Inability to comply with study protocol, in the opinion of the investigator

Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart 
failure New York Heart Association [NYHA] Class III/IV), pulmonary, renal, hepatic, 
endocrine, or GI disorders (excluding UC and CD)

Neurological conditions or diseases that may interfere with monitoring for PML

History of demyelinating disease

Clinically significant abnormalities on the screening PML Subjective Checklist

History of major neurological disorders, including stroke, multiple sclerosis, brain 
tumor, neurodegenerative disease, or poorly controlled epilepsy

History of alcohol, drug, or chemical abuse 6 months prior to screening

Conditions other than UC or CD that could require treatment with 10 mg/day of 
prednisone (or equivalent) during the course of the study


Etrolizumab—F. Hoffmann-La Roche Ltd
45/Protocol CA40192, Version 4

Presence of metal in the body that could pose a hazard during any potential 
scanning in patients for whom a magnetic resonance imaging (MRI) scan is 
considered unsafe

History of cancer, including hematologic malignancy, solid tumors, and carcinoma in 
situ, within 5 years before screening with the following caveats:
–
Local basal or squamous cell carcinoma of the skin that has been excised and 
is considered cured is not exclusionary.
–
A history of chronic myelogenous leukemia, hairy cell leukemia, melanoma, 
renal cell carcinoma, or Kaposi sarcoma is exclusionary, irrespective of the 
duration of time before screening.
–
History of a cervical smear indicating the presence of adenocarcinoma in situ 
(AIS), high-grade squamous intraepithelial lesions (HSIL), or cervical 
intraepithelial neoplasia (CIN) of Grade 1 is exclusionary, irrespective of the 
duration of time before screening.
4.1.2.6
Exclusion Criteria Related to Infection Risk

Congenital or acquired immune deficiency

Patients must undergo screening for HIV and test positive for preliminary and 
confirmatory tests

Positive hepatitis C virus (HCV) antibody test result, unless the patient (1) has 
undetectable HCV RNA levels for 6 months after completing a successful course of 
HCV anti-viral treatment and an undetectable HCV RNA at screening or (2) has a 
known history of HCV antibody positivity with a history of undetectable HCV RNA 
and undetectable HCV RNA at screening in the absence of history of HCV anti-viral 
treatment.

Patients must undergo screening for hepatitis B virus (HBV).  This includes testing 
for HBsAg (HBV surface antigen), anti-HBc total (HBV core antibody total), and HBV 
DNA (patients who test negative for these tests are eligible for this study):
–
Patients who test positive for surface antigen (HBsAg +) are not eligible for this 
study, regardless of the results of other hepatitis B tests.
–
Patients who test positive only for core antibody (anti-HBc +) must undergo 
further testing for hepatitis B DNA (HBV DNA test).
–
If the HBV DNA test is positive, the patient is not eligible for this study.
–
In the event the HBV DNA test cannot be performed, the patient is not eligible 
for this study.
–
If the HBV DNA test is negative, the patient is eligible for this study.  These 
patients will undergo periodic monitoring for HBV DNA during the study.

Positive stool test result for ova or parasites or positive stool culture for pathogens 
at time of screening


Etrolizumab—F. Hoffmann-La Roche Ltd
46/Protocol CA40192, Version 4

Evidence of or treatment for Clostridium difficile (as assessed by C. difficile toxin 
testing) within 60 days prior to Day 1or other intestinal pathogens (as assessed by 
stool culture and ova and parasite evaluation) within 30 days prior to Day 1

Evidence of or treatment for clinically significant cytomegalovirus (CMV) colitis 
(based on the investigator’s judgment) within 60 days prior to Day 1.  Laboratory 
confirmation of CMV from colon biopsy sample is required during screening 
evaluation only if clinical suspicion is high and to determine the need for CMV 
treatment

History of active or latent treated TB, regardless of treatment history)
–
Patients with a history of active or latent TB (based on a positive screening assay, 
either purified protein derivative [PPD] skin test or QuantiFERON-TB Gold test, see 
below) are not eligible for this study.
–
Patients with a chest X-ray (posteroanterior and lateral) within 3 months of 
Day 1 suspicious for pulmonary TB are not eligible for this study.

Suspicion of active TB on chest radiograph (X-ray, posteroanterior and lateral) taken 
within 3 months of randomization

History of recurrent opportunistic infections and/or history of severe disseminated 
viral infections (e.g., herpes)

Opportunistic infection within 3 months before screening

Any current or recent signs or symptoms (within 4 weeks before screening and 
during screening) of infection, except for the following:
–
Minor infections (e.g., common cold) that have, in the investigator’s judgment, 
completely resolved prior to Day 1
–
Fungal infections of the nail beds
–
Oral or vaginal candidiasis that has resolved with or without treatment prior to 
Day 1

Any major episode of infection requiring treatment with IV antibiotics within 8 weeks 
prior to screening or oral antibiotics within 4 weeks prior to screening
–
Treatment with antibiotics as adjunctive therapy for UC/CD in the absence of 
documented infection is not exclusionary.

Received a live attenuated vaccine within 4 weeks prior to Day 1

History of organ transplant
4.1.2.7
Exclusion Criteria Related to Laboratory Values (at Screening)

Serum creatinine 1.5 times upper limit of normal (ULN)

ALT or AST 3 ULN, or alkaline phosphatase 3 ULN, or total bilirubin 2.5 ULN 
(unconjugated hyperbilirubinemia that is associated with known Gilbert's syndrome
is not an exclusion criterion)

In patients with diabetes: glycosylated hemoglobin (HbA1c) 8.0%

Platelet count 100,000/mL


Etrolizumab—F. Hoffmann-La Roche Ltd
47/Protocol CA40192, Version 4

Hemoglobin 8 g/dL

Absolute neutrophil count 1500/mL

Absolute lymphocyte count 500/mL
4.2
METHOD OF TREATMENT ASSIGNMENT AND BLINDING 
After written informed consent and assent have been obtained, all patients will receive a 
screening number, which will be assigned by an interactive voice/Web-based response 
system (IxRS).  Following completion of the screening period and after all patient 
eligibility requirements are confirmed, patients will be assigned a patient number 
(a different number from the screening number) on Day 1 and will undergo 
randomization in a 1:1 ratio to receive either high-frequency dose of etrolizumab once 
every 4 weeks or low-frequency dose of etrolizumab once every 8 weeks.
Randomization will be stratified by weight (40 kg, 40 kg). A permuted blocks 
randomization method will be used to obtain an approximately 1:1 ratio between the two 
treatment arms within each stratum.
This is an open-label study, and no blinding of site, patient, or Sponsor will be 
implemented.  The primary objective is estimation of PK and PD parameters which can 
be performed objectively without blinding of the dose frequency received (low vs high).  
4.3
STUDY TREATMENT AND OTHER TREATMENTS RELEVANT 
TO THE STUDY DESIGN
The investigational medicinal product (IMP) for this study is etrolizumab. All patients will 
receive etrolizumab one subcutaneous injection of 0.01 mL per kg of patient weight 
(1.5 mg/kg) Q4W or injection of 0.02 mL per kg of patient weight (3 mg/kg) Q8W.
4.3.1
Study Treatment Formulation, Packaging, and Handling
4.3.1.1
Etrolizumab
F. Hoffmann-La Roche Ltd manufactures etrolizumab drug product. Etrolizumab drug 
product is a colorless to slightly yellow solution. The drug product is a sterile and 
preservative-free liquid intended for SC administration. 
The drug product contains 150 mg/mL of etrolizumab in 200 mM L-arginine succinate, 
20 mM L-histidine, and 0.04% (w/v) polysorbate 20, pH 5.8. Etrolizumab drug product 
will be provided in single-use, 3-cc glass vials that are stoppered with 13-mm fluororesin
laminated stoppers and capped with aluminum seals with flip-off plastic caps.
For further details, see the etrolizumab (PRO145223, RO5490261) Investigator’s 
Brochure. 
Upon arrival of investigational products at the site, the pharmacist or designee should 
check them for damage and verify proper identity, quantity, integrity of seals, and 
temperature conditions, and report any deviations or product complaints to the monitor 
upon discovery.


Etrolizumab—F. Hoffmann-La Roche Ltd
48/Protocol CA40192, Version 4
The study drug must be stored according to the details on the product label.  The drug 
label indicates the storage temperature.  
Under no circumstances is the investigator to allow study medication to be used other 
than as directed by the protocol.
Details about the packaging and labeling of the study drug will be provided in the 
protocol-supporting documents that include but are not limited to the study manual and 
laboratory manual.
For further details, see the current Investigator's Brochure.
4.3.2
Study Treatment Dosage, Administration, and Compliance
4.3.2.1
Etrolizumab
The treatment regimens are summarized in Section 3.1.
Etrolizumab will be administered at the site during the randomized treatment phase.   
During the OLE phase, etrolizumab may be administered at the site.
Patients will receive treatment with etrolizumab 1.5 mg per kg patient weight SC 
Q4W weeks or 3 mg per kg patient weight SC Q8W. Injections will be administered to 
the abdomen. If the abdomen is not available for injection, the patient may receive a SC 
dose in the thigh. Each patient will receive one SC injection of 0.01 mL per kg patient 
weight or injection of 0.02 mL per kg of patient weight at each treatment visit based on 
the treatment regimen (the low or high frequency arm). 
Etrolizumab vials are stable at 2°C−8°C (36°F−46°F). Etrolizumab vials should not be 
frozen or shaken and should be protected from direct sunlight. 
Any overdose or incorrect administration of etrolizumab should be noted on the 
Study Drug Administration electronic Case Report Form (eCRF).  Adverse events 
associated with an overdose or incorrect administration of any of the study treatments 
should be recorded on the Adverse Event eCRF.
Guidelines for etrolizumab treatment interruption or discontinuation for patients who 
experience adverse events are provided in Section 5.1.
Patients will be monitored for acute hypersensitivity reactions for at least 1 hour after the 
end of the injection.  Epinephrine and parenteral diphenhydramine must be readily 
available for immediate use if required to treat a hypersensitivity reaction; site personnel 
must be able to detect and treat such reactions.
Guidelines for etrolizumab administration will be provided in supporting documents. 


Etrolizumab—F. Hoffmann-La Roche Ltd
49/Protocol CA40192, Version 4
4.3.3
Investigational Medicinal Product Accountability
All IMPs required for completion of this study (etrolizumab) will be provided by the 
Sponsor where required by local health authority regulations.  The study site will 
acknowledge receipt of IMPs using the IxRS to confirm the shipment condition and 
content.  Any damaged shipments will be replaced. 
IMPs will either be disposed of at the study site according to the study site’s institutional 
standard operating procedure or will be returned to the Sponsor with the appropriate 
documentation.  The site’s method of IMP destruction must be agreed to by the Sponsor.  
The site must obtain written authorization from the Sponsor before any IMP is destroyed, 
and IMP destruction must be documented on the appropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of 
by the study site should be recorded on the Drug Inventory Log.
4.3.4
Continued Access to Etrolizumab
The Sponsor will offer continued access to Roche IMP etrolizumab free of charge to 
eligible patients in accordance with the Roche Global Policy on Continued Access to 
Investigational Medicinal Product, as outlined below.
A patient will be eligible to receive Roche IMP etrolizumab after completing the study if 
all of the following conditions are met:

The patient has a life-threatening or severe medical condition and requires 
continued Roche IMP treatment for his or her well-being

There are no appropriate alternative treatments available to the patient

The patient and his or her doctor comply with and satisfy any legal or regulatory 
requirements that apply to them
A patient will not be eligible to receive Roche IMP etrolizumab after completing the study 
if any of the following conditions are met:

The Roche IMP is commercially marketed in the patient's country and is reasonably 
accessible to the patient (e.g., is covered by the patient's insurance or wouldn't 
otherwise create a financial hardship for the patient)

The Sponsor has discontinued development of the IMP or data suggest that the IMP 
is not effective for etrolizumab

The Sponsor has reasonable safety concerns regarding the IMP as treatment for 
etrolizumab

Provision of the Roche IMP is not permitted under the laws and regulations of the 
patient's country


Etrolizumab—F. Hoffmann-La Roche Ltd
50/Protocol CA40192, Version 4
The Roche Global Policy on Continued Access to Investigational Medicinal Product is 
available at the following Web site:
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
4.4
CONCOMITANT THERAPY
Concomitant therapy consists of any medication (e.g., prescription drugs, 
over-the-counter drugs, vaccines, topical medications, herbal or homeopathic remedies, 
nutritional supplements) used by a patient in addition to protocol-mandated treatment 
from 8 weeks prior to initiation of study drug to the study completion/discontinuation visit.  
All such medications should be reported to the investigator and recorded on the 
Concomitant Medications eCRF. The doses of these therapies do not have to be stable 
at the time of screening and during the study period. 
4.4.1
Permitted Therapy 
Patients are permitted to use the following therapies during the study:

Oral contraceptives

Hormone-replacement therapy (e.g., growth hormone therapy)

Steroids (IV, oral, or topical)

5-ASA (oral or topical) 

Immunosuppressants (i.e., AZA, 6-MP, or MTX) 
Premedication with antihistamines, antipyretics, and/or analgesics may be administered 
at the discretion of the investigator.
In general, investigators should manage a patient’s care with supportive therapies as 
clinically indicated, per local standard practice. 
4.4.1.1
Coronavirus Disease 2019 Vaccines
Treatment decisions regarding the use of coronavirus disease 2019 (COVID-19)
vaccines for patients eligible to receive them should be based on the physician’s best 
clinical judgment. Based on a review of the underlying disease biology, patient 
population, the mechanism of action of etrolizumab, and the information available to 
date on COVID-19 vaccines, it is unlikely that etrolizumab will have an impact on the 
efficacy of currently approved COVID-19 vaccines (mRNA vaccines, inactivated 
vaccines, and replication deficient adenovirus vaccines) or that these currently 
approved vaccines will impact the safety or efficacy of etrolizumab.  
COVID-19 vaccines should be documented in the CRF as concomitant medication.  
For more detailed questions or questions about specific types of COVID-19 vaccines, 
please contact the Medical Monitor.


Etrolizumab—F. Hoffmann-La Roche Ltd
51/Protocol CA40192, Version 4
4.4.2
Cautionary Therapy
4.4.2.1
Herbal Therapies
Concomitant use of herbal therapies is not recommended because their 
pharmacokinetics, safety profiles, and potential drug-drug interactions are generally 
unknown.  However, herbal therapies not intended for the treatment of UC or CD may be
used during the study at the discretion of the investigator.
4.4.2.2
Rescue Therapies
The worsening of UC or CD may result in the use of rescue medications, based on the 
discretion of the Principal investigator. 
At any time during the study, patients who have worsening of their UC or CD will be 
permitted to receive additional therapy with steroids (IV, oral, or topical).  Addition of or 
increases in doses of 5-ASA (oral or topical) and/or immunosuppressants (i.e., AZA, 
6-MP, or MTX) will also be allowed if clinically indicated by the Principal Investigator.  
Rescue therapy with anti-TNF agents or their corresponding biosimilars, cyclosporine, 
tacrolimus, sirolimus, MMF, anti-adhesion molecules, natalizumab, vedolizumab, 
ustekinumab, efalizumab, rituximab, other lymphocyte depleting agents (except AZA and 
6-MP), or other biological or investigational therapeutics will not be allowed in 
conjunction with etrolizumab because of the level of immunosuppression anticipated with 
the use of these agents.  Patients who receive such therapies are not to receive further 
study treatment or enter the open-label treatment phase, and will be required to enter 
safety follow-up period. All patients will be offered participation in the 104week PML 
monitoring phase (includes 12week safety follow-up period after completion or early 
discontinuation from OLE).
4.4.3
Prohibited Therapy
Use of the following concomitant therapies is prohibited during the 24week randomized 
treatment phase as described below:

Any investigational treatment or experimental therapy including investigational 
vaccines and biologic agents

Use of lymphocyte-depleting agents (e.g., alemtuzumab or visilizumab), except for
AZA and 6-MP

Use of cyclosporine, tacrolimus, sirolimus, or MMF

Use of natalizumab, vedolizumab, ustekinumab, or rituximab

Use of TNF inhibitors, including biosimilars

Use of anakinra or abatacept and/or other biological therapeutics

Use of other anti-adhesion molecules

Use of other biologic agents


Etrolizumab—F. Hoffmann-La Roche Ltd
52/Protocol CA40192, Version 4
4.5
STUDY ASSESSMENTS
The Schedule of Assessments to be performed during the study is provided in 
Appendix 1.  All activities must be performed and documented for each patient.  
Randomized Treatment Phase Assessments
The randomized treatment phase will consist of assessments for a 16week treatment 
period and 8week safety followup period, which are outlined below.  
Treatment Period Assessments
Patients will be assessed for the 16week treatment period at intervals specified in 
Appendix 1a.
Safety Follow-up Period Assessments
Safety follow-up will be conducted for a period of 8 weeks. Patients will be assessed for 
the safety follow-up period at intervals specified in Appendix 1b.  The visits should be 
scheduled based on the date of the last dose in the treatment phase. 
Following the safety follow-up period, patients will have the option to continue into the 
OLE phase.  If the patient chooses not to continue to receive etrolizumab treatment in 
the OLE phase, they will be offered participation in the 104week PML monitoring phase
(includes 12week safety follow up period after completion or early discontinuation 
from OLE) as specified in Appendix 1e. Patients will participate in telephone 
assessments every 6 months to assess emergence of symptoms and signs of PML.  In 
total, follow-up for the development of any signs or symptoms of PML will be conducted 
for a period of 2 years after last dose of study drug.
Patients who discontinue from the study prior to completion of the safety follow-up phase 
will be asked to return to the clinic within 30 days (7 days) after the last dose of study 
drug or last scheduled visit for an early termination visit. 
Open-Label Extension Phase Assessments
The OLE phase assessments will be conducted on patients that choose to participate in 
the OLE. Patients will be assessed at intervals specified in Appendix 1c.
PML Monitoring Phase Assessments
All patients will be offered participation in the 104-week PML monitoring phase (which 
includes 12week safety follow up period after completion or early discontinuation from 
OLE).  The Schedule of Assessments for the PML monitoring phase can be found in
Appendix 1e.


Etrolizumab—F. Hoffmann-La Roche Ltd
53/Protocol CA40192, Version 4
4.5.1
Informed Consent Forms and Screening Log
Written informed consent and minor assent for participation in the study must be 
obtained before performing any study-specific screening tests or evaluations. Informed 
Consent Forms and Assent Forms for enrolled patients and for patients who are not 
subsequently enrolled (e.g., screen failures, eligible patients who choose not to enroll) 
will be maintained at the study site.
All screening evaluations must be completed and reviewed to confirm that patients meet
all eligibility criteria before enrollment. The investigator will maintain a screening log to 
record details of all patients screened and to confirm eligibility or record reasons for
screening failure, as applicable.
4.5.2
Rescreening
If a patient does not meet all the eligibility criteria within 35 days after the original
screening visit, rescreening is permitted. Patients found to be ineligible for entry into the
study may be rescreened twice (e.g., if the patient develops additional manifestations 
of UC or CD, a worsening of existing manifestations at a later time, if patient’s clinical 
status has changed such that the abnormal laboratory value may be directly affected 
[e.g., transfusion], or if there is evidence that the central laboratory sample may have 
degraded during transport) with the exception of certain laboratory testing (described 
below). Each patient must re-consent before rescreening occurs.
Rescreening is not required for the following assessments provided the results are
available from the initial screening, and the date of the initial screening assessment was
6 weeks prior to the rescreening randomization visit.

HIV preliminary and confirmatory tests

HCV antibody test

Hepatitis B assessment (i.e., surface antigen [HBsAg] core anti-body [HBcAb], and if
required, HBV DNA)
If, in the investigator’s judgment, the patient is deemed to have been at risk of any of the
above infections (based on medical history, or geographical or social circumstance) the
patient should be rescreened with the above tests.
Patients who are classified as screen failures due to the presence of C. difficile may be
rescreened 60 days after the end of successful treatment.
As described in Section 4.5.6 if a negative TB screening test result has been 
documented within 3 months before screening or rescreen, no repeat test is required.


Etrolizumab—F. Hoffmann-La Roche Ltd
54/Protocol CA40192, Version 4
4.5.3
Medical History, Concomitant Medication, and Demographic 
Data
Medical history includes clinically significant diseases, procedures, and all medication
taken in the 4 weeks prior to screening (including prescription, over-the-counter, and
herbal/homeopathic remedies and therapies). Demographic data, including age, sex, 
whether the patient is a twin sibling and self-reported race/ethnicity, will be collected 
during screening.
4.5.4
Physical Examinations
A complete physical examination will be performed at screening and should include the
evaluation of head, eye, ear, nose, and throat and cardiovascular, dermatological,
musculoskeletal, respiratory, GI, and neurological systems, including administration of
the PML Subjective Checklist by the investigator (see Appendix 7 for PML assessment 
details and Appendix 8 for PML algorithm).
Clinically significant findings from the physical examination should be recorded as
medical history during screening.
Symptom-driven physical examinations will be performed during the randomized 
treatment phase at the indicated timepoints in the Schedule of Assessments 
(see Appendix 1). New or worsened abnormalities from screening should be recorded 
as adverse events, if appropriate.
During the physical exam, Tanner stage (Appendix 5) will be assessed to determine the 
physical development.
During the OLE phase, a limited symptom-driven physical examination, including GI will 
be conducted. 
4.5.5
Vital Signs
Vital signs will include measurements of heart rate and systolic and diastolic blood
pressure after the patient has been in a seated position for 5 minutes, which will occur at 
the indicated timepoints in the Schedule of Assessments (see Appendix 1).  Record vital 
signs before study drug administration.
Height should be measured according to the Schedule of Assessments (Appendix 1).
Weight should also be measured according to the Schedule of Assessments 
(Appendix 1).
4.5.6
Laboratory, Biomarker, and Other Biological Samples
Laboratory assessments will be performed as indicated on the Schedule of Assessments 
(see Appendix 1). All laboratory assessments will be sent to one or more central 
laboratories for analysis with the exception of CMV. If there is suspicion for clinically 
significant CMV colitis, a colonic biopsy sample should be sent for CMV evaluation, 


Etrolizumab—F. Hoffmann-La Roche Ltd
55/Protocol CA40192, Version 4
which may be conducted locally depending on local requirements for the timing of the 
test result. Urine pregnancy testing will be conducted locally.
On days of study drug administration, laboratory samples should be drawn before the
administration of study drug. Laboratory assessments will include the following:

Hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count,
absolute differential count [neutrophils, eosinophils, lymphocytes, monocytes,
basophils, other cells], mean corpuscular volume, mean corpuscular hemoglobin,
mean corpuscular hemoglobin concentration, and RBC distribution width)

Serum chemistries, including liver function tests (sodium, potassium, chloride,
bicarbonate, glucose, blood urea nitrogen, creatinine, calcium, phosphorus,
magnesium, total and direct bilirubin, total protein, albumin, alanine
aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline
phosphatase, creatine phosphokinase, and uric acid)

Urinalysis

Tuberculosis: The PPD skin test and QuantiFERON-TB Gold are acceptable 
screening assays for latent Mycobacterium TB infection.
–
A positive PPD tuberculin skin test reaction is considered 5 mm. Patients with 
a history of Bacille Calmette-Guerin (BCG) vaccination should be screened 
using the QuantiFERON-TB Gold test only.  An indeterminate 
QuantiFERON-TB Gold test should be repeated. A positive QuantiFERON-TB 
Gold test or two successive indeterminate QuantiFERON-TB Gold test results 
should be considered a positive diagnostic TB test. An indeterminate
QuantiFERON-TB Gold test followed by a negative QuantiFERON-TB Gold 
test, should be considered a negative diagnostic TB test.
–
If a negative TB screening test has been documented within 3 months of 
screening, no new test is needed.

John Cunningham virus (JCV) antibodies:  A blood sample to test for antibodies to 
JCV will be taken and stored for possible later assessment of how widespread the 
JCV infection is in the study population.  Sample testing for the presence of JCV 
antibodies is not helpful in predicting risk for PML or for evaluating neurologic 
symptoms.  The sample may be tested if there is a strong belief that this information 
will be helpful in managing a patient's condition.

CRP

C. difficile toxin assay in stool, stool culture and sensitivity testing, stool ova and 
parasites analysis

Pregnancy test: All postpubertal female patients (including those who have had a 
tubal ligation) will have a serum pregnancy test at screening. Urine pregnancy tests 
will be performed at specified subsequent visits. If a urine pregnancy test result is 
positive, it must be confirmed by a serum pregnancy test.


Etrolizumab—F. Hoffmann-La Roche Ltd
56/Protocol CA40192, Version 4

Viral serology and detection tests
–
HBV (HBsAg, total HB core antibody [anti-HBc] and HBV DNA)
–
HCV antibody
–
HCV RNA: Measurement of HCV RNA with use of the Amplicor assay is 
required when the patient has a known history of HCV antibody positivity with 
past  documentation of undetectable HCV RNA, either with or without history of 
anti-viral treatment.  Patients with newly diagnosed HCV antibody positivity are 
not eligible for this study and, therefore, do not require measurement of HCV 
RNA.
–
HIV

PK assays
–
Serum samples will be collected for determination of etrolizumab 
concentrations in all patients. Samples will be analyzed using a validated 
assay.

Fecal calprotectin testing

PD biomarker assays
–
Serum samples will be collected and qualified methods will be used to measure 
MAdCAM-1
–
Serum samples, whole blood, and stool may be assessed for additional 
exploratory biomarkers
–
Whole blood will be used for flow cytometry with qualified methods to measure 
-7 receptor occupancy

Anti-drug antibody (ADA) assays
–
Serum samples will be collected for detection and characterization of antibodies 
against etrolizumab in all patients.  Samples will be analyzed using a validated 
assay.  For ADA samples without matched PK determinations, etrolizumab 
concentrations may be measured for the purpose of helping interpret ADA data.  
ADA samples may also be utilized for exploratory PD biomarkers.

CMV testing of colonic biopsy sample: ONLY necessary if there is suspicion for 
clinically significant CMV colitis. Colon biopsy sample (to be obtained at the base of 
the ulcer) will be analyzed for histologic presence of CMV, but otherwise is not 
necessary for inclusion in the study. Analysis should be performed locally if 
possible or can be sent to a central laboratory if necessary.
Routine hematology and biochemistry tests can be used to satisfy inclusion/exclusion 
criteria if samples are collected within the 35-day window between screening and 
baseline.  If these tests are not planned hematology and biochemistry samples should 
be collected at screening and analyzed accordingly.


Etrolizumab—F. Hoffmann-La Roche Ltd
57/Protocol CA40192, Version 4
The total volume of blood loss for laboratory assessments (including all safety, PK/PD, 
and efficacy samples) does not exceed the per-visit and cumulative-visit 
recommendations of the National Institutes of Health for the expected average weights 
of the patient population.  
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.
Unless the patient gives specific consent for his or her leftover samples to be stored for 
optional exploratory research (see Section 4.5.10), biological samples will be destroyed 
when the final Clinical Study Report has been completed, with the exception of stool and 
serum samples collected for PK, PD, or immunogenicity analysis samples, which will be 
destroyed no later than 5 years after the final Clinical Study Report has been completed.
4.5.7
Chest X-Ray
A chest X-ray (posteroanterior and lateral) will be performed at screening.  If a chest 
X-ray has been documented within the previous 3 months and has shown no clinically 
significant abnormalities, no additional chest X-ray is required.
4.5.8
Electrocardiograms
Electrocardiograms (ECG) recordings will be obtained at specified timepoints, as 
outlined in the Schedule of Assessments (see Appendix 1). 
ECGs for each patient should be obtained from the same machine whenever possible. 
To minimize variability, it is important that patients be in a resting position for 
10 minutes prior to each ECG evaluation. Body position should be consistently 
maintained for each ECG evaluation to prevent changes in heart rate.
Environmental distractions (e.g., television, radio, conversation) should be avoided
during the pre-ECG resting period and during ECG recording. ECGs should be
performed prior to meals and any scheduled vital sign measurements and blood draws.
For safety monitoring purposes, the investigator or designee must review, sign, and date
all ECG tracings. Paper copies will be kept as part of the patient's permanent study file
at the site. ECG outputs will be stored at site.
4.5.9
Clinical Outcome Assessments
Clinical outcome assessments (COAs; Pediatric Ulcerative Colitis Activity Index [PUCAI] 
and PCDAI) data will be collected to help characterize the treatment profile of 
etrolizumab.  The instruments will be translated as required in the local language.
In order to ensure instrument validity and that data standards meet health authority 
requirements, the COAs completed at the sites (PUCAI and PCDAI) should be 
administered at the investigational site prior to the completion of non-COA assessments 


Etrolizumab—F. Hoffmann-La Roche Ltd
58/Protocol CA40192, Version 4
and before the patient receives any disease-status information or study drug during that 
visit. 
COA data will be collected and assessed at visits according to the Schedule of 
Assessments in Appendix 1.
The sign/symptoms items of the PUCAI and PCDAI, described below, can either be 
completed by patients/caregivers on worksheets, or collected via interview. If the data is 
collected via interview, then the question and response options should be read verbatim, 
and the patient/caregiver response recorded. 
Pediatric Ulcerative Colitis Activity Index (PUCAI)
The PUCAI quantifies the signs and symptoms of patients with UC (see Appendix 2).  
The components of the PUCAI include patient- or caregiver-reported abdominal pain, 
rectal bleeding, stool consistency, number of stools, nocturnal stools, and activity level 
on average over the past two days (Turner et al. 2007). These signs and symptoms are 
reported by patients (age ≥7 years), or caregivers of patients 7 years of age, via 
worksheets or an interview with the clinician, and the remaining components are 
completed by the physician. A numerical value is assigned to each response; responses 
are summed to a total score of 0-85, with a higher score indicating more severe disease.
Please refer to Appendix 2 for details. 
Pediatric Crohn's Disease Activity Index (PCDAI)
The PCDAI quantifies the signs and symptoms of patients with CD (see Appendix 3).  
The components of the PCDAI include patient- or caregiver-reported number of stools, 
abdominal pain, and general well-being; presence of extraintestinal manifestations; 
physical examination findings; height and weight, and hematocrit, erythrocyte 
sedimentation rate, and serum albumin over the past week (Hyams et al. 1991). 
Of these components, number of soft stools, abdominal pain, and general well-being are 
reported by patients (age ≥7 years) or caregivers of patients 7years of age and the 
remaining components are completed by the physician. A numerical value is assigned 
to each response; responses are summed to a total score of 0100, with a higher score 
indicating more severe disease Please refer to Appendix 3 for details. 
4.5.10
Optional Samples for Research Biosample Repository
4.5.10.1
Overview of the Research Biosample Repository
The Research Biosample Repository (RBR) is a centrally administered group of facilities 
used for the long-term storage of human biologic specimens, including body fluids, solid 
tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides).  The collection, 
storage, and analysis of RBR specimens will facilitate the rational design of new 
pharmaceutical agents and the development of diagnostic tests, which may allow for 
individualized drug therapy for patients in the future.


Etrolizumab—F. Hoffmann-La Roche Ltd
59/Protocol CA40192, Version 4
Specimens for the RBR will be collected from patients who give specific consent to 
participate in this optional research.  RBR specimens will be used to achieve the 
following objectives:

To study the association of biomarkers with efficacy, adverse events, or disease 
progression

To increase knowledge and understanding of disease biology

To study drug response, including drug effects and the processes of drug absorption 
and disposition
4.5.10.2
Approval by the Institutional Review Board or Ethics 
Committee
Collection and submission of biological samples to the RBR is contingent upon the 
review and approval of the exploratory research and the RBR portion of the Informed 
Consent Form by each site's Institutional Review Board or Ethics Committee (IRB/EC) 
and, if applicable, an appropriate regulatory body.  If a site has not been granted 
approval for RBR sampling, this section of the protocol (Section 4.5.10) will not be 
applicable at that site.
4.5.10.3
Sample Collection
The following samples will be stored in the RBR and used for research purposes, 
including, but not limited to, research on biomarkers related to etrolizumab or UC or CD:

Saliva sample for exploratory analysis (first visit only)
Samples that are obtained for exploratory analysis of biomarkers (listed below) but are 
not utilized or are not entirely consumed will be transferred to the RBR.
Specimen types include the following (see Appendix 1 for specific collection timepoints):

Residual Serum

Residual Stool
Potential applications of RBR samples include, but are not limited to, assays for mRNA 
expression and other biomarker(s) that predict response or toxicity to etrolizumab.
Additionally, the above samples may be sent to one or more laboratories for analysis of 
germline or somatic mutations via whole genome sequencing (WGS), whole exome 
sequencing (WES), next-generation sequencing (NGS), or other genomic analysis 
methods.
Genomics is increasingly informing researcher's understanding of disease pathobiology.  
WGS and WES provide a comprehensive characterization of the genome and exome, 
respectively, and, along with clinical data collected in this study, may increase the 
opportunity for developing new therapeutic approaches.  Data will be analyzed in the 
context of this study but will also be explored in aggregate with data from other studies.  
The availability of a larger dataset will assist in identification of important pathways, 
guiding the development of new targeted agents.


Etrolizumab—F. Hoffmann-La Roche Ltd
60/Protocol CA40192, Version 4
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.  
RBR specimens are to be stored until they are no longer needed or until they are 
exhausted.  However, the RBR storage period will be in accordance with the 
IRB/EC-approved Informed Consent Form and applicable laws (e.g., health authority 
requirements).
4.5.10.4
Confidentiality
Specimens and associated data will be labeled with a unique patient identification 
number.
Patient medical information associated with RBR specimens is confidential and may be 
disclosed to third parties only as permitted by the Informed Consent Form (or separate 
authorization for use and disclosure of personal health information) signed by the 
patient, unless permitted or required by law.
Given the complexity and exploratory nature of the analyses of RBR specimens, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by law.  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication.
Data generated from RBR specimens must be available for inspection upon request by 
representatives of national and local health authorities, and Sponsor monitors, 
representatives, and collaborators, as appropriate.
Any inventions and resulting patents, improvements, and/or know-how originating from 
the use of the RBR data will become and remain the exclusive and unburdened property 
of the Sponsor, except where agreed otherwise.
4.5.10.5
Consent to Participate in the Research Biosample Repository
The Informed Consent Form will contain a separate section that addresses participation 
in the RBR.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the RBR.  Patients will be 
told that they are free to refuse to participate and may withdraw their consent at any time 
and for any reason during the storage period.  A separate, specific signature will be 
required to document a patient's agreement to provide optional RBR specimens.  
Patients who decline to participate will not provide a separate signature.
The investigator should document whether or not the patient has given consent to 
participate and (if applicable) the date(s) of consent, by completing the RBR Research 
Sample Informed Consent eCRF.
In the event of an RBR participant's death or loss of competence, the participant's 
specimens and data will continue to be used as part of the RBR research.


Etrolizumab—F. Hoffmann-La Roche Ltd
61/Protocol CA40192, Version 4
4.5.10.6
Withdrawal from the Research Biosample Repository
Patients who give consent to provide RBR samples have the right to withdraw their 
consent at any time for any reason.  However, if RBR samples have been tested prior to 
withdrawal of consent, results from those tests will remain as part of the overall research 
data.  If a patient wishes to withdraw consent to the testing of his or her RBR samples 
during the study, the investigator must inform the Medical Monitor in writing of the 
patient's wishes through use of the appropriate RBR Patient Withdrawal Form and must 
enter the date of withdrawal on the RBR Research Sample Withdrawal of Informed 
Consent eCRF.  If a patient wishes to withdraw consent to the testing of his or her RBR 
samples after closure of the site, the investigator must inform the Sponsor by emailing 
the study number and patient number to the following email address:
global_rcr-withdrawal@roche.com
A patient's withdrawal from this study does not, by itself, constitute withdrawal of consent 
for testing of RBR samples.  Likewise, a patient's withdrawal of consent for testing of 
RBR samples does not constitute withdrawal from this study.
4.5.10.7
Monitoring and Oversight
RBR specimens will be tracked in a manner consistent with Good Clinical Practice by a 
quality-controlled, auditable, and appropriately validated laboratory information 
management system, to ensure compliance with data confidentiality as well as 
adherence to authorized use of specimens as specified in this protocol and in the 
Informed Consent Form.  Sponsor monitors and auditors will have direct access to 
appropriate parts of records relating to patient participation in the RBR for the purposes 
of verifying the data provided to the Sponsor.  The site will permit monitoring, audits, 
IRB/EC review, and health authority inspections by providing direct access to source 
data and documents related to the RBR samples.
4.6
TREATMENT, PATIENT, STUDY, AND SITE DISCONTINUATION
4.6.1
Study Treatment Discontinuation
Patients must permanently discontinue study treatment if they experience any of the 
following:

Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient’s safety if he or she continues to receive study treatment

Investigator or Sponsor determines it is in the best interest of the patient

Pregnancy

Anaphylaxis or other severe hypersensitivity reaction

Develop colonic mucosal dysplasia

Malignancy (with the exception of local and resected basal or squamous cell
carcinoma of the skin) or cervical Pap test with AIS, HSIL, or CIN of Grade 1


Etrolizumab—F. Hoffmann-La Roche Ltd
62/Protocol CA40192, Version 4

Specific serious infection (see Section 5.1.1.1 for details on serious infection):
–
Any patient who experiences a specific de novo or reactivated serious viral
infection, such as HBV, HCV, HIV, should discontinue study medication.
–
Any patient who develops life-threatening infections during the study should 
discontinue study medication.
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  
Patients will return to the clinic for an early withdrawal from treatment or treatment 
discontinuation visit after the last dose of study drug (see Appendix 1 for additional 
details).
4.6.2
Patient Discontinuation from Study
Patients have the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include, but are not limited to, the following:

Patient withdrawal of consent

Study termination or site closure

Any medical condition the investigator or Sponsor determines may jeopardize the 
patient’s safety if he or she continues in the study

The investigator or Sponsor determines it is in the best interest of the patient

Patient non-compliance, specifically defined as missing scheduled visits or 
non-adherence with background medications

Patient non-compliance, defined as failure to comply with protocol requirements as 
determined by the investigator or Sponsor
Every effort should be made to obtain information on patients who withdraw from the 
study.  The primary reason for withdrawal from the study should be documented on the 
appropriate eCRF.  If a patient requests to be withdrawn from the study, this request 
must be documented in the source documents and signed by the investigator.  Patients 
who withdraw from the study will be replaced.
4.6.3
Study Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:

The incidence or severity of adverse events in this or other studies indicates a
potential health hazard to patients

Patient enrollment is unsatisfactory
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.


Etrolizumab—F. Hoffmann-La Roche Ltd
63/Protocol CA40192, Version 4
4.6.4
Site Discontinuation
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:

Excessively slow recruitment

Poor protocol adherence

Inaccurate or incomplete data recording

Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice

No study activity (i.e., all patients have completed the study and all obligations have 
been fulfilled)
5.
ASSESSMENT OF SAFETY
5.1
SAFETY PLAN 
The safety plan for this study is designed to ensure patient safety and mitigate potential 
risks.  The principles of the safety plan include education of investigators, patients, and 
their caregivers regarding all identified and potential safety risks, specific eligibility 
criteria to screen out at-risk patients, monitoring to ensure timely identification and 
management of a safety event, and management strategy such as guidelines for treating 
an event and for withholding or discontinuing study treatment, as appropriate.  
These principles are to be applied for all safety risks in the clinical program.  
5.1.1
Potential Risks Associated with Etrolizumab
The potential and/or hypothetical risks for etrolizumab are based on its mechanism of 
action, available nonclinical and clinical data, data from other anti-integrin drugs, and 
general risks associated with biologic agents.
Investigators should always refer to the Etrolizumab Investigator's Brochure (Section 6)
for a complete summary of safety information.
Important potential risks for etrolizumab include:

Infections, in particular, serious or life-threatening infections, such as:
–
Progressive multifocal leukoencephalopathy
–
Other serious infections (e.g., gastrointestinal, opportunistic)

Hypersensitivity reactions, in particular:
–
Anaphylactic, anaphylactoid reactions 
–
Other systemic hypersensitivity reactions

Hepatic effects

Local injection-site reactions

Malignancies


Etrolizumab—F. Hoffmann-La Roche Ltd
64/Protocol CA40192, Version 4

Immunogenicity

Decreased effectiveness of immunization
5.1.1.1
Serious Infections 
5.1.1.1.1
Progressive Multifocal Leukoencephalopathy 
Background
PML is a potentially fatal neurological condition linked to reactivation of a polyomavirus 
(JCV) and active viral replication in the brain.  Cases of PML have been reported in 
patients with CD and multiple sclerosis who received concomitant treatment with the 
anti-4 integrin natalizumab and immunosuppressives.  Integrin 41, which is inhibited 
by natalizumab, is a pleiotropic integrin that is believed to facilitate T cell migration into 
the CNS.  Inhibition of integrin 41 is thought to reduce (CNS) immune surveillance 
and facilitate development of PML.
According to the U.S. Package Insert for vedolizumab, which selectively impedes 
lymphocytes trafficking into gut tissue by specifically blocking only the 47 integrin 
and not the 41 integrin, one case of PML in an ENTYVIO (vedolizumab)-treated 
patient with multiple contributory factors has been reported in the post-marketing 
setting (e.g., HIV infection with a CD4 count of 300 cells/mm3 and prior 
and concomitant immunosuppression) to date. Although unlikely, a risk of PML 
cannot be ruled out.
Etrolizumab targets cells expressing the 7 integrin (47 and E7 cells) and not 
41 cells.  Despite the lack of theoretical or experimental evidence for a specific role of 
7 integrins in leukocyte homing to the CNS and given the observation of PML risk with 
natalizumab, the Sponsor will continue to conduct extensive risk-monitoring procedures 
during this study.  There have been no cases of PML in patients treated with 
etrolizumab.
Screening, Patient Selection, and PML Education
No known interventions can reliably prevent or treat PML if it occurs; therefore, it is 
important to exclude patients with a perceived higher baseline risk for PML, such as 
patients who have received natalizumab, efalizumab, rituximab, B or T cell depleting 
agents (e.g., alemtuzumab or visilizumab), with the exception of AZA and 6-MP,
cyclosporine, tacrolimus, sirolimus, or MMF.  Patients with a history of PML or 
neurological symptoms where suspected PML has not been ruled out are not eligible for 
this study (see Section 4.1.2). 
A blood sample to test for antibodies to JCV will be taken and stored for possible later 
assessment of how widespread the JCV infection is in the study population.  Sample 
testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for 
evaluating neurologic symptoms.  The sample may be tested if there is a strong belief 
that this information will be helpful in managing a patient's condition.


Etrolizumab—F. Hoffmann-La Roche Ltd
65/Protocol CA40192, Version 4
Study site personnel and patient participants should be educated regarding the signs 
and symptoms of PML.  Patients and partners/caregivers should be issued with alert 
cards to remind them of these and to advise them to contact the investigator right away if 
they notice any new or worsening neurological abnormalities.
See Appendix 1 for details of assessments regarding PML.  
PML Monitoring
During the study, patients should be closely monitored for any signs and symptoms of 
PML via regular subjective tests employing the use of the PML Subjective Checklist to 
assess the patient’s mental and neurological status; see Appendix 7 for details of 
assessments regarding PML.
During the in-clinic visits, patients will undergo PML monitoring assessments.
If a patient has a clinically significant positive finding on the PML Subjective Checklist 
the event should be expeditiously reported to the sponsor as adverse events of special
interest or serious adverse events, as appropriate, within 24 hours (see Section 5.1.1
and Appendix 8 for the Algorithm for Evaluation of PML).  
If PML is suspected, dosing with study drug for that patient will be suspended and the 
patient should be promptly referred to a neurologist.  Following formal evaluation by a 
neurologist, if PML cannot be ruled out, the case will be referred to an expert PML 
adjudication committee for further work-up, which may include brain MRI with and 
without contrast.  If there remains any suspicion for PML, the PML adjudication 
committee may recommend performing a lumbar puncture with cerebrospinal fluid (CSF)
analysis for JCV by polymerase chain reaction (PCR).  If JCV is detected, the patient 
should be treated as a PML case and the patient should permanently discontinue study 
drug and enter safety follow-up.  
Dosing with study drug can only be resumed in patients where PML has been ruled out.  
Refer to Appendix 8 for the Algorithm for Evaluation of Progressive Multifocal 
Leukoencephalopathy.
PML Treatment
There is no known effective treatment for PML.  Plasmapheresis has been employed in 
some patients in an effort to promote clearance of a suspected causative agent 
(Tan et al. 2011).  If an event of PML occurs, subsequent management of PML will be at 
the direction of the consulting neurologist. 
Additional information for the management of this potential risk is provided in Appendix 7
(Worksheet for the PML Neurologic Examination) and Appendix 8 (Algorithm for the 
Evaluation of PML).


Etrolizumab—F. Hoffmann-La Roche Ltd
66/Protocol CA40192, Version 4
5.1.1.1.2
Other Serious Infections
Background
From an overall review of safety data from completed etrolizumab UC clinical trials, no 
other safety concerns have been identified for etrolizumab in terms of infections to date,
besides appendicitis.  Nonetheless, serious infections are a potential risk because of the 
mechanism of action of etrolizumab, which blocks trafficking of gut-selective 
lymphocytes.
Patient Selection
Patients who experienced a life-threatening infection or a de novo or reactivated serious 
viral infection, such as HBV, HCV, or HIV, are not eligible for this study 
(see Section 4.1.2).  
Patients who have an ongoing serious infection event should not receive study drug until 
the event has completely resolved and treatment with anti-infective medications has 
been completed.  Patients with hepatitis B infection who test positive only for core 
antibody (anti-HBc) and test negative for HBV DNA test are eligible for the study; 
however, these patients must undergo periodic monitoring for HBV DNA during the 
study.
Patients with active or latent TB (not including patients who have prior vaccination with 
BCG will be excluded from the study.  Any immunosuppressed patient with a strong 
suspicion of TB exposure and no prior vaccination with BCG should be considered at 
risk for having latent TB infection.
Patients at risk for TB exposure include:

Patients who have household contact with a person with active TB

Patients living in areas with high incidence of TB

Patients who frequently visit areas with high prevalence of active TB

Patients who meet these criteria should be evaluated per local practice to exclude 
latent TB.
Education, Monitoring, and Management
Patients should be monitored closely for serious infections during the study.  Patients
and their caregivers and study staff should be informed of the possibility of increased 
susceptibility to infectious pathogens.  Investigators will be encouraged to promptly 
evaluate and aggressively treat any signs and symptoms consistent with an infection.  
Patients who experience a serious infection event should not receive further study drug 
until the event has completely resolved and treatment with anti-infective medications has 
been completed.  All efforts should be made to identify the infectious agent.  Patients 
who develop life-threatening infections, including de novo or reactivated serious viral 
infection, such as HBV, HCV, HIV, during the study should discontinue study drug.


Etrolizumab—F. Hoffmann-La Roche Ltd
67/Protocol CA40192, Version 4
5.1.1.2
Hypersensitivity Reactions
Background
An overall review of safety data from completed studies in UC identified a very small 
number of hypersensitivity reactions reported in patients receiving etrolizumab, all of 
which were mild or moderate in severity. No anaphylactic, anaphylactoid, or severe 
hypersensitivity reactions have been identified for etrolizumab to date. 
Anaphylaxis and hypersensitivity reactions will be closely monitored during the study.  
Patient Selection
Patients who have a history of moderate or severe allergic or anaphylactic/anaphylactoid 
reactions to chimeric, human, or humanized antibodies, fusion proteins, or murine 
proteins or hypersensitivity to etrolizumab (active drug substance) or any of the 
excipients (L-histidine, L-arginine, succinic acid, polysorbate 20) are not eligible for this 
study. 
Education, Monitoring, and Management
After each injection administered in the treatment phase and after the first four injections 
in the OLE phase, the patient must be monitored for 60 minutes for any possible 
hypersensitivity reaction. Medicinal products for the treatment of hypersensitivity 
reactions (e.g., epinephrine, antihistamines, and glucocorticoids) must be available for 
immediate use in the clinic for the event of an allergic reaction during administration of 
the study drug.  Resuscitation equipment should also be available.  
Patients and their caregivers should be instructed to recognize the symptoms of any 
anaphylactic, anaphylactoid, or hypersensitivity reaction and to contact a health care 
provider (HCP) or seek immediate care in case of any such symptoms.  Patients are to 
be provided with alert cards to remind them and a caregiver or partner of the above.
Please see Appendix 9 for diagnosing anaphylaxis. 
Patients with symptoms of anaphylaxis or with severe hypersensitivity reactions 
(e.g., stridor, angioedema, life-threatening change in vital signs) must be permanently 
withdrawn from study drug treatment.  These patients will not be eligible to receive 
open-label etrolizumab but are required to enter the safety follow-up phase, and offered 
participation in the PML monitoring phase.
All adverse events of systemic hypersensitivity reactions or anaphylactoid or anaphylaxis 
reactions must be reported within 24 hours to the Sponsor and the Medical Monitor must 
be informed as soon as is practical (see the Study Manual for contact information).
5.1.1.3
Hepatic Effects
Background
Liver toxicity has been reported with other drugs that target 4 integrins (natalizumab) 
and 47 integrins (vedolizumab).  Therefore, this potential risk is being monitored in all 
etrolizumab studies.  In nonclinical chronic toxicology studies, no abnormalities 


Etrolizumab—F. Hoffmann-La Roche Ltd
68/Protocol CA40192, Version 4
indicating liver toxicity with etrolizumab were observed.  The risk in humans is currently 
unknown.
From an overall review of safety data from completed studies in UC, there have been no
cases of potential drug-induced liver injury that have been attributed to etrolizumab. 
Patient Selection
Patients with significant liver function test abnormalities should be excluded from the 
etrolizumab clinical studies (see Section 4.1.2).
Education, Monitoring, and Management
Patients and their caregivers should receive guidance on reporting liver problems if they 
occur.  Liver function tests should continue to be monitored according to the schedule of 
assessments and as clinically indicated. Significant hepatic events should be evaluated 
promptly and managed accordingly.
5.1.1.4
Local Injection-Site Reactions
Background
A local injection-site reaction is any local reaction occurring at the site of injection 
following study drug administration.
From an overall review of safety data from completed UC studies, injection-site 
reactions were low in number in etrolizumab-treated patients, and all were non-serious 
and mild or moderate in severity. 
Monitoring
In the clinic setting, patients should be monitored for signs of injection-site reactions in 
the period immediately following injections.
5.1.1.5
Malignancies
Background
From an overall review of safety data from completed studies in UC, the number of 
malignancies reported were small and no specific pattern in the types of malignancies 
reported or in the time to onset since the first dose of etrolizumab was noted.
Nonetheless, given the elevated risk of malignancy in this patient population a priori, the 
trial includes selection criteria and additional information to minimize any hypothetical 
risk. 
Patient Selection
Patients who have a history of cancer within 5 years prior to screening (with the 
exception of local resected basal or squamous cell carcinoma of the skin), including AIS, 
HSIL, or CIN of Grade 1 or colonic dysplasia, are to be excluded from the study. 


Etrolizumab—F. Hoffmann-La Roche Ltd
69/Protocol CA40192, Version 4
Monitoring and Management
Investigators should remain vigilant for signs or symptoms of cancer in scheduled study 
assessments, including those of potential lymphoma.
Any signs or symptoms that could be suggestive of malignancy should be promptly and 
aggressively evaluated and reported to the Sponsor. Incident hematologic abnormalities 
(e.g., new or worsening neutropenia, anemia, thrombocytopenia, macrocytosis, or 
atypical cells in the WBC differential) should be carefully evaluated.
Patients who develop a malignancy (with the exception of local resected basal or 
squamous cell carcinoma of the skin) or who develop AIS, HSIL, or CIN of Grade 1 
on cervical Pap smear or who develop colonic dysplasia during the study should be 
withdrawn from study drug and must not receive additional doses of study drug
5.1.1.6
Immunogenicity
Background
As with administration of any exogenous protein, a potential exists for the development 
of ADAs.  Such antibodies can be neutralizing, with potential for reducing therapeutic 
effect of the drug, and/or sensitizing, with potential for eliciting allergic reactions.  On the 
basis of the clinical experience to date, approximately 5% of patients develop ADAs to 
etrolizumab.  Overall, the presence of ADAs had no impact on the safety of 
etrolizumab-treated patients.
Monitoring
To assess for the potential development of immunogenicity, ADA samples will be 
obtained at Day 1, at regular intervals during treatment, and during the Safety Follow-Up 
Period (Appendix 1a, Appendix 1b, and Appendix 1c) and stored appropriately for further 
evaluation as needed.
5.1.1.7
Decreased Effectiveness of Immunizations
Background
The effect of etrolizumab upon the efficacy of vaccinations is unknown. Whenever
possible, necessary vaccinations should be performed at a minimum of 4 weeks prior to
participating in a clinical trial with etrolizumab. Live attenuated vaccines should be
administered at least 4 weeks prior to administration of etrolizumab and should not be
administered for the duration of the clinical trial or for at least 2.5 months (approximately
5 half-lives) after final study drug administration (see Etrolizumab Investigators Brochure 
for reference).
These recommendations are in line with the most recent vedolizumab (ENTYVIO) label
according to which there are no data on the secondary transmission of infection by live 
vaccines in patients receiving ENTYVIO. In a placebo-controlled study of healthy 
volunteers, 61 subjects were given a single ENTYVIO 750 mg dose (2.5 times the 
recommended dose), and 62 subjects received placebo followed by intramuscular 


Etrolizumab—F. Hoffmann-La Roche Ltd
70/Protocol CA40192, Version 4
vaccination with Hepatitis B surface antigen and oral cholera vaccine.
After intramuscular vaccination with three doses of recombinant Hepatitis B surface 
antigen, those treated with ENTYVIO did not have lower rates of protective immunity to 
Hepatitis B virus. However, those exposed to ENTYVIO did have lower seroconversion 
rates and anti-cholera titers relative to placebo after receiving the two doses of a killed, 
oral cholera vaccine. The impact on other oral vaccines and on nasal vaccines in 
patients is unknown.
5.1.1.8
Risks Associated with Worsening of Ulcerative Colitis and 
Crohn’s Disease
Medical occurrences or symptoms of deterioration that are anticipated as part of 
ulcerative colitis or Crohn’s disease should be recorded as an adverse event if judged by 
the investigator to have unexpectedly worsened in severity or frequency or changed in 
nature at any time during the study.  Refer to Section 4.4.2.2 for acceptable rescue 
therapies.
5.1.2
Management of Patients Who Experience Specific Adverse 
Events.
5.1.2.1
Management Guidelines
Guidelines for management of specific adverse events are outlined in Table 4.  
Additional guidelines are provided in the subsections below.
Table 4
Guidelines for Management of Patients Who Experience Specific 
Adverse Events
Event
Action to Be Taken
Serious infections

Patients who experience a serious infection event (i.e., an infection 
that is a serious adverse event) should not receive further study drug 
until the event has completely resolved and treatment with 
anti-infective medications has been completed.

All efforts should be made to identify the infectious agent.

For those patients who recover from a serious infection, study 
medication may be restarted following consultation with the Medical 
Monitor.

Any patient who experiences a specific de novo or reactivated serious 
viral infection such as HBV, HCV, HIV, should immediately 
discontinue study drug.

Any patient who develops CMV colitis should not receive further study 
drug until the event has resolved and treatment with appropriate 
anti-viral medication has been completed.  Re-initiation of therapy 
requires consultation with the Medical Monitor.
Patients who develop life-threatening infections during the study should 
discontinue study drug.


Etrolizumab—F. Hoffmann-La Roche Ltd
71/Protocol CA40192, Version 4
Table 4
Guidelines for Management of Patients Who Experience Specific 
Adverse Events (cont.)
Event
Action to Be Taken
Signs and 
symptoms of 
possible PML

If a patient has a positive finding on the PML Subjective Checklist, or if 
there is strong clinical suspicion for PML, then the investigator is 
required to follow the process described in the PML algorithm (see 
Appendix 8).  If PML is suspected, a neurology consultation should be 
promptly arranged.  Based on this evaluation, brain magnetic 
resonance imaging and cerebral spinal fluid JCV analysis may be 
performed (see Appendix 8).

Investigators and HCPs should also be trained to accurately and 
appropriately report these events immediately to the Sponsor as 
adverse events of special interest and as serious adverse events, 
if appropriate (see Section 5.4).

The following are signs and symptoms that may potentially indicate 
PML:

Alteration in mental status (cognitive changes, including confusion, 
difficulty concentrating, memory loss) and altered behavior (including 
personality changes)

Higher cortical dysfunction, including impaired comprehension and/or 
formulation of language (aphasia), loss of ability to recognize objects, 
persons, sounds, shapes, or smells (agnosia)

Visual changes, including loss of visual fields (homonymous 
hemianopsia), double vision (diplopia)

Motor deficits, including weakness (hemiparesis, monoparesis), 
seizures, (generalized or partial), difficulties with speech (dysarthria,) or 
swallowing (dysphagia)

Sensory deficits, including sensory loss (paresthesias)

Coordination deficits, including difficulty walking and maintaining 
balance (ataxia), lack of voluntary coordination of limb movement (limb 
ataxia)

If PML is suspected then all investigational treatment should be 
withheld in that patient and may only be restarted if it is confirmed that 
the patient does not have PML.


Etrolizumab—F. Hoffmann-La Roche Ltd
72/Protocol CA40192, Version 4
Table 4
Guidelines for Management of Patients Who Experience Specific 
Adverse Events (cont.)
Event
Action to Be Taken
Vaccinations

For 4 weeks prior, during, and for 12 weeks after the last dose of study 
medication, patients should not receive live vaccines.
Malignancies

Any signs or symptoms that could be suggestive of malignancy should 
be promptly and aggressively evaluated and reported to the Sponsor.  
Incident hematologic abnormalities (e.g., new or worsening 
neutropenia, anemia, thrombocytopenia, macrocytosis, or atypical cells 
in the WBC differential) should be carefully evaluated.

If any dysplasias or abnormalities are noted that could be consistent 
with malignancy, an oncologist or appropriate specialist should be 
consulted and no further doses of investigational product should be 
administered until a thorough clinical evaluation has been completed.

Patients who develop a malignancy (with the exception of local and 
resected basal or squamous cell carcinoma of the skin), or who 
develop adenocarcinoma in situ, high-grade squamous intraepithelial 
lesions, or cervical intraepithelial neoplasia of Grade 1 on cervical 
Pap smear, or who develop colonic dysplasia during the study should 
be withdrawn from study drug and must not receive additional doses of 
study drug.
Hepatic effects
Liver toxicity has been reported with other class drugs that target 4 
integrins (natalizumab) and 47 integrins (vedolizumab).  Therefore, this 
potential risk is being monitored in the etrolizumab studies.  In nonclinical 
chronic toxicology studies, no abnormalities indicating liver toxicity with 
etrolizumab were observed; the risk in humans is currently unknown.

Patients with significant liver function test abnormalities should be 
excluded from the etrolizumab clinical studies.

Patients should receive guidance on reporting liver problems if they 
occur.

Liver function tests should continue to be monitored according to the 
schedule of assessments and as clinically indicated.

Investigators and HCPs should also be trained to accurately and 
appropriately report these events immediately to the Sponsor as 
adverse events of special interest and as serious adverse events, if 
appropriate (see Section 5.4).
Significant hepatic events should be evaluated promptly and managed 
accordingly.


Etrolizumab—F. Hoffmann-La Roche Ltd
73/Protocol CA40192, Version 4
Table 4
Guidelines for Management of Patients Who Experience Specific 
Adverse Events (cont.)
Event
Action to Be Taken
Hypersensitivity 
reactions
An overall review of safety data from completed studies in UC identified 
a very small number of hypersensitivity reactions reported in patients 
receiving etrolizumab, all of which were mild or moderate in severity. 
No anaphylactic, anaphylactoid, or severe hypersensitivity reactions have 
been identified for etrolizumab to date. Anaphylaxis and hypersensitivity 
reactions will be closely monitored during the study.  

Patients with a history of moderate or severe allergic or 
anaphylactic/anaphylactoid reactions to chimeric, human, or 
humanized antibodies, fusion proteins, or murine proteins are excluded 
from study participation.

All injections will be administered in the clinic.  After each injection 
administered in the treatment phase and after the first four 
injections in the OLE phase, the patient must be monitored for 60
minutes.  Health care professionals administering the study 
medication in the clinic must be trained in the appropriate 
administration procedures and be able to recognize the symptoms 
associated with potential anaphylactic, anaphylactoid, or 
hypersensitivity reactions and should be familiar with Sampson’s 
criteria for defining anaphylaxis (Sampson et al. 2006; see Appendix 9).

Investigators and HCPs should also be trained to accurately and 
appropriately report these events immediately to the Sponsor as 
adverse events of special interest and as serious adverse events, 
if appropriate (see Section 5.4).

Medicinal products for the treatment of hypersensitivity reactions 
(e.g., epinephrine, antihistamines, and glucocorticoids) must be 
available for immediate use in the clinic for the event of an allergic 
reaction during administration of the study medication.  Resuscitation 
equipment should also be available.

If a patient has symptoms of anaphylaxis or severe hypersensitivity, the 
administration of etrolizumab must be discontinued permanently.

HCPs should also instruct patients how to recognize the symptoms of 
any anaphylactic, anaphylactoid, or hypersensitivity reaction and to 
contact a HCP or seek emergency care in case of any such symptoms.

If etrolizumab is administered at home by a nursing professional the 
patient will be advised to seek emergency care in response to any 
potential symptom of hypersensitivity.
Detailed information regarding anaphylactic, anaphylactoid, or 
hypersensitivity reactions that occur during the study will be collected, 
regardless of whether the events are serious (see Section 5.4.2) or 
non-serious (see Section 5.3.1).
Injection reactions
In the clinic setting, patients will be monitored for signs of injection site 
reactions in the period immediately following injections.
CMV cytomegalovirus; HBV hepatitis B virus; HCP health-care professional; 
HCV hepatitis C virus; JCV John Cunningham virus; PML progressive multifocal 
leukoencephalopathy; WBC white blood cell.


Etrolizumab—F. Hoffmann-La Roche Ltd
74/Protocol CA40192, Version 4
5.2
SAFETY PARAMETERS AND DEFINITIONS
Safety assessments will consist of monitoring and recording adverse events, including 
serious adverse events and adverse events of special interest, performing 
protocol-specified safety laboratory assessments, measuring protocol-specified vital 
signs, and conducting other protocol-specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.
5.2.1
Adverse Events
According to the International Conference on Harmonisation (ICH) guideline for Good 
Clinical Practice, an adverse event is any untoward medical occurrence in a clinical 
investigation patient administered a pharmaceutical product, regardless of causal 
attribution.  An adverse event can therefore be any of the following:

Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product

Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition) (see Section 5.3.5.10
and Section 5.3.5.11 for more information)

Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline

Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug

Adverse events that are related to a protocol-mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies)
5.2.2
Serious Adverse Events (Immediately Reportable to the 
Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:

Is fatal (i.e., the adverse event actually causes or leads to death)

Is life threatening (i.e., the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)
–
This does not include any adverse event that, had it occurred in a more severe 
form or was allowed to continue, might have caused death.

Requires or prolongs patient hospitalization (see Section 5.3.5.12)


Etrolizumab—F. Hoffmann-La Roche Ltd
75/Protocol CA40192, Version 4

Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient’s ability to conduct normal life 
functions)

Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug

Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)
The terms "severe" and "serious" are not synonymous.  Severity refers to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to National 
Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE]; 
see Section 5.3.3); the event itself may be of relatively minor medical significance (such 
as severe headache without any further findings).
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.
Serious adverse events are required to be reported by the investigator to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2
for reporting instructions).
5.2.3
Adverse Events of Special Interest (Immediately Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by the investigator to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
are as follows:

Cases of potential drug-induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's 
Law (see Section 5.3.5.8)

Suspected transmission of an infectious agent by the study drug, as defined below
–
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal product.  This term applies only
when a contamination of the study drug is suspected.

Adverse events of special interest specific to etrolizumab:
–
Systemic hypersensitivity reactions and anaphylactic and anaphylactoid 
reactions (see Section 5.1.1.2 and Sampson’s Criteria in Appendix 9)


Etrolizumab—F. Hoffmann-La Roche Ltd
76/Protocol CA40192, Version 4
–
Neurological signs, symptoms, and adverse events that may suggest possible 
progressive multifocal leukoencephalopathy, on the basis of a positive finding 
on the PML Subjective Checklist or if there is strong clinical suspicion for 
progressive multifocal leukoencephalopathy (see Appendix 7 and 
Section 5.1.1.1.1)
5.3
METHODS AND TIMING FOR CAPTURING AND ASSESSING 
SAFETY PARAMETERS
The investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Section 5.4 5.6.  
The investigator is also responsible for reporting medical device complaints (see 
Section 5.4.4).
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity 
(see Section 5.3.3), and causality (see Section 5.3.4).  
5.3.1
Adverse Event Reporting Period
Investigators will seek information on adverse events at each patient contact.  
All adverse events, whether reported by the patient or noted by study personnel, will be 
recorded in the patient's medical record and on the Adverse Event eCRF.
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol-mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported 
(see Section 5.4.2 for instructions for reporting serious adverse events).
After initiation of study drug, all adverse events will be reported regardless of relationship 
to study drug, up until the patient completes his or her last study visit (in the Safety 
Follow-Up Phase) or 12-weeks after the last study drug administration whichever is 
longer. After the Safety Follow-Up Phase, the investigator should report any serious 
adverse events that are believed to be related to prior study drug treatment 
(see Section 5.6).  In addition, the Sponsor should be notified if the investigator becomes 
aware of any post-study events of confirmed or suspected PML, regardless of 
relationship to study drug, for up to 2 years after the patient’s last dose of study drug 
(see Section 5.6).
Instructions for reporting adverse events that occur after the adverse event reporting 
period are provided in Section 5.6.


Etrolizumab—F. Hoffmann-La Roche Ltd
77/Protocol CA40192, Version 4
5.3.2
Eliciting Adverse Event Information
A consistent methodology of non-directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non-directive 
questions include the following:
"How have you (or your child) felt since your last clinic visit?"
"Have you (or your child) had any new or changed health problems since you were 
last here?"
5.3.3
Assessment of Severity of Adverse Events 
The adverse event severity grading scale for the current version of the NCI CTCAE will
be used for assessing adverse event severity. Table 5 will be used for assessing 
severity for adverse events that are not specifically listed in the NCI CTCAE.
Table 5
Adverse Event Severity Grading Scale for Events Not Specifically 
Listed in NCI CTCAE
Grade
Severity
1
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
or intervention not indicated
2
Moderate; minimal, local, or non-invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily living a
3
Severe or medically significant, but not immediately life threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; or 
limiting self-care activities of daily living b,c
4
Life-threatening consequences or urgent intervention indicated d
5
Death related to adverse event d
NCI CTCAENational Cancer Institute Common Terminology Criteria for Adverse Events.
Note:  Based on the most recent version of NCI CTCAE (v4.0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
a Instrumental activities of daily living refer to preparing meals, shopping for groceries or 
clothes, using the telephone, managing money, etc.
b Examples of self-care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by patients who are 
not bedridden.
c If an event is assessed as a "significant medical event," it must be reported as a serious 
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.2.
d Grade 4 and 5 events must be reported as serious adverse events (see Section 5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2.


Etrolizumab—F. Hoffmann-La Roche Ltd
78/Protocol CA40192, Version 4
5.3.4
Assessment of Causality of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to the study drug, indicating "yes" or "no" 
accordingly.  The following guidance should be taken into consideration (see also 
Table 6):

Temporal relationship of event onset to the initiation of study drug

Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)

Known association of the event with the study drug or with similar treatments

Known association of the event with the disease under study

Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event

Presence of non-treatment-related factors that are known to be associated with the 
occurrence of the event
Table 6
Causal Attribution Guidance
Is the adverse event suspected to be caused by the study drug on the basis of facts, evidence, 
science-based rationales, and clinical judgment?
YES
There is a plausible temporal relationship between the onset of the adverse event and 
administration of the study drug, and the adverse event cannot be readily explained by 
the patient’s clinical state, intercurrent illness, or concomitant therapies; and/or the 
adverse event follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the study drug or dose 
reduction and, if applicable, reappears upon re-challenge.
NO
An adverse event will be considered related, unless it fulfills the criteria specified below.  
Evidence exists that the adverse event has an etiology other than the study drug 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, 
or concomitant medication); and/or the adverse event has no plausible temporal 
relationship to administration of the study drug (e.g., cancer diagnosed 2 days after 
first dose of study drug).
For patients receiving combination therapy, causality will be assessed individually for 
each protocol-mandated therapy.
5.3.5
Procedures for Recording Adverse Events
Investigators should use correct medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF.


Etrolizumab—F. Hoffmann-La Roche Ltd
79/Protocol CA40192, Version 4
5.3.5.1
Injection-Site Reactions
Local cutaneous adverse events that occur at or around the injection site during or within 
24 hours following study drug injection should be captured on the Adverse Event eCRF 
as individual signs (e.g., erythema at injection site, induration at injection site, and 
swelling at injection site as separate events) or symptoms (e.g., pain at injection site and 
pruritus at injection site as separate events) rather than a diagnosis of allergic reaction 
or injection-site reaction.
5.3.5.2
Worsening Ulcerative Colitis and Crohn’s Disease
When recording an unanticipated worsening ulcerative colitis or Crohn’s disease on the 
Adverse Event eCRF, it is important to convey the concept that the condition has 
changed by including applicable descriptors (e.g., “accelerated ulcerative colitis or 
Crohn’s disease” or “worsening of ulcerative colitis or Crohn’s disease”).
5.3.5.3
Diagnosis versus Signs and Symptoms
For adverse events other than injection site reactions (see Section 5.3.5.1), a diagnosis 
(if known) should be recorded on the Adverse Event eCRF rather than individual signs 
and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, 
and elevated transaminases).  However, if a constellation of signs and/or symptoms 
cannot be medically characterized as a single diagnosis or syndrome at the time of 
reporting, each individual event should be recorded on the Adverse Event eCRF.  If a 
diagnosis is subsequently established, all previously reported adverse events based on 
signs and symptoms should be nullified and replaced by one adverse event report based 
on the single diagnosis, with a starting date that corresponds to the starting date of the 
first symptom of the eventual diagnosis.
5.3.5.4
Adverse Events That Are Secondary to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by their primary cause, with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:

If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.

If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.

If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF.

If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.

If neutropenia is accompanied by an infection, both events should be reported 
separately on the eCRF.


Etrolizumab—F. Hoffmann-La Roche Ltd
80/Protocol CA40192, Version 4
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
5.3.5.5
Persistent or Recurrent Adverse Events
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 
more severe, the most extreme severity should also be recorded on the Adverse Event 
eCRF.  Details regarding any increases in severity will be captured on the Adverse 
Event Intensity or Grade Changes eCRF.  If the event becomes serious, it should be 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning that the 
event became serious; see Section 5.4.2 for reporting instructions).  The Adverse Event 
eCRF should be updated by changing the event from "non-serious" to "serious," 
providing the date that the event became serious, and completing all data fields related 
to serious adverse events.
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF.
5.3.5.6
Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:

Is accompanied by clinical symptoms

Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)

Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy

Is clinically significant in the investigator’s judgment
It is the investigator’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5ULN associated with cholestasis), only the 
diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating whether the test result is above or below the normal range 
(e.g., "elevated potassium," as opposed to "abnormal potassium").  If the laboratory 


Etrolizumab—F. Hoffmann-La Roche Ltd
81/Protocol CA40192, Version 4
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term should be recorded as the adverse event.  For example, an elevated serum 
potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF. The initial severity of the 
event should be recorded, and the severity or seriousness should be updated any time 
the event worsens. (See Section 5.3.5.5 for details on recording persistent adverse 
events).
5.3.5.7
Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it meets any of the following criteria:

Is accompanied by clinical symptoms

Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)

Results in a medical intervention or a change in concomitant therapy

Is clinically significant in the investigator’s judgment 
It is the investigator’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF.
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.5 for 
details on recording persistent adverse events).
5.3.5.8
Abnormal Liver Function Tests
The finding of an elevated ALT or AST (3ULN) in combination with either an elevated 
total bilirubin (2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as 
defined by Hy's Law).  Therefore, investigators must report as an adverse event the 
occurrence of either of the following:

Treatment-emergent ALT or AST 3ULN in combination with total bilirubin 
2ULN

Treatment-emergent ALT or AST 3ULN in combination with clinical jaundice


Etrolizumab—F. Hoffmann-La Roche Ltd
82/Protocol CA40192, Version 4
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.3) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest (see
Section 5.4.2).
5.3.5.9
Deaths
All deaths that occur during the protocol-specified adverse event reporting period 
(see Section 5.3.1), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2).  
This includes death attributed to progression of ulcerative colitis or Crohn’s disease.
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "unexplained death" should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death" should 
be replaced by the established cause of death.  The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").
If the death is attributed to progression of UC or CD, "ulcerative colitis or Crohn’s 
disease progression" should be recorded on the Adverse Event eCRF.  
Deaths that occur after the adverse event reporting period should be reported as 
described in Section 5.6.
5.3.5.10
Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  When 
recording such events on the Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by including applicable descriptors 
(e.g., "more frequent headaches").
5.3.5.11
Lack of Efficacy or Worsening of Ulcerative Colitis or Crohn’s 
Disease
Medical occurrences or symptoms of deterioration that are anticipated as part of 
ulcerative colitis or Crohn’s disease should be recorded as an adverse event if judged by 
the investigator to have unexpectedly worsened in severity or frequency or changed in 
nature at any time during the study.  When recording an unanticipated worsening of 
ulcerative colitis or Crohn’s disease on the Adverse Event eCRF, it is important to 


Etrolizumab—F. Hoffmann-La Roche Ltd
83/Protocol CA40192, Version 4
convey the concept that the condition has changed by including applicable descriptors 
(e.g., "accelerated worsening of ulcerative colitis or Crohn’s disease").
5.3.5.12
Hospitalization or Prolonged Hospitalization
Any adverse event that results in hospitalization (i.e., inpatient admission to a hospital) 
or prolonged hospitalization should be documented and reported as a serious adverse 
event (per the definition of serious adverse event in Section 5.2.2), except as outlined 
below.  
An event that leads to hospitalization under the following circumstances should not be 
reported as an adverse event or a serious adverse event:

Hospitalization for respite care

Planned hospitalization required by the protocol (e.g., for study drug administration 
or insertion of access device for study drug administration)

Hospitalization for a preexisting condition, provided that all of the following criteria 
are met:
–
The hospitalization was planned prior to the study or was scheduled during the 
study when elective surgery became necessary because of the expected 
normal progression of the disease.
The patient has not experienced an adverse event.
The following hospitalization scenarios are not considered to be serious adverse events,
but should be reported as adverse events instead:

Hospitalization that was necessary because of patient requirement for outpatient
care outside of normal outpatient clinic operating hours
5.3.5.13
Adverse Events Associated with an Overdose or Error in Drug 
Administration
An overdose is the accidental or intentional use of a drug in an amount higher than the 
dose being studied.  An overdose or incorrect administration of study treatment is not 
itself an adverse event, but it may result in an adverse event.  All adverse events 
associated with an overdose or incorrect administration of study drug should be 
recorded on the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2).
Any study drug overdose or incorrect administration of study drug should be noted on 
the Study Drug Administration eCRF.
5.3.5.14
Clinical Outcomes Assessment Data
Adverse event reports will not be derived from COA data by the Sponsor, and safety 
analyses will not be performed using COA data.  However, if any COA responses 
suggestive of a possible adverse event are identified during site review of the COA data, 


Etrolizumab—F. Hoffmann-La Roche Ltd
84/Protocol CA40192, Version 4
the investigator will determine whether the criteria for an adverse event have been met 
and, if so, will report the event on the Adverse Event eCRF.
5.4
IMMEDIATE REPORTING REQUIREMENTS FROM 
INVESTIGATOR TO SPONSOR
Certain events require immediate reporting to allow the Sponsor to take appropriate 
measures to address potential new risks in a clinical trial.  The investigator must report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than 24 hours after the investigator learns of the event.  The following is a list 
of events that the investigator must report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:

Serious adverse events (defined in Section 5.2.2; see Section 5.4.2 for details on 
reporting requirements)

Adverse events of special interest (defined in Section 5.2.3; see Section 5.4.2 for 
details on reporting requirements)

Pregnancies (see Section 5.4.3 for details on reporting requirements)
The investigator must report new significant follow-up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:

New signs or symptoms or a change in the diagnosis

Significant new diagnostic test results

Change in causality based on new information

Change in the event’s outcome, including recovery

Additional narrative information on the clinical course of the event
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.
5.4.1
Emergency Medical Contacts
Medical Monitor Contact Information
F. Hoffmann-La Roche Medical Monitor contact information:
Medical Monitor:
, M.D. (Primary)
Telephone No.:
 (United States)
Mobile Telephone No.:
(United States)
Medical Monitor:
, M.D. (Secondary)
Primary Telephone No.:
 (United States)
Mobile Telephone No.:
 (United States)


Etrolizumab—F. Hoffmann-La Roche Ltd
85/Protocol CA40192, Version 4
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the Roche Medical Emergency List, escalate emergency medical calls, provide 
medical translation service (if necessary), connect the investigator with a Roche Medical 
Responsible (listed above and/or on the Roche Medical Emergency List), and track all 
calls.  The Emergency Medical Call Center Help Desk will be available 24 hours per day, 
7 days per week.  Toll-free numbers for the Help Desk, as well as Medical Monitor and 
Medical Responsible contact information, will be distributed to all investigators. 
5.4.2
Reporting Requirements for Serious Adverse Events, Adverse 
Events of Special Interest
5.4.2.1
Events That Occur prior to Study Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol-mandated intervention should be reported.  
The paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest 
Reporting Form provided to investigators should be completed and submitted to the 
Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
event), either by faxing or by scanning and emailing the form using the fax number or 
email address provided to investigators.
5.4.2.2
Events That Occur after Study Drug Initiation
After initiation of study drug, serious adverse events and adverse events of special 
interest will be reported until 12 weeks after the last dose of study drug.  Investigators 
should record all case details that can be gathered immediately (i.e., within 24 hours 
after learning of the event) on the Adverse Event eCRF and submit the report via the 
electronic data capture (EDC) system.  A report will be generated and sent to Safety 
Risk Management by the EDC system.
In the event that the EDC system is unavailable, the paper Clinical Trial Serious Adverse 
Event/Adverse Event of Special Interest Reporting Form provided to investigators should 
be completed and submitted to the Sponsor or its designee immediately (i.e., no more 
than 24 hours after learning of the event), either by faxing or by scanning and emailing 
the form using the fax number or email address provided to investigators.  Once the 
EDC system is available, all information will need to be entered and submitted via the 
EDC system.  
Instructions for reporting serious adverse events that occur more than 12 weeks after the 
last dose of study treatment are provided in Section 5.6.
5.4.3
Reporting Requirements for Pregnancies
5.4.3.1
Pregnancies in Female Patients
Female patients of childbearing potential will be instructed through the Informed 
Consent Form to immediately inform the investigator if they become pregnant during the 
study or within 24 weeks after the last dose of study drug.  A paper Clinical Trial 
Pregnancy Reporting Form should be completed and submitted to the Sponsor or its 


Etrolizumab—F. Hoffmann-La Roche Ltd
86/Protocol CA40192, Version 4
designee immediately (i.e., no more than 24 hours after learning of the pregnancy), 
either by faxing or by scanning and emailing the form using the fax number or email 
address provided to investigators.  Pregnancy should not be recorded on the Adverse 
Event eCRF.  The investigator should discontinue study drug and counsel the patient, 
discussing the risks of the pregnancy and the possible effects on the fetus.  Monitoring 
of the patient should continue until conclusion of the pregnancy.  Any serious adverse 
events associated with the pregnancy (e.g., an event in the fetus, an event in the mother 
during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be 
reported on the Adverse Event eCRF.  In addition, the investigator will submit a Clinical 
Trial Pregnancy Reporting Form when updated information on the course and outcome 
of the pregnancy becomes available.  
5.4.3.2
Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
24 weeks after the last dose of study drug.  The investigator should report the 
pregnancy on the paper Clinical Trial Pregnancy Reporting Form and submit the form to 
the Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
pregnancy), either by faxing or by scanning and emailing the form using the fax number
or email address provided to investigators.  Attempts should be made to collect and 
report details of the course and outcome of any pregnancy in the partner of a male 
patient exposed to study drug.  When permitted by the site, the pregnant partner would
need to sign an Authorization for Use and Disclosure of Pregnancy Health Information to 
allow for follow-up on her pregnancy.  If the authorization has been signed, the 
investigator should submit a Clinical Trial Pregnancy Reporting Form with additional
information on the pregnant partner and the course and outcome of the pregnancy as it
becomes available.  An investigator who is contacted by the male patient or his pregnant 
partner may provide information on the risks of the pregnancy and the possible effects 
on the fetus, to support an informed decision in cooperation with the treating physician 
and/or obstetrician.
5.4.3.3
Congenital Anomalies/Birth Defects and Abortions
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a serious adverse event, recorded on the Adverse Event eCRF and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2).  Any therapeutic or spontaneous abortion should be reported in the same 
fashion (as the Sponsor considers abortions to be medically significant events).
5.4.4
Reporting Requirements for Vial and Syringe 
Complaints/Events
In this study, the vial and syringe are considered a medical device.  The investigator 
must report all medical device complaints to the Sponsor.  The investigator should 
document as much information as possible on the PD 103IMP Deviation Form, including 


Etrolizumab—F. Hoffmann-La Roche Ltd
87/Protocol CA40192, Version 4
the product batch number, and forward the form to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event) (refer to the pharmacy manual for further 
details).  The PD103 IMP deviation form, together with pictures of the defective vial and 
syringe, should be sent to kaiseraugst.global_impcomplaint_management@roche.com.
Where possible, the investigator will retrieve the vial and syringe unit(s) involved in the 
complaint and attempt to return it to the Sponsor for further assessment, if necessary.
If the medical device (vial and syringe) results in an adverse event to the study patient, 
the event must be reported on the Adverse Event eCRF and submitted through the EDC 
system.  If the event is serious, the Adverse Event eCRF must be completed 
immediately (i.e., no more than 24 hours after learning of the event), as outlined in 
Section 5.4.2. If the medical device results in an adverse event to an individual other 
than the study patient, the device complaint must be reported on the PD103 form and 
the adverse event must be reported as a spontaneous adverse event to the Sponsor.
5.5
FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS
5.5.1
Investigator Follow-Up
The investigator should follow each adverse event until the event has resolved to 
baseline grade or better, the event is assessed as stable by the investigator, the patient
is lost to follow-up, or the patient withdraws consent.  Every effort should be made to 
follow all serious adverse events considered to be related to study drug or trial-related 
procedures until a final outcome can be reported.
During the study period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient’s medical record to facilitate source data 
verification.  
All pregnancies reported during the study should be followed until pregnancy outcome.
5.5.2
Sponsor Follow-Up
For serious adverse events, adverse events of special interest, and pregnancies, the 
Sponsor or a designee may follow up by telephone, fax, email, and/or a monitoring visit 
to obtain additional case details and outcome information (e.g., from hospital discharge 
summaries, consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case.
5.6
ADVERSE EVENTS THAT OCCUR AFTER THE ADVERSE 
EVENT REPORTING PERIOD
The Sponsor should be notified if the investigator becomes aware of any serious 
adverse event that occurs after the end of the adverse event reporting period (defined as 
12 weeks after the last dose of study drug, see Section 5.3.1) if the event is believed to 
be related to prior study drug treatment.  In addition, the Sponsor should be notified if the 
investigator becomes aware of any post-study events of confirmed or suspected 


Etrolizumab—F. Hoffmann-La Roche Ltd
88/Protocol CA40192, Version 4
progressive multifocal leukoencephalopathy, regardless of relationship to study drug, for 
up to 2 years after the patient’s last dose of study drug.  These events should be 
reported through use of the Adverse Event eCRF.  However, if the EDC system is not 
available, the investigator should report these events directly to the Sponsor or its 
designee, either by faxing or by scanning and emailing the paper Clinical Trial Serious 
Adverse Event/Adverse Event of Special Interest Reporting Form using the fax number 
or email address provided to investigators.
5.7
EXPEDITED REPORTING TO HEALTH AUTHORITIES, 
INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, 
AND ETHICS COMMITTEES
The Sponsor will promptly evaluate all serious adverse events and adverse events of 
special interest against cumulative product experience to identify and expeditiously 
communicate possible new safety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events using the following reference document:

Etrolizumab Investigator's Brochure
–
Within the Investigator’s Brochure, the reference safety information is provided 
in Section 6.4 (Identified Risks and Adverse Drug Reactions [Reference Safety 
Information]).
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by the Sponsor as needed.
6.
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN
The primary analysis of the study will be performed when all the data from the 
randomized controlled part of the study are in the database and has been cleaned and 
verified.
6.1
DETERMINATION OF SAMPLE SIZE
A sample size of 1216 patients has been considered sufficient in order to evaluate the 
PK and PD endpoints.  No formal sample size and power calculations were performed.  
6.2
SUMMARIES OF CONDUCT OF STUDY
The number of patients who enroll, discontinue, or complete the study will be 
summarized.  Reasons for premature study withdrawal will be listed and summarized.  


Etrolizumab—F. Hoffmann-La Roche Ltd
89/Protocol CA40192, Version 4
Enrollment and other major protocol deviations will be listed and evaluated for their 
potential effects on the interpretation of study results.
6.3
SUMMARIES OF TREATMENT GROUP COMPARABILITY
Demographic and baseline characteristics such as age, sex, race, duration of disease, 
disease activity scores, prior anti-TNF use, concomitant corticosteroids or 
immunosuppressant use will be summarized by means of descriptive statistics, and 
presented overall and by dose regimen.
6.4
PHARMACOKINETIC ANALYSES
The PK analysis population will consist of patients with sufficient data to enable 
estimation of key parameters such as AUC (area under the curve), Cmax (maximum 
concentration), Ctrough (trough concentration) and t1/2 (elimination half-life). 
Non-compartmental analysis will be used to derive PK parameters including Cmax and 
Tmax after the first and final dose, t1/2, AUC within dosing interval (AUC84-112) and 
(AUC56-112) for 1.5 mg/kg Q4W and 3 mg/kg Q8W, respectively.   
All PK parameters will be listed and summarized by descriptive summary statistics 
including means, geometric means, ranges, standard deviations, and coefficients of 
variation.
Individual and mean concentration versus time data will be tabulated and plotted by 
dose level. 
PK data from this study may be combined with data from the adult study to perform a 
population PK analysis. Population typical value of PK parameters will be estimated for 
the entire study population, along with estimates of intra- and inter-patient variance and 
an estimate of random error. Individual patient parameter estimates will be computed 
using the post hoc analysis procedure.  A prospective analysis plan will be prepared, 
and the population PK analysis will be presented in a report separate from the Clinical 
Study Report of this study.
Additional exploratory PK/PD analyses or modeling may be conducted as appropriate.
6.5
PHARMACODYNAMIC ANALYSES
All PD parameters will be listed and summarized by descriptive summary statistics 
including means, standard deviations, medians, ranges, and coefficients of variation.
6.6
SAFETY ANALYSES
The safety analysis population will consist of all patients who received at least one dose 
of study drug, with patients grouped according to dose regimen received. 


Etrolizumab—F. Hoffmann-La Roche Ltd
90/Protocol CA40192, Version 4
Safety will be assessed through descriptive summaries of adverse events (including 
serious adverse events, malignancies, infections – in particular GI infections, systemic 
hypersensitivity events, and injection site reactions), laboratory test results, and vital 
signs.
6.7
IMMUNOGENICITY ANALYSES 
The immunogenicity analysis population will consist of all patients with at least one ADA
assessment.  Patients will be grouped according to treatment received or, if no treatment 
is received prior to study discontinuation, according to treatment assigned.
The numbers and proportions of ADA-positive patients and ADA-negative patients at 
baseline (baseline prevalence) and after etrolizumab treatment (post-treatment 
incidence) will be summarized by treatment group.  When determining post treatment
incidence, patients are considered to be ADA positive if they are ADA negative or have 
missing data at baseline but developed an ADA response following study drug exposure 
(treatment-induced ADA response), or if they are ADA positive at baseline and the titer 
of one or more postbaseline samples is at least 0.60 titer unit greater than the titer of the 
baseline sample (treatment-enhanced ADA response).  Patients are considered to be 
ADA negative if they are ADA negative or have missing data at baseline and all 
postbaseline samples are negative, or if they are ADA positive at baseline but do not 
have any postbaseline samples with a titer that is at least 0.60 titer unit greater than the 
titer of the baseline sample (treatment unaffected).
The relationship between ADA status and safety, efficacy, PK, and PD endpoints will be 
assessed and reported via descriptive statistics.
6.8
BIOMARKER ANALYSES
Beta-7 receptor occupancy and serum MAdCAM-1 results will be summarized by dosing
group and timepoints as absolute values and/or change from baseline.  Summary 
statistics may be provided.
A PK/PD model may be developed to evaluate the PK/PD relationship after combining 
data from adult’s study.  This modeling work will be reported separately outside the 
Clinical Study Report of this study.
6.9
EXPLORATORY ANALYSES 
PUCAI/PCDAI response or remission rates will be summarized descriptively over time 
within each treatment group.  Disease activity scores and subscores, fecal calprotectin 
levels and serum CRP levels and their change from baseline will also be summarized 
descriptively over time to assess the efficacy of etrolizumab in reducing signs and 
symptoms of disease and levels of inflammatory biomarkers.


Etrolizumab—F. Hoffmann-La Roche Ltd
91/Protocol CA40192, Version 4
7.
DATA COLLECTION AND MANAGEMENT
7.1
DATA QUALITY ASSURANCE
The Sponsor will be responsible for data management of this study, including quality 
checking of the data.  Data entered manually will be collected via EDC through use of 
eCRFs.  Sites will be responsible for data entry into the EDC system.  In the event of 
discrepant data, the Sponsor will request data clarification from the sites, which the sites 
will resolve electronically in the EDC system.
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laboratory data will be sent 
directly to the Sponsor, using the Sponsor’s standard procedures to handle and process 
the electronic transfer of these data.
eCRFs and correction documentation will be maintained in the EDC system’s audit trail.  
System backups for data stored by the Sponsor and records retention for the study data 
will be consistent with the Sponsor’s standard procedures.
COA data will be collected on paper questionnaires that may be administered via 
interview with the clinician.  The data from the questionnaires will be entered into the 
EDC system by site staff.
7.2
ELECTRONIC CASE REPORT FORMS 
eCRFs are to be completed through use of a Sponsor-designated EDC system.  
Sites will receive training and have access to a manual for appropriate eCRF 
completion.  eCRFs will be submitted electronically to the Sponsor and should be 
handled in accordance with instructions from the Sponsor.
All eCRFs should be completed by designated, trained site staff.  eCRFs should be 
reviewed and electronically signed and dated by the investigator or a designee.
At the end of the study, the investigator will receive patient data for his or her site in a 
readable format on a compact disc that must be kept with the study records.  
Acknowledgement of receipt of the compact disc is required.
7.3
SOURCE DATA DOCUMENTATION
Study monitors will perform ongoing source data verification and review to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by authorized site 
personnel are accurate, complete, and verifiable from source documents. 
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospital records, 
clinical and office charts, laboratory notes, memoranda, patient-reported outcomes, 
evaluation checklists, pharmacy dispensing records, recorded data from automated 


Etrolizumab—F. Hoffmann-La Roche Ltd
92/Protocol CA40192, Version 4
instruments, copies of transcriptions that are certified after verification as being accurate 
and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, 
patient files, and records kept at pharmacies, laboratories, and medico-technical 
departments involved in a clinical trial.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.5.
To facilitate source data verification and review, the investigators and institutions must 
provide the Sponsor direct access to applicable source documents and reports for 
trial-related monitoring, Sponsor audits, and IRB/EC review.  The study site must also 
allow inspection by applicable health authorities.
7.4
USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site’s computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  
An acceptable computerized data collection system allows preservation of the original 
entry of data.  If original data are modified, the system should maintain a viewable audit 
trail that shows the original data as well as the reason for the change, name of the 
person making the change, and date of the change.
7.5
RETENTION OF RECORDS
Records and documents pertaining to the conduct of this study and the distribution of 
IMP, including eCRFs, paper COA data, Informed Consent Forms, laboratory test 
results, and medication inventory records, must be retained by the Principal Investigator 
for 15 years after completion or discontinuation of the study or for the length of time 
required by relevant national or local health authorities, whichever is longer.  After that 
period of time, the documents may be destroyed, subject to local regulations.  
No records may be disposed of without the written approval of the Sponsor.  
Written notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.
Roche will retain study data for 25 years after the final Clinical Study Report has been 
completed or for the length of time required by relevant national or local health 
authorities, whichever is longer.


Etrolizumab—F. Hoffmann-La Roche Ltd
93/Protocol CA40192, Version 4
8.
ETHICAL CONSIDERATIONS
8.1
COMPLIANCE WITH LAWS AND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the laws and 
regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the United States or under a 
U.S. Investigational New Drug (IND) application will comply with U.S. FDA regulations 
and applicable local, state, and federal laws.  Studies conducted in the European Union 
or European Economic Area will comply with the E.U. Clinical Trial Directive 
(2001/20/EC).
8.2
INFORMED CONSENT
The Sponsor’s sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as a Child’s Informed Assent Form) will be provided to each site.  
If applicable, it will be provided in a certified translation of the local language.  
The Sponsor or its designee must review and approve any proposed deviations from the 
Sponsor's sample Informed Consent Forms or any alternate consent forms proposed by 
the site (collectively, the "Consent Forms") before IRB/EC submission.  The final 
IRB/ECapproved Consent Forms must be provided to the Sponsor for health authority 
submission purposes according to local requirements.
If applicable, the Informed Consent Form will contain separate sections for any optional 
procedures.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential risks associated with each optional procedure.  
Patients will be told that they are free to refuse to participate and may withdraw their 
consent at any time for any reason.  A separate, specific signature will be required to 
document a patient's agreement to participate in optional procedures.  Patients who 
decline to participate will not provide a separate signature.
The Consent Forms must be signed and dated by the patient or the patient’s legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each patient shall document the informed consent process and that 
written informed consent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient
to participate.  The final revised IRB/EC-approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.
Patients must be re-consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 


Etrolizumab—F. Hoffmann-La Roche Ltd
94/Protocol CA40192, Version 4
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical records for each patient shall document the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.
A copy of each signed Consent Form must be provided to the patient or the patient’s 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient’s study file or in the site file and must be available for verification by study 
monitors at any time.
For sites in the United States, each Consent Form may also include patient authorization 
to allow use and disclosure of personal health information in compliance with the U.S. 
Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of personal 
health information under the HIPAA regulations, the review, approval, and other 
processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
8.3
INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE
This protocol, the Informed Consent Forms, any information to be given to the patient, 
and relevant supporting information must be submitted to the IRB/EC by the Principal 
Investigator and reviewed and approved by the IRB/EC before the study is initiated.  
In addition, any patient recruitment materials must be approved by the IRB/EC. 
The Principal Investigator is responsible for providing written summaries of the status of 
the study to the IRB/EC annually or more frequently in accordance with the 
requirements, policies, and procedures established by the IRB/EC.  Investigators are 
also responsible for promptly informing the IRB/EC of any protocol amendments 
(see Section 9.6).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safety-related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by their IRB/EC and 
archived in the site’s study file. 
8.4
CONFIDENTIALITY
The Sponsor maintains confidentiality standards by coding each patient enrolled in the 
study through assignment of a unique patient identification number.  This means that 
patient names are not included in data sets that are transmitted to any Sponsor location.


Etrolizumab—F. Hoffmann-La Roche Ltd
95/Protocol CA40192, Version 4
Patient medical information obtained by this study is confidential and may be disclosed 
to third parties only as permitted by the Informed Consent Form (or separate 
authorization for use and disclosure of personal health information) signed by the 
patient, unless permitted or required by law.
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsible for the patient’s welfare, for treatment purposes.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by law.  The aggregate results of any conducted research will 
be available in accordance with the effective Roche policy on study data publication 
(see Section 9.5 )
Data generated by this study must be available for inspection upon request by 
representatives of national and local health authorities; Sponsor monitors, 
representatives, and collaborators; and the IRB/EC for each study site, as appropriate.
8.5
FINANCIAL DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study (see definition of end of 
study in Section 3.2).
9.
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION
9.1
STUDY DOCUMENTATION
The investigator must maintain adequate and accurate records to enable the conduct of 
the study to be fully documented, including, but not limited to, the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes to 
data.
9.2
PROTOCOL DEVIATIONS
The investigator should document and explain any protocol deviations. The investigator 
should promptly report any deviations that might have an impact on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.  The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to health authorities.  As per the Sponsor's standard operating procedures, 


Etrolizumab—F. Hoffmann-La Roche Ltd
96/Protocol CA40192, Version 4
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.
9.3
SITE INSPECTIONS
Site visits will be conducted by the Sponsor or an authorized representative for 
inspection of study data, patients' medical records, and eCRFs.  The investigator will 
permit national and local health authorities; Sponsor monitors, representatives, and 
collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study.
9.4
ADMINISTRATIVE STRUCTURE
This trial will be sponsored and managed by F. Hoffmann-La Roche Ltd.  The Sponsor 
will provide clinical operations management, data management, and medical monitoring.
Approximately 20 sites globally will participate to enroll approximately 24 patients.  
Enrollment will occur through an IxRS.  
Central facilities will be used for certain study assessments throughout the study 
(e.g., specified laboratory tests, biomarker and PK analyses), as specified in Section 4.5.  
Accredited local laboratories will be used for routine monitoring; local laboratory ranges 
will be collected.
A Safety Monitoring Committee will be employed to monitor and evaluate patient safety 
throughout the study.
9.5
PUBLICATION OF DATA AND PROTECTION OF TRADE 
SECRETS
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, both at scientific 
congresses and in peer-reviewed journals. The Sponsor will comply with all 
requirements for publication of study results.  For more information, refer to the Roche 
Global Policy on Sharing of Clinical Study Information at the following Web site:
www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involving an IMP for which a marketing authorization application
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within 6 months after the availability of 
the respective Clinical Study Report.  In addition, for all clinical trials in patients involving 
an IMP for which a marketing authorization application has been filed or approved in any 
country, the Sponsor aims to publish results from analyses of additional endpoints and 
exploratory data that are clinically meaningful and statistically sound.


Etrolizumab—F. Hoffmann-La Roche Ltd
97/Protocol CA40192, Version 4
The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior 
to submission for publication or presentation.  This allows the Sponsor to protect 
proprietary information and to provide comments based on information from other 
studies that may not yet be available to the investigator.
In accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator will be designated by mutual agreement.
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by the investigator and the 
appropriate Sponsor personnel.
Any inventions and resulting patents, improvements, and/or know-how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
9.6
PROTOCOL AMENDMENTS
Any protocol amendments will be prepared by the Sponsor.  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact information).


Etrolizumab—F. Hoffmann-La Roche Ltd
98/Protocol CA40192, Version 4
10.
REFERENCES
Abramson O, Durant M, Mow W, et al. Incidence, prevalence, and time trends of 
pediatric inflammatory bowel disease in Northern California. J Pediatr 
2010;157:233239 e231.
Agnarsson U, Björnsson S, Jóhansson JH, et al. Inflammatory bowel disease in 
Icelandic children 1951-2010. Population-based study involving one nation over six 
decades. Scand J Gastroenterol. 2013;48:1399–1404.
Beckman DA, Feuston M. Landmarks in the Development of the Female Reproductive 
System. Birth Defects Research (Part B) 2003;68:137143.
Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory 
bowel disease: a systematic review of international trends. Inflammatory bowel
diseases. 2011 Jan 1;17(1):42339.
Bradley GM, Oliva-Hemker M. Infliximab for the treatment of pediatric ulcerative colitis. 
Expert Rev Gastroenterol Hepatol 2012;6:65965.
Cepek KL, Parker CM, Madara JL, et al. Integrin alpha E beta 7 mediates adhesion of 
T lymphocytes to epithelial cells. The Journal of Immunology. 1993 Apr 
15;150(8):345970.
Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis factor-in the 
treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatology 
2006;3:220.
Chebli LA, Chaves LD, Pimentel FF, et al. Azathioprine maintains long-term steroid-free 
remission through 3 years in patients with steroid-dependent ulcerative colitis. 
Inflamm Bowel Dis 2010;4:6139.
de Greef E, Mahachie John JM, Hoffman I, et al. Profile of pediatric Crohn's disease in 
Belgium. Journal of Crohn's and Colitis. 2013 Dec 1;7(11):e58898.
de Vries HS, van Oijen MG, Driessen RJ, et al. Appropriate infliximab infusion dosage 
and monitoring: results of a panel meeting of rheumatologists, dermatologists and 
gastroenterologists.  Br J Clin Pharmacol 2011;71:719.
Elewaut D, Van Damme N, De Keyser F, et al. Altered expression of E7 integrin on 
intra-epithelial and lamina propria lymphocytes in patients with Crohn’s disease.  
Acta Gastroenterol Belg 1998;61:28894.
Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid 
therapy for inflammatory bowel disease: a population-based study. 
Gastroenterology 2001;121:25560.
Feagan BG, Rutgeerts PG, Sand BE, et al.  Vedolizumab as induction and maintenance 
therapy for ulcerative colitis.  N Engl J Med 2013;369(8):699710.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s 
disease: the ACCENT I randomised trial. Lancet 2002;359:154149.


Etrolizumab—F. Hoffmann-La Roche Ltd
99/Protocol CA40192, Version 4
Henderson P, Hansen R, Cameron FL, Gerasimidis K, Rogers P, Bisset WM, Reynish 
EL, Drummond HE, Anderson NH, Van Limbergen J, et al. Rising incidence of 
pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis. 
2012;18:999–1005.
Herrinton LJ, Liu L, Lewis JD, et al. Incidence and prevalence of inflammatory bowel 
disease in a Northern California managed care organization, 1996-2002. Am J 
Gastroenterol 2008;103:19982006.
Holladay SD, Smialowicz RJ. Development of the murine and human immune system: 
differential effects of immunotoxicants depend on time of exposure. Environ Health 
Perspect 2000;108(Suppl 3):46373.
Holzmann B, McIntyre BW, Weissman IL. Identification of a murine Peyer’s 
patchspecific lymphocyte homing receptor as an integrin molecule with an 
-chain homologous to human VLA-4-α. Cell 1989;56:3746.
Hu M, Crowe DT, Weissman IL, et al. Cloning and expression of mouse integrin p(7): 
a functional role in Peyer's patch–specific lymphocyte homing. Proc Natl Acad Sci 
USA 1992;89:82548.
HumiraSummary of Product Characteristics. 40 mg/0.8 ml solution for injection for 
paediatric use. - Summary of Product Characteristics (SPC) - (eMC). [online] 
Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf [Accessed 16 August 
2017].
Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, 
Katz AJ, Grand RJ, Boyle JT, Michener WM. Development and validation of a 
pediatric Crohn's disease activity index. Journal of pediatric gastroenterology and 
nutrition. 1991 May 1;12(4):449.
Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for 
moderate to severe Crohn's disease in children. Gastroenterology 
2012;143:36574.e2.
Humira (adalimumab, injection) U.S. Package Insert, AbbVie Inc.  Available from:
https://www.rxabbvie.com/pdf/humira.pdf.
Kappelman, MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic 
distribution of Crohn's disease and ulcerative colitis in the United States. Clin 
Gastroenterol Hepatol 2007; 5:14241429.
Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn’s 
disease and ulcerative colitis in a commercially insured US population. Digestive 
diseases and sciences. 2013;58(2):51925. 
Khan N, Abbas AM, Moehlen M, et al. Methotrexate in ulcerative colitis: a nationwide 
retrospective cohort from the Veterans Affairs Health Care System. Inflamm Bowel 
Dis. 2013; 19:7.


Etrolizumab—F. Hoffmann-La Roche Ltd
100/Protocol CA40192, Version 4
Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics 
of children with newly diagnosed inflammatory bowel disease in Wisconsin: a 
statewide population-based study. J Pediatr 2003;143: 525-531.
Larsen MD, Baldal ME, Nielsen RG, Nielsen J, Lund K, Nørgård BM. The incidence of 
Crohn’s disease and ulcerative colitis since 1995 in Danish children and 
adolescents 17 yearsbased on nationwide registry data. Scand J Gastroenterol. 
2016;51:1100–1105.
Lehtinen P, Ashorn M, Iltanen S, et al., Incidence trends of pediatric inflammatory bowel 
disease in Finland, 1987–2003, a nationwide study. Inflamm Bowel Dis. 2011;17: 
1778–1783.
Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn’s disease in 
adults.  Am J Gastroenterol 2009;104:465-83.
Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment 
with 6-mercaptopurine for ulcerative colitis. The American journal of 
gastroenterology. 2004 Mar 1;99(3):462.
Malaty HM, Fan X, Opekun AR, et al. Rising incidence of inflammatory bowel disease 
among children:  a 12-year study. J Pediatr Gastroenterol Nutr 2010;50:2731.
Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study 
(ECCDS): results of drug treatment. Gastroenterology. 1984;86(2):249-66. 
Mañosa M, García V, Castro L, García-Bosch O, Chaparro M, Acosta MB, Carpio D, 
Aguas M. Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical 
use and efficacy. Journal of Crohn's and Colitis. 2011;5(5):397-401. 
Martín-de-Carpi J, Rodríguez A, Ramos E, Jiménez S, Martínez-Gómez MJ, Medina E. 
Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-
2009): the SPIRIT Registry. Inflamm Bowel Dis. 2013;19:73–80. 
Marty MS, Chapin RE, Parks LG, et al. Development and Maturation of the Male 
Reproductive System.  Birth Defects Research (Part B) 2003;68:125136.
Oshitani N, Watanabe K, Maeda K, et al.  Differential expression of homing receptor 
CD103 on lamina propria lymphocytes and association of CD103 with epithelial 
adhesion molecules in inflammatory bowel disease.  Int J Mol 
Med. 2003 Nov;12(5):7159.
Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's 
disease in population-based cohorts.  Am J Gastroenterol 2010;105:28997.
Peyrin-Biroulet L, and Lémann M. Review article: remission rates achievable by current 
therapies for inflammatory bowel disease.  Aliment Pharmacol Ther 
2011;33:870-9.


Etrolizumab—F. Hoffmann-La Roche Ltd
101/Protocol CA40192, Version 4
RemicadeSummary of Product Characteristics Remicade 100 mg powder for 
concentrate for solution for infusion. Summary of Product Characteristics 
(SPC)-(eMC). [online] Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000240/WC500050888.pdf [Accessed 16 August 
2017].
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance 
therapy for ulcerative colitis. N Engl J Med 2005;353:246276.
Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the 
definition and management of anaphylaxis:  summary report—second National 
Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium. J Allergy Clin Immunol 2006;117:3917.
Sandborn WJ, Colombel JF, D’Haens G, et al. One-year maintenance outcomes among 
patients with moderately-to-severely active ulcerative colitis who responded to 
induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment 
Pharmacol Ther 2013;37:20413.
Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance 
therapy for Crohn's disease. N Engl J Med 2005;353:191225.
Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn 
disease previously treated with infliximab: a randomized trial.  Ann Intern Med 
2007:19;146:829-38. Epub 2007 Apr 30.
Siegal CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of 
Crohn’s disease. Therap Adv Gastroenterol 2009;2:24551.
Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab 
effectiveness in pediatric inflammatory bowel disease. Inflammatory bowel 
diseases. 2016 Sep 1;22(9):21216. 
Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative crohn’s disease 
study:  results of drug treatment. Gastroenterology 1979;77:84769.
Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in 
natalizumab-associated PML. Neurology. 2011 Sep 13;77(11):10617.
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric 
monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. New 
England Journal of Medicine. 1997 Oct 9;337(15):102936. 
Turner D, Otley AR, Mack D et al. Development and evaluation of a Pediatric Ulcerative 
Colitis Activity Index (PUCAI): a prospective multicenter 
study. Gastroenterology 2007;133:423–432.
Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis. J Ped 
Gastroenterol Nutrition 2012;55:34061.


Etrolizumab—F. Hoffmann-La Roche Ltd
102/Protocol CA40192, Version 4
Urlep D, Blagus R, Orel R. Incidence Trends and Geographical Variability of Pediatric 
Inflammatory Bowel Disease in Slovenia: A Nationwide Study. Biomed Res Int. 
2015;2015:921730.
Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based 
Consensus on the diagnosis and management of Crohn's disease: Special 
situations. J Crohns Colitis. 2010;4:63101.
van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in 
patients with ankylosing spondylitis: results of a multicenter, randomized, 
double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:213646.
Yang LS, Alex G, Catto-Smith AG. The use of biologic agents in pediatric inflammatory 
bowel disease. Current opinion in pediatrics. 2012 Oct 1;24(5):60914.


Etrolizumab—F. Hoffmann-La Roche Ltd
103/Protocol CA40192, Version 4
Appendix 1a
Schedule of Assessments:  Randomized Treatment Phase (Treatment Period)
Assessments
Screening 
Day b
35 to 0
Study Days (3 days) a
1 c
4
28
(Wk 4)
56
(Wk 8)
60 d
70 d
84
(Wk 12)
88
98
112 
(Wk 16)
Unscheduled 
Visit e
Early 
Withdrawal 
from Treatment 
or 
Discontinuation
Informed consent
x
Review eligibility criteria
x
x f
Demographic data
x
Pregnancy test g
x
x f
x f
xf
x f
x
x
Vital signs (BP and 
pulse)
x
x f
x
x f
x f
x f
x
x
x
x
x
ECG
x
x
Chest X-ray h
x
Height 
x
x
x
x
x
x
x
x
Weight
x
x
x
x
x
x
x
x
Tanner Stage
x
x
Medical history
x
Physical examination i
x
x
x
x
x
PML neurologic 
examination j
x
x
x
x e
x
Hematology
x
x f
x
x f
x
x
x
x e
x l
ESR k
x
x
x
x
x
x
x
Chemistry
x
x f
x k
x f
x k
x
x 
x e
x l
Urinalysis
x
x f
x f
x e


Appendix 1a
Schedule of Activities: Randomized Treatment Phase (Treatment Period) (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
104/Protocol CA40192, Version 4
Assessments
Screening 
Day b
35 to 0
Study Days (3 days) a
1 c
4
28
(Wk 4)
56
(Wk 8)
60 d
70 d
84
(Wk 12)
88
98
112 
(Wk 16)
Unscheduled 
Visit e
Early 
Withdrawal 
from Treatment 
or 
Discontinuation
TB screen m
x
Viral serology and 
detection tests n
x
Saliva sample o
x
Stool sample
x p
x q
x q
x q
PK sampling (serum) r
x
x
x
x
x
x
x
x
x
x
xe
x l
Anti-drug antibody 
sample (serum) r,s
x
x
x
x
x e
x l
Plasma sample (storage 
for post-study JCV 
antibody testing) t
x
PUCAI or PCDAI u
x
x
x
x
x
x e
x l
Serum sample (CRP)
x f
x f
x
x e
x l
PD (receptor 
occupancy) flow 
cytometry sampling
(whole blood) r
x
x
x
x
x
x
x
x
Serum PD measures 
(MAdCAM-1) r
x
x
x
x
x
x
x
x
Colonic biopsy (CMV, if 
required)
x v
x e


Appendix 1a
Schedule of Activities: Randomized Treatment Phase (Treatment Period) (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
105/Protocol CA40192, Version 4
Assessments
Screening 
Day b
35 to 0
Study Days (3 days) a
1 c
4
28
(Wk 4)
56
(Wk 8)
60 d
70 d
84
(Wk 12)
88
98
112 
(Wk 16)
Unscheduled 
Visit e
Early 
Withdrawal 
from Treatment 
or 
Discontinuation
Concomitant 
medications
x
x
x
x
x
x
x
x
x
x
Adverse events
x
x
x
x
x
x
x
x
x
x
x
Randomization 
x w
Etrolizumab 
administration Q4W a, x
x
x
x
x
Etrolizumab 
administration Q8W a, x
x
x
ADAanti-drug antibody; BPblood pressure; CDCrohn’s Disease; CMVcytomegalovirus; CRPC-reactive protein; ECGelectrocardiogram; 
eCRFelectronic Case Report Form; ESR erythrocyte sedimentation rate; HBc HBV core antibody total; HBsAgHBV surface antigen; 
HBVhepatitis B virus; HCVhepatitis C virus; JCVJohn Cunningham virus; MAdCAM-1mucosal vascular addressin cell adhesion molecule-1; 
MCSMayo Clinic Score; PDpharmacodynamics; PKpharmacokinetic; PMLprogressive multifocal leukoencephalopathy; PCDAIPediatric 
Crohn's Disease Activity Index; PUCAIPediatric Ulcerative Colitis Activity Index; Q4W every 4 weeks; Q8W every 8 weeks; TBtuberculosis; 
UCUlcerative Colitis; Wkweek.
Note:  All study assessments and blood draws are to be conducted prior to study drug administration.
a The time window for days etrolizumab is administered is 1 day.
b All assessments must be performed after obtaining informed consent.  
c Day 1 of Week 0.
d These samples are only collected for patients receiving 3 mg/kg etrolizumab administration Q8W.


Appendix 1a
Schedule of Activities: Randomized Treatment Phase (Treatment Period) (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
106/Protocol CA40192, Version 4
e Conducted at the discretion of the investigator.  Unscheduled visit represents a visit that is not per the Schedule of Assessments and is required 
for an adverse event or for potential relapse assessment.  All indicated assessments are NOT performed at each unscheduled visit.  
Assessments should be symptom driven (e.g., only perform PML neurologic examination if patient reports symptoms suspected of PML; for 
disease worsening, infectious etiologies may be investigated if clinically indicated; and confirmation of clinical relapse is performed by the MCS 
assessment).  Assessments corresponding to items noted in this column should be recorded on the eCRF.
f
On days etrolizumab is administered, perform prior to administration.
g Administer a serum pregnancy test at screening for all postpubertal female patients.  A urine test may be performed at other specified visits; 
however, if the urine test result is positive, a confirmatory serum test must be performed.  Patients must be reminded throughout the study that 
that in case of a positive pregnancy test, administration of study drug will be stopped immediately.  Do not administer etrolizumab unless the 
serum pregnancy test result is negative.  A urine pregnancy test is only required in female patients at Tanner Stage 2 or greater, or after onset of 
menarche.  The test must be performed on a fresh voided sample.
h Not required if patient has a normal chest X–ray result within 3 months prior to screening.  
i
Full physical examination required at screening; symptom-driven physical examination at all other timepoints indicated.
j
PML neurologic examination consists of the PML Subjective Checklist.  Administer before other assessments, per Appendix 7.
k For patients with Crohn's disease only. Hematocrit, albumin, and erythrocyte sedimentation rate (ESR) will be collected to calculate the PCDAI 
score.
l
Not required if unscheduled visit leads to withdrawal and assessment previously conducted at unscheduled visit.
m The following tests are acceptable screening assays for latent TB in this study:  purified protein derivative (a tuberculin skin test reaction; 
e.g., Mantoux test), INF-based test (e.g., QuantiFERON-TB Gold).
n Viral serology and detection tests include HIV test, hepatitis B and C serology, hepatitis B DNA and hepatitis C RNA (Amplicor).  Patients must 
undergo screening for HBV and HCV. This includes testing for HBsAg, anti-HBc, and hepatitis C antibody.  Enrolled patients who are hepatitis B 
core antibody positive should have hepatitis B DNA measured at these timepoints.  Measurement of HCV RNA with use of the Amplicor assay is 
required when the patient has a known history of HCV antibody positivity with past documentation of undetectable HCV RNA, either with or 
without history of anti-viral treatment.  Patients with newly diagnosed HCV antibody positivity are not eligible for this study and, therefore, do not 
require measurement of HCV RNA.
o Will be retained in the Research Biosample Repository for possible genetic analysis.
p Samples will be used for fecal calprotectin assay and culture and sensitivity testing; ova, parasites, and Clostridium difficile toxin testing.  
q Samples will be used for, but not limited to, fecal calprotectin and microbiota analysis.
r
On days that etrolizumab is administered, sample should be taken prior to administration.  If no ADA sample is specified for a visit, a PK sample 
may be used for ADA analysis.


Appendix 1a
Schedule of Activities: Randomized Treatment Phase (Treatment Period) (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
107/Protocol CA40192, Version 4
s If serum sickness or a clinically significant allergic drug reaction is suspected, the Sponsor should be notified, and serum for etrolizumab level 
and ADAs should be drawn and sent to the central laboratory.  ADA samples may also be utilized for exploratory PD assessments or 
assessment of drug concentrations.
t
A blood sample to test for antibodies to JCV will be taken and stored for possible later assessment of how widespread the JCV infection is in the 
study population.  Sample testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for evaluating neurologic 
symptoms.  The sample may be tested if there is a strong belief that this information will be helpful in managing a patient's condition.
u PUCAI and PCDAI should be calculated prior to randomization.  For children who are 6 years of age or younger, the parent or caregiver can 
respond to the questions on the patient’s behalf.  
v IF REQUIRED:  Only if there is suspicion for clinically significant CMV colitis, one biopsy sample should be obtained from the base of the ulcer to 
evaluate for histological presence of CMV.  Analysis should be performed locally if possible, or can be sent to a central laboratory if necessary.  
Result must be negative for CMV prior to dosing on Day 0.  
w Randomization to occur prior to first dose at Day 0.
x Patients will be randomized in a 1:1 ratio to receive either high-frequency dose of etrolizumab once every 4 weeks or low-frequency dose of 
etrolizumab once every 8 weeks.  The high-frequency dose of 1.5 mg/kg etrolizumab will be administered once every 4 weeks at Weeks 0, 4, 8, 
and 12.  The low-frequency dose of 3 mg/kg etrolizumab will be administered once every 8 weeks at Weeks 0 and 8.


Etrolizumab—F. Hoffmann-La Roche Ltd
108/Protocol CA40192, Version 4
Appendix 1b
Schedule of Assessments: Randomized Treatment Phase (Safety Follow-up Period)
Assessments
Week (3 days)
Unscheduled Visit b
Week 18
Week 20
Week 24 or Early 
Withdrawal Visit a
Concomitant medications
x
x
x
x
Adverse events
x
x
x
x
ECG
x
Urine pregnancy test c
x
Physical examination
x
x
x
PD (receptor occupancy), 
flow cytometry sampling 
(whole blood) d
x
x
x
Serum PD measures 
(MAdCAM-1) d
x
x
x
PK sampling (serum) d
x
x
x
Anti-drug antibody sample 
(serum) e, f
x
PML neurologic 
examination g
x
x
x


Appendix 1b
Schedule of Assessments: Randomized Treatment Phase (Safety Follow-up Period) (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
109/Protocol CA40192, Version 4
ADAanti-drug antibody; ECGelectrocardiogram; MAdCAM-1mucosal vascular addressin cell adhesion molecule-1; PDpharmacodynamic; 
PKpharmacokinetic; PMLprogressive multifocal leukoencephalopathy.
a All assessments indicated for the Early Withdrawal Visit should be performed if the patient discontinues prior to completion of the 8-week safety 
follow-up period.
b Unscheduled visit for safety monitoring.
c A urine test may be performed; however, if urine test result is positive, a confirmatory serum test must be performed.  A urine pregnancy test is 
only required in female patients at Tanner Stage 2 or greater, or after onset of menarche.  The test must be performed on a fresh voided 
sample.
d PD and PK samples will be collected at Days 126 (Week 18), 140 (Week 20) and 168 (Week 24).
e If serum sickness or a clinically significant allergic drug reaction is suspected, the Sponsor should be notified and serum for the analysis of 
study drug level and ADAs should be drawn and sent to the central laboratory.  ADA samples may be used for PK and/or exploratory PD 
assessments.
f
ADA samples only need to be taken on Week 24 and at the Early Withdrawal Visit.
g PML neurologic examination consists of the PML Subjective Checklist.  Administer before other assessments as per Appendix 7. 


Etrolizumab—F. Hoffmann-La Roche Ltd
110/Protocol CA40192, Version 4
Appendix 1c
Schedule of Assessments:  Open-Label Extension Phase
Clinic Visits Week 0Week 44
Assessments
Etrolizumab Administration Every 4 Weeks
Clinic Visit Starting at Day 1 of Week 0 (3 days)
0 a,b
4
8
12
16
20
24
28
32
36
40
44
Vital signs (BP, pulse rate)
x
x
x
x
ECG
x
Concomitant medications
x
x
x
x
x
x
x
x
x
x
x
x
Height
x
x
x
x
x
x
Weight
x
x
x
x
x
x
x
x
x
x
x
x
Tanner Stage
x
Adverse events
x
x
x
x
x
x
x
x
x
x
x
x
Limited symptom driven physical 
examination,
including GI
x
x
x
x
x
PML neurologic examination e
x
x
x
x
PUCAI and PCDAI f
x
x
x
x
x
Pregnancy test g
x
x
x
x
x
x
x
x
x
x
x
x
Hematology
x
x h
x h
x
x
x
ESR h
x
x
x
x
x


Appendix 1c
Schedule of Assessments:  Open-Label Extension Phase (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
111/Protocol CA40192, Version 4
Clinic Visits Week 0Week 44 (cont.)
Assessments
Etrolizumab Administration Every 4 Weeks
Clinic Visit Starting at Day 1 of Week 0 (3 days)
0 a,b
4
8
12
16
20
24
28
32
36
40
44
Chemistry
x
x h
x h
x
x
x
Hepatitis B DNA i
x
x
x
x
Serum sample (CRP)
x
Etrolizumab PK sample
(serum) j
x
x
Anti-drug antibody sample 
(serum) j, k
x
x
Etrolizumab administration
x
x
x
x
x
x
x
x
x
x
x
x


Appendix 1c
Schedule of Assessments:  Open-Label Extension Phase (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
112/Protocol CA40192, Version 4
Clinic Visits Week 48-Week 92
Assessments
Etrolizumab Administration Every 4 Weeks
Clinic Visit 
(7 days)
Clinic Visit (3 days)
48
52
56
60
64
68
72
76
80
84
88
92
Vital signs (BP, pulse rate)
x
x
x
x
ECG
x
Concomitant medications
x
x
x
x
x
x
x
x
x
x
x
x
Height
x
x
x
x
Weight
x
x
x
x
x
x
x
x
x
x
x
x
Tanner Stage
Adverse events
x
x
x
x
x
x
x
x
x
x
x
x
Limited symptom driven physical 
examination,
including GI
x
x
x
x
PML neurologic examination e
x
x
x
x
PUCAI and PCDAI f
x
x
x
x
Pregnancy test g
x
x
x
x
x
x
x
x
x
x
x
x
Hematology
x
x
x
x


Appendix 1c
Schedule of Assessments:  Open-Label Extension Phase (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
113/Protocol CA40192, Version 4
Clinic Visits Week 48-Week 92 (cont.)
Assessments
Etrolizumab Administration Every 4 Weeks
Clinic Visit 
(7 days)
Clinic Visit (3 days)
48
52
56
60
64
68
72
76
80
84
88
92
ESR h
x
x
x
x
Chemistry
x
x
x
x
Hepatitis B DNA i
x
x
x
x
Serum sample (CRP)
x
Etrolizumab PK sample
(serum) j
x
Anti-drug antibody sample 
(serum) j, k
x
Etrolizumab administration
x
x
x
x
x
x
x
x
x
x
x
x


Appendix 1c
Schedule of Assessments:  Open-Label Extension Phase (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
114/Protocol CA40192, Version 4
Clinic Visits Week 96Week 312, Unscheduled, and Early Withdrawal from Treatment
Assessments
Clinic Visit
(7 days)
Clinic Visit (3 days)
Clinic Visit
(3 days)
Clinic Visit
(14 days)
Unscheduled 
Visit c
Early 
Withdrawal 
from 
Treatment 
Visit d
Weeks 96, 
120, 144, 168, 
192, 216, 240, 
264,  288
Weeks 100, 104 , 112, 116, 124, 128, 
136, 140, 148, 152, 160, 164, 172, 176, 
184, 188, 196, 200, 208, 212, 220, 224, 
232, 236, 244, 248, 256, 260, 268, 272, 
280, 284, 292, 296, 304, 308
Weeks 108, 
132, 156, 
180, 204, 
228, 252, 
276, 300
Week 312
Vital signs (BP, pulse rate)
x
x
x
x
ECG
x
x
x
Concomitant medications
x
x
x
x
x
x
Height
x
x
x
x
x
Weight
x
x
x
x
x
x
Tanner Stage
x
x
x
x
x
Adverse events
x
x
x
x
x
x
Limited symptom driven 
physical examination, including 
GI
x
x
x
x
x
PML neurologic examination e
x
x
x
x c
x
PUCAI and PCDAI f
x
x
x
x c
x


Appendix 1c
Schedule of Assessments:  Open-Label Extension Phase (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
115/Protocol CA40192, Version 4
Clinic Visits Week 96Week 312, Unscheduled, and Early Withdrawal from Treatment (cont.)
Assessments
Clinic Visit
(7 days)
Clinic Visit (3 days)
Clinic Visit
(3 days)
Clinic Visit
(14 days)
Unscheduled 
Visit c
Early 
Withdrawal 
from 
Treatment 
Visit d
Weeks 96, 
120, 144, 168, 
192, 216, 240, 
264,  288
Weeks 100, 104 , 112, 116, 124, 128, 
136, 140, 148, 152, 160, 164, 172, 176, 
184, 188, 196, 200, 208, 212, 220, 224, 
232, 236, 244, 248, 256, 260, 268, 272, 
280, 284, 292, 296, 304, 308
Weeks 108, 
132, 156, 
180, 204, 
228, 252, 
276, 300
Week 312
Pregnancy test g
x
x
x
x
x
Hematology
x
x
x
x c
x m
ESR h
x
x
x
x
x
Chemistry
x
x
x
x c
x m
Hepatitis B DNA i
x
x
x
Serum sample (CRP)
x
x c
x m
Etrolizumab PK sample 
(serum) j
x
x
x
x
Anti-drug antibody sample 
(serum) j, k
x
x
x
x l
x l, m
Etrolizumab administration
x
x
x
x


Appendix 1c
Schedule of Assessments:  Open-Label Extension Phase (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
116/Protocol CA40192, Version 4
ADAanti-drug antibody; BPblood pressure; CRPc-reactive protein; ECG electrocardiogram; eCRF electronic case report form; 
ESR erythrocyte sedimentation rate; GIgastrointestinal; PDpharmacodynamics; PKpharmacokinetic; PCDAIPediatric Crohn's Disease 
Activity Index; PMLprogressive multifocal leukoencephalopathy; PUCAIPediatric Ulcerative Colitis Activity Index.
a Day 1 of Week 0.
b Week 0 procedures and laboratory assessments that have been collected as part of the final visit for the safety follow-up period (within the 
treatment phase) do not need to be repeated, with the exception of ADAs, which must be recollected at Week 1 if the Week 0 visit 
occurs 7 days after the final visit of the safety follow-up period.
c Unscheduled visit represents a visit that is not as per the Schedule of Assessments and is required for an adverse event or for potential relapse 
assessment.  All indicated assessments are NOT performed at each unscheduled visit.  Assessments would be symptom driven (e.g., only 
perform PML neurologic examination if patient reports symptoms suspected to indicate PML). Assessments corresponding to items noted in this 
column should be recorded on the eCRF.
d Denotes the early withdrawal from treatment visit for the open-label treatment period.  To be performed within 30 days of last dose of study drug. 
Study drug is not administered at the Early Withdrawal from Treatment visit.
e PML neurologic examination consists of the PML Subjective Checklist. Administer before other assessments, per Appendix 7.
f
For children who are 6 years of age or younger, the parent or caregiver can respond to the questions on the patients behalf. 
g A urine test may be performed; however, if the urine test result is positive, a confirmatory serum test must be performed.  Do not administer 
etrolizumab unless the serum pregnancy test result is negative.  A urine pregnancy test is only required in female patients at Tanner Stage 2 or 
greater, or after onset of menarche.  Test must be performed on fresh voided sample.
h For patients with Crohn's disease only.  Hematocrit, albumin, and erythrocyte sedimentation rate (ESR) will be collected to calculate the PCDAI 
score.
i
Assessment is required if the patient becomes Hepatitis B antibody positive.  Not mandatory for all patients.
i
All samples to be collected prior to administration of etrolizumab.
k If serum sickness or a clinically significant allergic drug reaction is suspected, Sponsor should be notified, and serum for etrolizumab level and 
ADAs should be drawn and sent to the central laboratory.  ADA samples may also be utilized for exploratory PD assessments or assessment of 
drug concentrations.
l
PD and drug concentrations may be assessed from these ADA samples.
m Not required if unscheduled visit leads to withdrawal and assessment previously conducted at unscheduled visit


Etrolizumab—F. Hoffmann-La Roche Ltd
117/Protocol CA40192, Version 4
Appendix 1d
Schedule of Assessments:  12-week Safety Follow-Up After Completion or Early Termination of
Open-Label Extension Phase
Assessments
Week (3 days)
Unscheduled Visit c
Week 4 a
Week 8 a
Week 12 or Early 
Withdrawal Visit b
Concomitant medications
x
x
x
x
Adverse events
x
x
x
x
Urine pregnancy test d
x
Physical examination
x
Anti-drug antibody sample 
(serum) e
x
PML neurologic 
examination f
x
ADA anti-drug antibody; PD pharmacodynamic; PK pharmacokinetic; PML progressive multifocal leukoencephalopathy.
a Week 4 and Week 8 study assessments are to be made by telephone call and not by clinic visit.
b All assessments indicated for the Early Withdrawal Visit should be performed if the patient discontinues prior to completion of the 12-week 
safety follow-up period.
c
Unscheduled visit for safety monitoring.
d A urine test may be performed; however, if urine test result is positive, a confirmatory serum test must be performed.  A urine pregnancy 
test is only required in female patients at Tanner Stage 2 or greater, or after onset of menarche.  The test must be performed on a fresh 
voided sample.
e
If serum sickness or a clinically significant allergic drug reaction is suspected, the Sponsor should be notified, and serum for the analysis of 
study drug level and ADA should be drawn.  If etrolizumab concentrations or PD assessments are needed then ADA sample can be used.  
f
PML neurologic examination consists of the PML Subjective Checklist.  Administer before other assessments as per Appendix 7.


Etrolizumab—F. Hoffmann-La Roche Ltd
118/Protocol CA40192, Version 4
Appendix 1e
Schedule of Assessments:  Progressive Multifocal 
Leukoencephalopathy Monitoring Phase
Extended PML Monitoring Phase a
Assessments
24, 48, 68, and 92 b Weeks after 
Discontinuation from Study Treatment c
OR Symptom-Driven Unscheduled 
Telephone Call d OR Early Termination e, f, 
OR After Completion of OLE g
Unscheduled Visit h
PML Subjective Checklist i
x
x
Adverse event reporting to the 
Sponsor j
x
x
OLEopen-label extension; PMLprogressive multifocal leukoencephalopathy.
Note:  The extended PML monitoring period is to be conducted for patients completing or 
discontinuing from the randomized treatment phase after completion of the safety follow-up 
AND for patients entering or discontinuing from the open-label extension phase.
a The total length of the PML monitoring period is 104 weeks.  The extended PML monitoring 
period telephone calls will occur at the indicated timepoints for the extended PML monitoring 
period.  The extended PML monitoring will be conducted using a PML Subjective Checklist 
over the telephone.  PML monitoring should occur within 7 days of the specified day.
b Patients that complete the 24-week treatment phase but do not enter the OLE phase. 
The last PML monitoring call will be 92 weeks after completion of the randomized treatment 
phase. For patients that discontinue early from the treatment phase, the last PML monitoring 
call will be 96 weeks after discontinuation.  For the patients that complete OLE, the last PML 
monitoring call will be 104 weeks after OLE completion.
c For patients that complete the treatment phase, the PML monitoring phase includes Week 12 
to Week 16 of the treatment phase plus the 8-week safety follow-up and the 92-week PML 
safety monitoring phase.
d Unscheduled telephone call represents a call that is not as per Schedule of Assessments and 
it is symptom driven.
e For patients that discontinue early from the 24-week randomized treatment phase, the PML 
monitoring phase includes 8-week safety follow up and 96 weeks of PML safety monitoring.
f
For patients that discontinue after the 24-week randomized treatment phase but prior to study 
completion (end of extended PML monitoring period), the early termination visit from the 
extended PML monitoring period should be performed (a subjective checklist by telephone).
g For patients that complete the OLE treatment, the PML monitoring phase includes 
104 weeks of PML safety monitoring.
h Unscheduled visit represents a visit that is not as per Schedule of Assessments and it is 
symptom driven.
i
If there are any signs or symptoms suggestive of PML identified on the subjective checklist 
during the telephone call, the patient will be asked to come into the clinic for further 
evaluation and if indicated referral to a neurologist. .
j
Investigators are not required to actively monitor patients for adverse events; however, if he 
or she becomes aware of any other serious adverse events that are believed to be related to 
prior study drug treatment, these should be reported directly to Roche or its designee either 
by faxing or by scanning and e-mailing the Serious Adverse Event/Adverse Event of Special 
Interest Reporting Form with use of the fax number or e-mail address provided to the 
investigators.  The investigator may become aware of such events at these timepoints or via 
other means, but the data are not to be collected routinely.




Appendix 2
Pediatric Ulcerative Colitis Activity Index (PUCAI) (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
120/Protocol CA40192, Version 4
PUCAI User Guide
Most items contained in the PUCAI can be scored using the instructions provided within 
the instrument.  The following issues require additional clarification.
Time period for evaluation

Answers should reflect a daily average of the last two days. 

However, if clinical conditions are changing rapidly (e.g., during intense intravenous 
therapy), the previous 24 hours should be considered. 

For patients undergoing colonoscopy, answers should reflect the two days before 
bowel cleanout was started.
Activity level

Occasional limitation of activity= could attend school or equivalent, but reduced 
activity (e.g., attends school but does not play at breaks).

Severe restricted activity=could not attend school or equivalent activity.
PUCAI definitions of disease activity, remission, and response to therapy
(all are based on analysis of data generated during development process during 2006)

Remission: total score less than 10 points

Mild disease activity: total score between 10 and 30 points inclusive

Moderate disease activity: total score between 35 and 60 points inclusive

Severe disease activity: total score of 65 points or greater 

Response (minimal clinically significant change in score over time): a change in 
score of at least 20 points.


Etrolizumab—F. Hoffmann-La Roche Ltd
121/Protocol CA40192, Version 4
Appendix 3
Pediatrics Crohn’s Disease Activity Index (PCDAI)


Etrolizumab—F. Hoffmann-La Roche Ltd
122/Protocol CA40192, Version 4
Appendix 4
Anaphylaxis Precautions 
The following equipment is needed in the event of a suspected anaphylactic reaction 
during study drug administration:

Monitoring devices:  ECG monitor, blood pressure monitor, oxygen saturation 
monitor, and thermometer

Oxygen

Epinephrine for intravenous, intramuscular, and endotracheal administration in 
accordance with institutional guidelines

Antihistamines

Corticosteroids

Intravenous infusion solutions, tubing, catheters, and tape
The following are the procedures to follow in the event of a suspected anaphylactic 
reaction during study drug administration:

Stop the study drug infusion. 

Call for additional medical assistance.

Maintain an adequate airway.

Ensure that appropriate monitoring is in place, with continuous ECG and pulse 
oximetry monitoring, if possible.

Administer antihistamines, epinephrine, or other medications as required by patient
status and as directed by the physician in charge.

Continue to observe the patient and document observations.

Draw serum/plasma samples for immunogenicity testing.

Ask patient to return for washout immunogenicity sample if appropriate.


Etrolizumab—F. Hoffmann-La Roche Ltd
123/Protocol CA40192, Version 4
Appendix 5
Tanner Stages
Sexual Maturity Stages in Boys and Girls
Male Genitalia
Pubic Hair
Female Breasts
1
Preadolescent—testes, 
scrotum, and penis are 
childlike in size
Stage None; may be vellus 
hair, as over abdomen
Preadolescent—elevation of 
papilla only
2
Slight enlargement of 
scrotum with reddening of 
skin; little or no 
enlargement of penis
Sparse growth of long, 
slightly pigmented, downy 
hair, straight or slightly 
curled, primarily at base of 
penis or along labia
Breast bud stage; breast and 
papilla form a small mound; 
areolar diameter enlarges
3
Further enlargement of 
scrotum; penis enlarges, 
mainly in length
Hair considerably darker, 
coarser, and more curled; 
spreads sparsely over 
junction of pubes
Further enlargement of breast 
and areola with no separation 
of their contours
4
Further enlargement and 
darkening of scrotum; 
penis enlarges, especially 
in breadth; glans develops
Adult-type hair that does not 
extend onto thighs, covering 
a smaller area than in adult
Areola and papilla project to 
form a secondary mound 
above the contour of the 
breast; stage 4 development 
of the areolar mound does not 
occur in 10% of girls and is 
slight in 20%; when present, it 
may persist well into 
adulthood
5
Adult in size and shape
Adult in quantity and type 
with extension onto thighs 
but not up linea alba
Mature female; papilla 
projects and areola recesses 
to general contour of breast
Data from Tanner JM: Normal growth and techniques of growth assessment. Clin Endocrinol 
Metab 15:436, 1986.
In boys, if different scores are obtained for pubic hair and genitalia, the score for 
genitalia should be used.
In girls, if different scores are obtained for pubic hair and breast development, the score 
for breast development should be used. 


Etrolizumab—F. Hoffmann-La Roche Ltd
124/Protocol CA40192, Version 4
Appendix 6
Childbearing Potential, Pregnancy Testing, and Contraception
All females of childbearing potential (including those who have had a tubal ligation) will 
have a serum pregnancy test at screening and a urine pregnancy test prior to 
administration of study drug at subsequent visits.  If a urine pregnancy test result is 
positive, study drug will not be administered until pregnancy is ruled out.  The result 
must be confirmed by a serum pregnancy test (conducted by the central laboratory).  
See Section 5.4.3 of the protocol for management of a patient with a confirmed 
pregnancy.
All postpubertal female patients are considered to be of childbearing potential unless 
they meet one of the following criteria:

The patient has been postmenopausal (nontherapy-induced amenorrhea) for at 
least 12 months

The patient had a surgical bilateral oophorectomy (with or without hysterectomy) 
more than 6 weeks prior to enrollment

The patient had a hysterectomy
Female patients of reproductive or childbearing potential who are unwilling to use a 
highly effective method of contraception or remain abstinent during the treatment period 
and for at least 24 weeks after the last dose of study drug will be excluded from study 
participation.
Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of 
the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or 
postovulation methods) and withdrawal are not acceptable methods of 
contraception.
Examples of highly effective contraception include the following:

Combined oral contraceptive pill

Contraceptive transdermal patch

Intrauterine device

Implants for contraception

Injections for contraception (with prolonged release)

Hormonal vaginal device

Sterilization, surgical tubal ligation

Sole sexual partner consisting of surgically sterilized male partner with appropriate 
postsurgical verification of the absence of spermatozoa in the ejaculate


Appendix 6
Childbearing Potential, Pregnancy Testing, and Contraception
(cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
125/Protocol CA40192, Version 4

Double-barrier methods:  condom and occlusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/suppository (Note: a female condom and 
male condom should not be used together because friction between the two can 
result in either product failing)
Patients may provide verbal confirmation that the partner completed appropriate 
follow-up after vasectomy.  Sites are not required to obtain partner medical records.
With female partners of childbearing potential or pregnant female partners, men must 
remain abstinent or use a condom during the treatment period and for at least 24 weeks 
after the last dose of study drug.  Men must refrain from donating sperm during this 
same period.
For men and women:  The reliability of sexual abstinence should be evaluated in relation 
to the duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) 
and withdrawal are not acceptable methods of contraception.


Etrolizumab—F. Hoffmann-La Roche Ltd
126/Protocol CA40192, Version 4
Appendix 7
Worksheet for the PML Neurologic Examination
PML Subjective Checklist of neurologic assessment to monitor for progressive 
multifocal leukoencephalopathy (PML) in the Etrolizumab Pediatric Studies
PML usually manifests with subacute, progressive neurologic deficits including:
Neurologic Domain
Signs/Symptoms
Relevant PML
Subjective
Checklist Question
Altered mental status
Can encompass a variety of presenting 
signs and symptoms including cognitive 
changes (confusion, difficulty 
concentrating, memory loss) and altered 
behavior (including personality changes)
Q2, Q5, Q6
Higher cortical dysfunction
Impaired comprehension and/or 
formulation of language (aphasia), loss of 
ability to recognize objects, persons, 
sounds, shapes, or smells (agnosia)
Q2, Q5, Q6
Visual changes
Loss of visual fields (homonymous 
hemianopsia), double vision (diplopia)
Q1
Motor deficits
Weakness (hemiparesis or monoparesis), 
seizures (generalized or partial), difficulties 
with speech (dysarthria) or swallowing 
(dysphagia)
Q2, Q3
Sensory deficits
Sensory loss (i.e. paresthesia)
Q7
Coordination
Difficulty walking and maintaining balance 
(ataxia), lack of voluntary coordination of 
limb movement (limb ataxia)
Q4
In order to monitor patients for PML, a systematic review of symptoms seeking any new 
neurological deficits will be performed with the patient and parents. Significant new 
symptoms should trigger referral to a pediatric neurology specialist to confirm and 
investigate.
At screening and all other visits the PML Subjective Checklist should be performed.
During the evaluation, if there is a “yes” response to the questions, the symptoms of the 
patient should be discussed with the patient or patients parent/legal guardian to confirm 
that these are new and significant changes that cannot be ruled out by every day events.  


Appendix 7
Worksheet for the PML Neurologic Examination (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
127/Protocol CA40192, Version 4
PML Subjective Checklist
Symptoms
“Compared to how you 
(your child) usually
feel, have you (your 
child) had a significant 
change in any of the 
following?”
If the answer is “Yes”, obtain a 
description of the symptom(s) 
with examples
YES
NO
1) Have you (your child) experienced 
any new difficulty with vision (ex. 
Blurred vision or seeing double), new 
difficulty with reading, or loss of 
vision?
2) Have you (your child) had new 
onset difficulty speaking, 
understanding, or communicating. 
(e.g., word finding trouble, using the 
wrong words)
3) Have you (your child) been 
experiencing new onset weakness in 
face, arms and/or legs?
4)Has your child recently developed 
clumsiness, difficulty with balance, or 
falling more than normal?
5. Has your child recently developed 
difficulty understanding others, or 
been less aware of the environment?


Appendix 7
Worksheet for the PML Neurologic Examination (cont.)
Etrolizumab—F. Hoffmann-La Roche Ltd
128/Protocol CA40192, Version 4
6. Has your child experienced change 
in behavior, or new problems with 
attention, recall, memory, or 
thinking?
7. Have you (your child) been 
experiencing any new numbness or 
other loss of sensation?
Please refer to the PML Algorithm in the Protocol Appendix for details.

If there is a clinically significant abnormal finding on the PML Subjective Checklist,
this should be appropriately documented on the worksheet and in the eCRF.

If there are any clinically significant abnormalities found on the PML Subjective
Checklist or if there is high clinical suspicion for PML (in the opinion of the
investigator):
  This must be reported as an adverse event of special interest (AESI) within 24 
hours
  An urgent referral to a neurologist should be made.
  Dosing with study drug will be suspended until PML can be ruled out.
  Further evaluation will proceed according to the PML Algorithm in the Protocol
Appendix.
   Any confirmed diagnosis of PML should be reported as a serious adverse event
(SAE).
Please complete the PML eCRF.
Was the PML Subjective Checklist administered? (Yes/No)
If yes, date of administration of PML Subjective Checklist (Date)
If yes, were there any clinically significant abnormalities on the PML Subjective
Checklist? (Yes/No) 
Is PML suspected? (Yes/No)




Etrolizumab—F. Hoffmann-La Roche Ltd
130/Protocol CA40192, Version 4
Appendix 9
Clinical Criteria for Diagnosing Anaphylaxis
These criteria are taken from a summary report from the second symposium on the 
definition and management of anaphylaxis, conducted by the National Institute of Allergy 
and Infectious Disease/Food Allergy and Anaphylaxis Network.1  Anaphylaxis is highly 
likely when any one of the following three criteria is fulfilled:
1.
Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen
lips-tongue-uvula)
AND AT LEAST ONE OF THE FOLLOWING:

Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced 
peak expiratory flow, hypoxemia)

Reduced blood pressure or associated symptoms of end-organ dysfunction
(e.g., hypotonia, syncope, incontinence)
2.
Two or more of the following that occur rapidly after exposure to a likely allergen for 
that patient (minutes to several hours):

Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush, swollen 
lips-tongue-uvula)

Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced 
peak expiratory flow, hypoxemia)

Reduced blood pressure or associated symptoms (e.g., hypotonia, syncope, 
incontinence)

Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting) 
3.
Reduced blood pressure after exposure to known allergen for that patient (minutes to
several hours):

Infants and children:  low systolic blood pressure (age specific)2 or greater than 30% 
decrease in systolic blood pressure

Adults:  systolic blood pressure of less than 90 mmHg or greater than 30% decrease 
from that person’s baseline
                                           
1
Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition 
and management of anaphylaxis: summary report—second National Institute of Allergy and 
Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin
Immunol 2006;117:3917.
2
Low systolic blood pressure for children is defined as less than 70 mmHg from 1 month to 
1 year, less than (70 mmHg + [2 x age]) from 1 to 10 years, and less than 90 mmHg from
11 to 17 years.